

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/085860 A1(51) International Patent Classification⁷: C07D 231/18, 231/20, A61K 31/415, 31/4162, 31/4155, A61P 31/18, C07D 403/06, 413/06, 401/12, 403/12, 405/12, 403/04, 498/04, 401/06, 471/04

Sandwich, Kent CT13 9NJ (GB). SELBY, Matthew, Duncan [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). STUPPLE, Paul, Anthony [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(21) International Application Number: PCT/IB02/01234

(22) International Filing Date: 4 April 2002 (04.04.2002)

(74) Agents: LANE, Graham, Mark et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
0108999.4 10 April 2001 (10.04.2001) GB
0127426.5 15 November 2001 (15.11.2001) GB

(71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant (for all designated States except GB): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:

(75) Inventors/Applicants (for US only): JONES, Lyn, Howard [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). MOWBRAY, Charles, Eric [GR/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). PRICE, Davis, Anthony [GB/GB]; Pfizer Global Research and Development, Ramsgate Road,

— with international search report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

(54) Title: PYRAZOLE DERIVATIVES FOR TREATING HIV

WO 02/085860



(I)

(57) Abstract: This invention relates to pyrazole derivatives of the formula, or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

PYRAZOLE DERIVATIVES FOR TREATING HIV


This invention relates to pyrazole derivatives and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them 5 and the uses of such derivatives.

The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. Reverse transcriptase is implicated in the infectious lifecycle of HIV, and compounds 10 which interfere with the function of this enzyme have shown utility in the treatment of conditions including AIDS. There is a constant need to provide new and better modulators, especially inhibitors, of HIV reverse transcriptase since the virus is able to mutate, becoming resistant to the effects of known modulators.

15 The compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as 20 Acquired Immune Deficiency Syndrome (AIDS).

European patent application EP 0 786 455 A1 discloses a class of imidazole compounds which inhibit the growth of HIV. A class of N-phenylpyrazoles which act as reverse transcriptase inhibitors are disclosed in *J. Med. Chem.*, 2000, **43**, 25 1034. Antiviral activity is ascribed to a class of N-(hydroxyethyl)pyrazole derivatives in US patent number 3,303,200.

According to the present invention there is provided a compound of the formula



30 or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

either R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, -CN, -OR⁷,

-CO₂R¹⁰, -CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR¹⁰, S(O)_xR¹⁰, -CO₂R¹⁰, -CONR⁵R¹⁰, -OCONR⁵R¹⁰, -NR⁵CO₂R¹⁰, -NR¹⁰R¹¹, -NR⁵COR¹⁰, -SO₂NR⁵R¹⁰, -NR⁵CONR⁵R¹⁰, -NR⁵SO₂R¹⁰ or R¹⁰; and

5

R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -OR⁵, -OR¹², -CN, -CO₂R⁷, -OCONR⁵R⁵, -CONR⁵R⁵, -C(=NR⁵)NR⁵OR⁵, -CONR⁵NR⁵R⁵, -NR⁶R⁶, -NR⁵R¹², -NR⁵COR⁵, -NR⁵COR⁸, -NR⁵COR¹², -NR⁵CO₂R⁵, -NR⁵CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -NR⁵SO₂NR⁵R⁵, R⁸ or R⁹;

or, R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, optionally substituted by oxo, optionally wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R¹⁰;

R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, -CN, -OR⁷, -CO₂R⁵, -CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR⁵, -CO₂R⁵, -CONR⁵R⁵, -OCONR⁵R⁵, -NR⁵CO₂R⁵, -NR⁶R⁶, -NR⁵COR⁵, -SO₂NR⁵R⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹;

R⁴ is phenyl, naphthyl or pyridyl, each being optionally substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, -CONR⁵R⁵, OR¹³, So_xR⁶, O-(C₁-C₆ alkylene)-CONR⁵R⁵, O-(C₁-C₆ alkylene)-NR⁵R⁵, or O-(C₁-C₆ alkylene)-OR⁶;

each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

R^8 is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl;

R^9 is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C₁-C₆ alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -NR⁵COOR⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵ or -CN;

R^{10} is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by -OR⁵, -OR¹³, R⁸, R⁹, R¹³ or -COR¹³;

R^{11} is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -CONR⁵R⁵, R⁸ or R⁹;

R^{12} is C₁-C₆ alkyl substituted by R⁸, R⁹, -OR⁵, -CONR⁵R⁵, -NR⁵COR⁵ or -NR⁵R⁵;

R^{13} is phenyl optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and

x is 0, 1 or 2;

with the proviso that (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl.

In the above definitions, halo means fluoro, chloro, bromo or iodo. Unless otherwise stated, alkyl, alkenyl, alkynyl, alkylene and alkoxy groups containing the requisite number of carbon atoms can be unbranched or branched chain. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl. Examples of alkenyl include ethenyl, propen-1-yl, propen-2-yl,

propen-3-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methylpropen-1-yl or 2-methylpropen-3-yl. Examples of alkynyl include ethynyl, propyn-1-yl, propyn-3-yl, 1-butyn-1-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl. Examples of alkylene include methylene, 1,1-ethylene, 1,2-5 ethylene, 1,1-propylene, 1,2-propylene, 2,2-propylene and 1,3-propylene. Examples of alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Where R¹ and R² are taken together, they form, along with the nitrogen atom and the carbon atom of the 10 pyrazole ring to which they are attached, a 5- or 6-membered ring. Where a heterocyclic group R⁸ or R⁹ is attached to an oxygen, sulphur or nitrogen heteroatom the heterocyclic group R⁸ or R⁹ must be linked through a ring carbon atom. Further, where a heterocyclic group R⁹ is attached to an oxygen, sulphur 15 or nitrogen heteroatom the heterocyclic group R⁹ must be linked through a ring carbon atom that is not adjacent to a ring heteroatom.

The pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition and the base salts thereof.

20 Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, para-25 toluenesulphonate and pamoate salts.

Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.

30 For a review on suitable salts see Berge *et al*, *J. Pharm. Sci.*, **66**, 1-19, 1977.

The pharmaceutically acceptable solvates of the compounds of the formula (I) include the hydrates thereof.

35 Also included within the present scope of the compounds of the formula (I) are polymorphs thereof.

The compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds. Examples of such derivatives are described in: Drugs of Today, Volume 19, Number 9, 1983, pp 499 – 538; Topics in Chemistry, Chapter 31, pp 306 – 316; 5 and in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference) and include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, sulphonamides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.

10 A compound of the formula (I) may contain one or more asymmetric carbon atoms and therefore exist in two or more stereoisomeric forms. The present invention includes the individual stereoisomers of the compounds of the formula (I) together with, where appropriate, the individual tautomers thereof, and 15 mixtures thereof.

20 Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or high performance liquid chromatography (HPLC) of a stereoisomeric mixture of a compound of the formula (I) or a suitable salt or derivative thereof. An individual enantiomer of a compound of the formula (I) may also be prepared from a corresponding optically 25 pure intermediate or by resolution, such as by HPLC of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

Preferably, R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -OR⁷, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by halo, -CN, -OR¹⁰, S(O)_xR¹⁰, -CO₂R¹⁰, -CONR⁵R¹⁰, -OCONR⁵R¹⁰, -NR⁵CO₂R¹⁰, -NR¹⁰R¹¹, 30 -NR⁵COR¹⁰, -SO₂NR⁵R¹⁰, -NR⁵CONR⁵R¹⁰, -NR⁵SO₂R¹⁰ or R¹⁰. Preferably, R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -OR⁷, said C₁-C₆ alkyl being optionally substituted by halo, -OR¹⁰, -NR¹⁰R¹¹, -NR⁵COR¹⁰ or R¹⁰. Preferably, R¹, when taken separately, is H, C₁-C₄ alkyl, cyclopropyl, or -OCH₃, 35 said C₁-C₄ alkyl being optionally substituted by bromo, -OH, -O(C₁-C₂ alkyl), -NR¹⁰R¹¹, -NHCOR¹³ or R¹⁰. Preferably, R¹, when taken separately, is H, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -C(CH₃)₃, cyclopropyl, -OCH₃, -CH₂OH, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂Br, -CH₂NH₂, -CH₂NHCH₃, -CH₂N(CH₃)₂, -CH₂NHCH₂(cyclopropyl),

$-\text{CH}_2\text{NHCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{NHCH}_2\text{CH}_2\text{NHCOCOCH}_3$, $-\text{CH}_2\text{NHCO(4-cyanophenyl)}$,
 $-\text{CH}_2\text{NHCO(3-cyanophenyl)}$, $-\text{CH}_2\text{NHCH}_2(4\text{-cyanophenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-fluorophenyl})$,
 $-\text{CH}_2\text{NHCH}_2(4\text{-methoxyphenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-aminosulphonylphenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-aminocarbonylphenyl})$, $-\text{CH}_2\text{NHCH}_2(\text{pyrid-3-yl})$,
 $-\text{CH}_2\text{N}(\text{CH}_3)(4\text{-cyanophenylmethyl})$, $-\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2\text{OH})(4\text{-cyanophenylmethyl})$, $4\text{-methoxypiperidin-1-ylmethyl}$, $4\text{-aminocarbonylpiperidin-1-ylmethyl}$, $4\text{-methylcarbonylaminopiperidin-1-ylmethyl}$, $\text{piperazin-1-ylmethyl}$, $4\text{-methylpiperazin-1-ylmethyl}$, $4\text{-methylcarbonylpiperazin-1-ylmethyl}$, $4\text{-methoxymethylcarbonylpiperazin-1-ylmethyl}$, $4\text{-methoxycarbonylpiperazin-1-ylmethyl}$, $4\text{-methylsulphonylpiperazin-1-ylmethyl}$, $\text{morpholin-4-ylmethyl}$, $2\text{-methylimidazol-1-ylmethyl}$, $\text{pyrazol-1-ylmethyl}$ or $1,2,4\text{-triazol-1-ylmethyl}$.
 Preferably, R^1 , when taken separately, is, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, cyclopropyl,
 $-\text{CH}_2\text{NHCH}_2(4\text{-cyanophenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-fluorophenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-methoxyphenyl})$, $-\text{CH}_2\text{NHCH}_2(4\text{-aminosulphonylphenyl})$ or $-\text{CH}_2\text{NHCH}_2(4\text{-aminocarbonylphenyl})$.

Preferably, R^2 , when taken separately, is H , $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ alkenyl or R^9 , said $\text{C}_1\text{-C}_6$ alkyl being optionally substituted by halo, $-\text{OR}^5$, $-\text{OR}^{12}$, $-\text{CN}$, $-\text{CO}_2\text{R}^7$, $-\text{OCONR}^5\text{R}^5$, $-\text{CONR}^5\text{R}^5$, $-\text{C}(\text{=NR}^5)\text{NR}^5\text{OR}^5$, $-\text{CONR}^5\text{NR}^5\text{R}^5$, $-\text{NR}^6\text{R}^6$, $-\text{NR}^5\text{R}^{12}$,
 $-\text{NR}^5\text{COR}^5$, $-\text{NR}^5\text{COR}^8$, $-\text{NR}^5\text{COR}^{12}$, $-\text{NR}^5\text{CO}_2\text{R}^5$, $-\text{NR}^5\text{CONR}^5\text{R}^5$, $-\text{SO}_2\text{NR}^5\text{R}^5$,
 $-\text{NR}^5\text{SO}_2\text{R}^5$, R^8 or R^9 .
 Preferably, R^2 , when taken separately, is H , $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ alkenyl or R^9 , said $\text{C}_1\text{-C}_6$ alkyl being optionally substituted by $-\text{OR}^5$, $-\text{OR}^{12}$, $-\text{CN}$, $-\text{CO}_2\text{R}^7$, $-\text{CONR}^5\text{R}^5$, $-\text{C}(\text{=NR}^5)\text{NR}^5\text{OR}^5$, $-\text{CONR}^5\text{NR}^5\text{R}^5$, $-\text{NR}^6\text{R}^6$, $-\text{NR}^5\text{R}^{12}$, $-\text{NR}^5\text{COR}^8$, $-\text{NR}^5\text{COR}^{12}$,
 $-\text{NR}^5\text{CO}_2\text{R}^5$, R^8 or R^9 .
 Preferably, R^2 , when taken separately, is H , $\text{C}_1\text{-C}_3$ alkyl, propenyl or R^9 , said $\text{C}_1\text{-C}_3$ alkyl being optionally substituted by $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_2\text{NH}_2$, $-\text{CN}$, $-\text{CO}_2\text{CH}_3$, $-\text{CO}_2\text{CH}_2\text{CH}_3$, $-\text{CONH}_2$, $-\text{C}(\text{=NH})\text{NHOH}$, $-\text{CONHNH}_2$, $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{NHCH}_2\text{CH}_2\text{NHCOCH}_3$, $-\text{NHCH}_2\text{CH}_2\text{OCH}_3$, $-\text{NHCH}_2\text{R}^9$, $-\text{NHCOR}^8$, $-\text{NHCOCH}_2\text{OCH}_3$, $-\text{NHCO}_2\text{C}(\text{CH}_3)_3$, R^8 or R^9 .
 Preferably, R^2 , when taken separately, is H , methyl, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CN}$, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{CONHNH}_2$, $-\text{CH}_2\text{CO}_2\text{CH}_3$, $-\text{CH}_2\text{CO}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{C}(\text{=NH})\text{NHOH}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{NHCOCH}_2\text{OCH}_3$, $-\text{CH}_2\text{CH}_2\text{NHCO}_2\text{C}(\text{CH}_3)_3$, $2\text{-(pyrid-2-ylcarbonylamino)eth-1-yl}$, $2\text{-(pyrazin-2-ylcarbonylamino)eth-1-yl}$, $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{NHCH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2\text{NHCOCH}_3$, $-\text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$, $(3\text{-hydroxypyrazol-5-yl)methyl}$, $2\text{-hydroxy-1,3,4-oxadiazol-5-ylmethyl}$, $2\text{-amino-1,3,4-oxadiazol-5-yl}$, $5\text{-hydroxy-1,2,4-oxadiazol-3-ylmethyl}$, 6-

hydroxy-2-methylpyrimidin-4-ylmethyl, 6-hydroxy-2-aminopyrimidin-4-ylmethyl, 2-(morpholin-4-yl)eth-1-yl, 2-(4-methylcarbonylpiperazin-1-yl)eth-1-yl, morpholin-3-ylmethyl, (2-(tetrahydrofuran-2-ylmethylamino)eth-1-yl, 1-methylazetidin-3-yl or azetidin-3-yl.

5 Preferably, R², when taken separately, is H, -CH₂CH₂OH or -CH₂CH₂NH₂.

Preferably, R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, optionally substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R¹⁰.

10 Preferably, R¹ and R², when taken together, represent unbranched propylene wherein one methylene group is replaced by an oxygen atom or unbranched butylene wherein one methylene group is replaced by a nitrogen atom, said propylene and butylene being optionally substituted by oxo and said nitrogen atom being optionally substituted by R¹⁰.

15 Preferably, R¹ and R², when taken together, represent ^x-OCH₂CH₂^y, ^x-CONHCH₂CH₂^y, ^x-CH₂NHCH₂CH₂^y, ^x-CH₂N(CH₃)CH₂CH₂^y, ^x-CH₂N(4-cyanophenylmethyl)CH₂CH₂^y or ^x-CH₂N(4-methoxyphenylmethyl)CH₂CH₂^y wherein 'x' represents the point of attachment to the carbon atom of the pyrazole ring and 'y' represents the point of attachment to the nitrogen atom of the pyrazole ring.

20 Preferably, R³ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being optionally substituted by halo, -CN, -OR⁵, -CO₂R⁵, -CONR⁵R⁵, -OCONR⁵R⁵, -NR⁵CO₂R⁵, -NR⁶R⁶, -NR⁵COR⁵, -SO₂NR⁵R⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹.

25 Preferably, R³ is H or C₁-C₆ alkyl.

Preferably, R³ is H or C₁-C₄ alkyl.

Preferably, R³ is H, -CH₃, -CH₂CH₃, -CH(CH₃)₂ or -C(CH₃)₃.

30 Preferably, R³ is -CH₃, -CH₂CH₃, -CH(CH₃)₂ or cyclopropyl.

Preferably, R⁴ is phenyl optionally substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.

Preferably, R⁴ is phenyl substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.

35 Preferably, R⁴ is phenyl substituted by halo, -CN or C₁-C₆ alkyl.

Preferably, R⁴ is phenyl substituted by fluoro, chloro, -CN or methyl.

Preferably, R⁴ is 3-cyanophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-fluorophenyl, 2-fluorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-

difluorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 2,5-difluorophenyl, 3,5-dicyanophenyl, 3,5-dimethylphenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-fluorophenyl, 2-chloro-4-cyanophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl or 4-cyano-2,6-dimethylphenyl.

5 Preferably, R^4 is 3,5-dicyanophenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl or 3-cyano-5-methylphenyl.

In an alternative set of preferences:

Preferably, R^4 is phenyl optionally substituted by R^8 , halo, -CN, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, -CONR⁵R⁵, OR¹³, SO_xR⁶, O-(C_1 - C_6 alkylene)-CONR⁵R⁵, O-(C_1 - C_6 alkylene)-NR⁵R⁵, or O-(C_1 - C_6 alkylene)-OR⁶; or naphthyl.

Preferably, R^4 is phenyl substituted by R^8 , halo, -CN, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, -CONR⁵R⁵, OR¹³, SO_xR⁶, O-(C_1 - C_6 alkylene)-CONR⁵R⁵, O-(C_1 - C_6 alkylene)-NR⁵R⁵, or O-(C_1 - C_6 alkylene)-OR⁶.

Preferably, R^8 is pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each being optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C_1 - C_6 alkylene)-NR⁵R⁵, C_1 - C_6 alkyl, fluoro(C_1 - C_6)alkyl or C_3 - C_7 cycloalkyl.

Preferably, R^8 is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C_1 - C_6 alkylene)-NR⁵R⁵, C_1 - C_6 alkyl, fluoro(C_1 - C_6)alkyl or C_3 - C_7 cycloalkyl.

Preferably, R^8 is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being optionally substituted by -OR⁵, -NR⁵R⁵ or C_1 - C_6 alkyl.

30 Preferably, R^8 is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being optionally substituted by -OH, -NH₂ or methyl.

Preferably, R^8 is pyrazol-1-yl, 2-methylimidazol-1-yl, 1,2,4-triazol-1-yl, 3-hydroxypyrazol-5-yl, 2-hydroxy-1,3,4-oxadiazol-5-yl, 2-amino-1,3,4-oxadiazol-5-yl, 35 5-hydroxy-1,2,4-oxadiazol-3-yl, 2-methyl-4-hydroxypyrimidin-6-yl, 2-amino-4-hydroxypyrimidin-6-yl, pyridin-3-yl, pyridin-2-yl or pyrazin-2-yl.

Preferably, R^9 is azetidinyl, tetrahydropyrrolyl, piperidinyl, azepinyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, oxepinyl, morpholinyl, piperazinyl or

diazepinyl, each being optionally substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C₁-C₆ alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -NR⁵COOR⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵ or -CN.

5 Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being optionally substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C₁-C₆ alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -NR⁵COOR⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵ or -CN.

10 Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being optionally substituted by C₁-C₆ alkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C₁-C₆ alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by -OR⁵ or -NR⁵COR⁵.
Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morphoninyl, each being optionally substituted by -CH₃, -SO₂CH₃, -CONH₂, -COOCH₃, -COCH₂OCH₃ or -COCH₃ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by -OCH₃ or -NHCOCH₃.
Preferably, R⁹ is 4-methoxypiperidin-1-yl, 4-aminocarbonylpiperidin-1-yl, 4-methylcarbonylaminopiperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methylcarbonylpiperazin-1-yl, 4-methoxymethylcarbonylpiperazin-1-yl, 4-methoxycarbonylpiperazin-1-yl, 4-methylsulphonylpiperazin-1-yl, morpholin-4-yl, tetrahydrofuran-2-yl, morpholin-3-yl, azetidin-3-yl or 1-methylazetidin-3-yl.

25 Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or -(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being optionally substituted by -OR⁵, -OR¹³, R⁸, R⁹, R¹³ or -COR¹³.
Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or -(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being optionally substituted by -OR⁵ or R¹³.
Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, -CH₃, -CH₂CH₃ or -CH₂(cyclopropyl), said -CH₃ and -CH₂CH₃ being optionally substituted by -OCH₃ or R¹³.

30 Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, -CH₃, -CH₂CH₃, -CH₂CH₂OCH₃, -CH₂(cyclopropyl), 4-cyanophenylmethyl, 4-fluorophenylmethyl, 4-methoxyphenylmethyl, 4-aminosulphonylphenylmethyl or 4-aminocarbonylphenylmethyl.

35 Preferably, R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being optionally substituted by -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -CONR⁵R⁵, R⁸ or R⁹.
Preferably, R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being optionally substituted by -OR⁵ or -NR⁵COR⁵.

Preferably, R^{11} is H, -CH₃ or -CH₂CH₃, said -CH₃ and -CH₂CH₃ being optionally substituted by -OH or -NHCOCH₃.

Preferably, R^{11} is H, -CH₃, -CH₂CH₂NHCOCH₃ or -CH₂CH₂OH.

5 Preferably, R^{12} is C₁-C₄ alkyl substituted by R^8 , R^9 , -OR⁵, -CONR⁵R⁵, -NR⁵COR⁵ or -NR⁵R⁵.

Preferably, R^{12} is C₁-C₄ alkyl substituted by R^9 , -OR⁵, -NR⁵COR⁵ or -NR⁵R⁵.

Preferably, R^{12} is C₁-C₂ alkyl substituted by tetrahydrofuryl, -OCH₃, -NHCOCH₃ or -NH₂.

10 Preferably, R^{12} is -CH₂CH₂NH₂, -CH₂CH₂OCH₃, tetrahydrofuran-2-ylmethyl, -CH₂CH₂NHCOCH₃ or -CH₂OCH₃.

Preferably, R^{13} is phenyl substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl,

15 halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.


Preferably, R^{13} is phenyl substituted by halo, -CN, -CONR⁵R⁵, -SO₂NR⁵R⁵ or -OR⁵.

Preferably, R^{13} is phenyl substituted by fluoro, -CN, -CONH₂, -SO₂NH₂ or -OCH₃.

Preferably, R^{13} is 4-cyanophenyl, 3-cyanophenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-aminocarbonylphenyl or 4-aminosulphonylphenyl.

Preferred groups of compounds according to the invention include all combinations of the preferred definitions for individual substituents given above.

25 Also preferred according to the invention are the compounds of formula (I)



or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

30 R^1 is H, C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OC₃-C₇ cycloalkyl, said C₁-C₆ alkyl being optionally substituted by R^{15} ;

35 R^2 is H, C₁-C₃ alkyl, propenyl or C-linked R^{15} , said C₁-C₃ alkyl being optionally substituted by -OH, -OCH₃, -OCH₂CH₂NH₂, -CN, -CO₂CH₃, -CONH₂, -C(=NH)NH₂, -CONHNH₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHCH₂CH₂NHCOCH₃, -

35 NHCH₂CH₂OCH₃, -NHCH₂R¹⁵, -NHCOR¹⁵, -NHCOCH₂OCH₃, or R¹⁵

R^3 is C_1 - C_6 alkyl;

5 R^4 is phenyl optionally substituted by halo, -CN, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_7 cycloalkyl or C_1 - C_6 alkoxy; and

10 R^{15} is azetidinyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyridinyl or pyrimidinyl each being optionally substituted by -OH, -NH₂, oxo or C_1 - C_6 alkyl or -CO(C_1 - C_6 alkyl).

15 Preferred individual compounds according to the invention include the Examples below, particularly Examples 117, 118, 119, 120, 122, 123, 124, 125, 126, 127 and 128, and the pharmaceutically acceptable salts and solvates thereof.

20 All of the compounds of the formula (I) can be prepared by conventional routes such as the procedures described in the general methods presented below or by the specific methods described in the Examples section, or by similar methods thereto. The present invention also encompasses any one or more of these processes for preparing the compounds of formula (I), in addition to any novel intermediates used therein.

In the following general methods, R^1 , R^2 , R^3 and R^4 are as previously defined for a compound of the formula (I) unless otherwise stated.

25 Except where either R^1 or R^3 is halo, -OR⁸ or -CN, compounds of the formula (I) may be prepared using the route shown in Scheme 1 that follows.

In Scheme 1, compounds of the formula (I) may be prepared by the condensation of a compound of the formula (II) with a compound of the formula


30 H_2NNHR^2 (V),

or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of the formula (II) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the appropriate acid or base, at a temperature of from room temperature to the reflux



temperature of the solvent. In a preferred procedure, the reaction mixture is heated under reflux.

Scheme 1

5




10 Functional equivalents of compounds of the formula (II) may also be used in this reaction. These include compounds of the formula (VI) or (VII), in which L^1 and L^2 , respectively, are each suitable leaving groups, preferably $-N(C_1-C_6\text{ alkyl})_2$, most preferably $-N(CH_3)_2$.



15 Thus, a compound of the formula (I) may be prepared by the condensation of a compound of the formula (VI) or (VII) with a compound of the formula (V), or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of 20 the formula (VI) or (VII) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the

appropriate acid or base, at a temperature of from room temperature to the reflux temperature of the solvent. In a preferred procedure, the reaction mixture is heated under reflux. Compounds of the formula (VI) or (VII) are particularly suitable for the synthesis of compounds of the formula (I) in which R¹ or R³, 5 respectively, is H.

Compounds of the formula (VI) in which R¹ is H and L¹ is dimethylamino may be prepared by the reaction of a compound of the formula (VIII) with 10 dimethylformamide dimethylacetal at an elevated temperature, preferably at about 100°C. Compounds of the formula (VII) in which R¹ is H and L¹ is dimethylamino may be prepared by the reaction of a compound of the formula (IX) under the same conditions. Other compounds of the formula (VI) or (VII) in which L¹ or L² is dimethylamino may be prepared analogously.



15 Compounds of the formula (VIII) are either commercially available or may be prepared by the reaction of a compound of the formula




20 with a compound of the formula



25 In a typical procedure, a solution of the compound of the formula (XI) in a suitable solvent, such as acetone, is treated with a suitable base, such as caesium carbonate, and the compound of the formula (X). In a preferred procedure, the reaction mixture is heated, for example under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added

30 Compounds of the formula (IX) are either commercially available or may be prepared from a compound of the formula



and a compound of the formula (XI) in the same way that a compound of the formula (VIII) may be prepared from a compound of the formula (X).

5

Compounds of the formula (II) may be prepared by the reaction of a compound of the formula (III) with a compound of the formula (XI).

10

In a typical procedure, a solution of the compound of the formula (III) in a suitable solvent such as acetone is treated with a compound of the formula (XI) and a suitable base, such as potassium or caesium carbonate, and heated, preferably under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added.

15

Compounds of the formula (III) are either commercially available or may be prepared by the reaction of a compound of the formula (IV) with a chlorinating reagent. In a typical procedure, a cooled solution of the compound of the formula (IV) in a suitable solvent such as acetonitrile is treated first with tetrabutylammonium bromide and chlorotrimethylsilane and then dry dimethylsulphoxide. In another typical procedure, the compound of the formula (IV) is treated with sulphuryl chloride, optionally in the presence of a suitable solvent such as dichloromethane.


20

Compounds of the formula (I) in which R^1 or R^3 is $-OR^8$ may be prepared using the route shown in Scheme 2 that follows, in which R^a is C_1 - C_6 alkyl and L^3 is a suitable leaving group, preferably trifluoromethanesulphonate.

25

In Scheme 2, compounds of the formula (I) in which R^1 is $-OR^8$ may be prepared by the reaction of a compound of the formula (XIII) with an alcohol of the formula


30



35

in the presence of a suitable palladium catalyst and carbon monoxide. In a typical procedure a mixture of the compound of the formula (XIII), a suitable palladium catalyst such as 1,1'-bis(diphenylphosphino)ferrocenepalladium(II)chloride, the alcohol of the formula (XXI) and, optionally, a suitable solvent such as N,N-dimethylformamide is heated, preferably to about 50°C, under an atmosphere of carbon monoxide, preferably at a pressure of 345 kPa.

Scheme 2



5 Compounds of the formula (XIII) may be prepared by the derivatisation of a compound of the formula (XV). In the case where L^3 is trifluoromethanesulphonate a suitable derivatising agent is phenyltriflame. In a typical procedure, where L^3 is trifluoromethanesulphonate, a solution of the compound of the formula (XV) and a suitable base, preferably a trialkylamine base such as triethylamine, in a suitable solvent such as dichloromethane is treated with phenyltriflame.

10

Compound of the formula (XV) may be prepared by the reaction of a compound of the formula (XVII) with a compound of the formula (V), or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being

5 a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of the formula (XVII) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the appropriate acid or base, at a temperature of from room temperature to the reflux temperature of the solvent. In

10 a preferred procedure, the reaction mixture is heated under reflux.

Compounds of the formula (XVII) may be prepared by the reaction of a compound of the formula (XIX) with a compound of the formula (XI). In a typical procedure, a solution of the compound of the formula (XVII) in a suitable solvent

15 such as acetone is treated with a compound of the formula (XI) and a suitable base, such as potassium or caesium carbonate, and heated, preferably under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added.

20 In Scheme 2, compounds of the formula (I) in which R³ is -OR⁸ may be prepared from a compound of the formula (XX) in the same way that a compound of the formula (I) in which R¹ is -OR⁸ is prepared from a compound of the formula (XIX), as set out above, *mutatis mutandis*.

25 Chloroketoesters of the formula (XIX) and (XX) are either commercially available or may be prepared by the chlorination of the corresponding ketoesters, for instance using sulphonyl chloride.

30 Alternatively, compounds of the formula (I) in which R¹ or R³ is -OR⁸ may be prepared from compounds of the formula (XV) or (XVI), respectively, by reaction with a compound of the formula (XXI) under dehydrating conditions, e.g. using the Mitsunobu reaction. In a typical procedure, a solution of the compound of the formula (XV) or (XVI) in a suitable solvent, such as tetrahydrofuran is treated with diethylazodicarboxylate, triphenylphosphine and a compound of the formula (XXI).

Compounds of the formula (I) in which R¹ or R³ is halo can be prepared by the reaction, respectively, of a compound of the formula (XV) or a compound of the formula (XVI) with a suitable halogenating agent. In a typical procedure, the

compound of the formula (XV) or (XVI) is treated with POCl_3 , optionally in the presence of a suitable solvent such as dimethylformamide, to give a compound of the formula (I) in which R^1 or R^3 , respectively, is chloro.

5 It will be appreciated by those skilled in the art that, in many cases, compounds of the formula (I) may be converted into other compounds of the formula (I) by functional group transformations. For instance:

10 (a) compounds of the formula (I) in which R^2 is H may be converted into compounds of the formula (I) in which R^2 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl by reaction with an appropriate alkylating agent. In a typical procedure, a solution of a compound of the formula (I) in which R^2 is H in a suitable solvent such as ethanol or N,N-dimethylformamide is treated with an alkyl bromide and a base such as sodium ethoxide or sodium hydride and heated at a temperature of from 15 room temperature to the reflux temperature of the solvent. A preferred combination is N,N-dimethylformamide as the solvent, sodium hydride as the base and room temperature as the temperature. Examples of specific alkylating agents include bromoacetonitrile, ethyl 4-chloroacetoacetate, methyl bromoacetate and chloroethylamine hydrochloride. The use of further specific 20 alkylating agents is illustrated by the Examples below;

25 (b) compounds of the formula (I) in which R^1 , R^2 or R^3 contains an ester functionality may be reduced with a suitable reducing agent, such as lithium aluminium hydride, to give corresponding compounds of the formula (I) in which R^1 , R^2 or R^3 contains a hydroxy group. In a typical procedure, a solution of the compound of the formula (I), in which R^1 , R^2 or R^3 contains an ester group, in a suitable solvent, such as diethyl ether, is treated with lithium aluminium hydride, preferably with cooling to a temperature of from -78°C to 0°C;

30 (c) compounds of the formula (I) in which R^1 , R^2 or R^3 are substituted by a heterocycle of the formula R^6 may be prepared by standard heterocycle-forming reactions well known to the skilled man (see, for example, Advanced Organic Chemistry, 3rd Edition, by Gerry March or Comprehensive Heterocyclic Chemistry, A.R. Katritzky, C.W. Rees, E.F.V. Scriven, Volumes 1-11). For 35 instance, compounds of the formula (I) in which R^2 is (2-amino-6-hydroxypyrimidin-4-yl)methyl may be prepared by the sequential reaction of a compound of the formula (I) in which R^2 is H with chloroacetoacetate and then guanidine hydrochloride. This and other similar heterocycle-forming reactions are illustrated by the Examples below; and

(d) compounds of the formula (I) in which R¹ or R³ is -CO₂R⁵, wherein R⁵ is other than H, may be converted into compounds of the formula (I) in which R¹ or R³, respectively, is -CO₂H by hydrolysis. Typically the reaction will be carried out

5 in a suitable solvent, such as aqueous ethanol, or aqueous 1,4-dioxan and in the presence of a base such as sodium hydroxide. Such an acid may be converted to a primary amide by reaction with ammonia and a suitable coupling agent, such as a carbodiimide, e.g. dicyclohexylcarbodiimide. Such a primary amide may then be converted into a nitrile by dehydration with a suitable dehydrating agent,

10 such as phosphoryl chloride.

(e) compounds of the formula (I) in which R¹ or R³ is C₁-C₆ alkyl may be converted into the compounds of the formula (I) in which R¹ or R³, respectively, is C₁-C₆ alkyl substituted by halo (such as bromo), by halogenation, using a suitable

15 halogenating agent. Conveniently the reaction is effected in the presence of a solvent, such as a haloalkane (e.g. dichloromethane) and at ambient temperature. Suitable halogenating agents include halogens (e.g. bromine) or N-halosuccinimides (e.g. N-bromosuccinimide).

Compounds of the formula (I) containing an -OH, -NH- or -NH₂ group may be

20 prepared by the deprotection of the corresponding compound bearing an -OP¹, -NP¹- or -NHP¹ group, respectively, wherein the group P¹ is a suitable protecting group. Examples of suitable protecting groups will be apparent to the skilled person [see, for instance, 'Protecting groups in Organic Synthesis (Second Edition)' by Theodora W. Green and Peter G. M. Wuts, 1991, John Wiley and Sons]. Such compounds bearing an -OP¹, -NP¹- or -NHP¹ group may be

25 prepared using the routes described above, *mutatis mutandis*.

Compounds of the formula (IV), (V) and (XXI) are either commercially available or easily prepared by methods well known to those skilled in the art.

30 The compounds of the formula (I) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

35 For example, the compounds of the formula (I) can be administered orally, buccally or sublingually in the form of tablets, capsules, multi-particulates, gels, films, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or

controlled-release applications. The compounds of the formula (I) may also be administered as fast-dispersing or fast-dissolving dosage forms or in the form of a high energy dispersion or as coated particles. Suitable formulations of the compounds of the formula (I) may be in coated or uncoated form, as desired.

5

Such solid pharmaceutical compositions, for example, tablets, may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

15

General Example

A formulation of the tablet could typically contain from 0.01mg to 500mg of active compound whilst tablet fill weights may range from 50mg to 1000mg. An example of a formulation for a 10mg tablet is illustrated below:

20

<u>Ingredient</u>	<u>%w/w</u>
Compound of the formula (I) or salt	10.000*
Lactose	64.125
Starch	21.375
Croscarmellose sodium	3.000
Magnesium Stearate	1.500

* Quantity adjusted in accordance with drug activity.

30 The tablets are manufactured by a standard process, for example, direct compression or a wet or dry granulation process. The tablet cores may be coated with appropriate overcoats.

35 Solid compositions of a similar type may also be employed as fillers in gelatin or HPMC capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the formula (I) may be combined

with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

5 The compounds of the formula (I) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion or needleless injection techniques. For such parenteral administration they are best used in the form of
10 a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
15

For oral and parenteral administration to human patients, the daily dosage level of the compounds of the formula (I) will usually be from 0.01 to 30 mg/kg, preferably from 0.01 to 5 mg/kg (in single or divided doses).

20 Thus tablets or capsules of the compound of the formula (I) may contain from 1 to 500 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age,
25 weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will appreciate that, in the treatment of certain conditions the compounds of the formula (I) may be taken as a single dose as
30 needed or desired.

The compounds of formula (I) can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomiser or nebuliser, with or without the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be

determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray, atomiser or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan 5 trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the formula (I) and a suitable powder base such as lactose or starch.

Alternatively, the compounds of the formula (I) can be administered in the form of 10 a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the formula (I) may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.

15 They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a 20 benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin, the compounds of the formula (I) can be 25 formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for 30 example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldecanol, benzyl alcohol and water.

The compounds of the formula (I) may also be used in combination with a 35 cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a

carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

5 It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

Oral administration is preferred.

10 Included within the scope of the present invention are embodiments comprising the co-administration of a compound of the present invention with one or more additional therapeutic agents, and compositions containing a compound of the present invention along with one or more additional therapeutic agents. Such a combination therapy is especially useful for the prevention and/or treatment of
15 infection by HIV and related retroviruses which may evolve rapidly into strains resistant to any monotherapy. Alternatively, additional therapeutic agents may be desirable to treat diseases and conditions which result from or accompany the disease being treated with the compound of the present invention. For example, in the treatment of an HIV or related retroviral infection, it may be desirable to
20 additionally treat opportunistic infections, neoplasms and other conditions which occur as a result of the immuno-compromised state of the patient being treated.

25 Preferred combinations of the present invention include simultaneous or sequential treatment with a compound of the formula (I), as defined above, or a pharmaceutically acceptable salt thereof, and:

(a) one or more reverse transcriptase inhibitors such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and adefovir;
30 (b) one or more non-nucleoside reverse transcriptase inhibitors such as nevirapine, delavirdine and efavirenz;
(c) one or more HIV protease inhibitors such as indanavir, ritonavir, saquinavir and nelfinavir;
35 (d) one or more CCR5 antagonists such as TAK-779;
(e) one or more CXCR4 antagonists such as AMD-3100;
(f) one or more integrase inhibitors;
40 (g) one or more inhibitors of viral fusion such as T-20;
(h) one or more investigational drugs such as trizivir, KNI-272, amprenavir, GW-33908, FTC, PMPA, S-1153, MKC-442, MSC-204, MSH-372, DMP450, PNU-140690, ABT-378, KNI-764, DPC-083, TMC-120 or TMC-125; or

(i) one or more antifungal or antibacterial agents such as fluconazole.

The activity of the compounds of the invention as reverse transcriptase inhibitors and as agents for treating HIV infections may be measured using the following assays.

A. Inhibition of HIV-1 reverse transcriptase enzyme

The reverse transcriptase activity of the compounds of the invention may be assayed as following. Using the purified recombinant HIV-1 reverse transcriptase (RT, EC, 2.7.7.49) obtained by expression in Escherichia Coli, a 96-well plate assay system was established for assaying a large number of samples using either the Poly(rA)-oligo(dT) Reverse Transcriptase [³H]-SPA enzyme assay system (Amersham NK9020) or the [³H]-flashplate enzyme assay system (NEN - SMP 103) and following the manufacturer's recommendations. The compounds were dissolved in 100% DMSO and diluted with the appropriate buffer to a 5% final DMSO concentration. The inhibitory activity was expressed in percent inhibition relative to the DMSO control. The concentration at which the compound inhibited the reverse transcriptase by 50% was expressed as the IC₅₀ of the compound. The compounds of examples 7, 20 and 51, when tested according to the above procedure, had IC₅₀ values of, respectively, 39000, 3200 and 248 nanomolar.

B. Anti-Human Immunodeficiency Virus (HIV-1) cell culture assay

25 The anti-HIV activity of selected Examples of the invention was assayed by the following procedures.

1) SupT1 cells were cultured in an RPMI-1640 medium supplemented with 10% foetal calf serum and were split so that they were in growth phase on the day of use.

2) The compounds were dissolved in 100% DMSO and diluted with the above culture medium to predetermined concentrations and distributed in 20 μ l aliquots into a 96-well microtiter plate (0.1% DMSO final concentration).

3) To prepare infected cells, 100 μ l of RF viruses (TCID50 of 10^7 /ml) were added to 10^6 cells and incubated for 1 hour at 37°C. The cells were then washed twice in PBS and resuspended in the culture medium at a density of 2.2×10^5 cells/ml.

35 4) 180 μ l of these infected cells was transferred to wells of the 96 well plate containing the compounds.

5) The plate was incubated in a CO₂ incubator at 37°C for 4 days. The cell survival rates were measured following the manufacturer's recommendations (CellTiter 96[®] AQ_{ueous} Non-Radioactive Assay - Promega (cat no: G5430)). The

concentration at which the compound inhibited the cytotoxic effect of the virus by 50% was expressed as the EC₅₀.

Thus the invention provides:

- (i) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof;
- 5 (ii) a process for the preparation of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof;
- (iii) a pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, together with a pharmaceutically acceptable excipient, diluent or carrier;
- 10 (iv) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use as a medicament;
- (v) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use as a reverse transcriptase inhibitor or modulator;
- 15 (vi) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use in the treatment of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS);
- (vii) the use of a compound of the formula (I) or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity;
- 20 (viii) the use of a compound of the formula (I) or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a medicament for the treatment of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS);
- 25 (ix) a method of treatment of a mammal, including a human being, with a reverse transcriptase inhibitor or modulator including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof;
- 30 (x) a method of treatment of a mammal, including a human being, to treat an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS) including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof; and
- 35 (xi) certain novel intermediates disclosed herein.

The following Examples illustrate the preparation of the compounds of the formula (I). The synthesis of certain intermediates used therein are described in the Preparations section that follows the Examples.


5 ¹H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used: HRMS, high

10 resolution mass spectrometry; hplc, high performance liquid chromatography; nOe, nuclear Overhauser effect; m.p., melting point; CDCl₃, deuteriochloroform; D₆-DMSO, deuteriodimethylsulphoxide; CD₃OD, deuteromethanol. Where thin layer chromatography (TLC) has been used it refers to silica gel TLC using silica gel 60 F₂₅₄ plates, R_f is the distance travelled by a compound divided by the

15 distance travelled by the solvent front on a TLC plate.

EXAMPLE 1

2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanol



20

2-Hydroxyethyl hydrazine (21.5 μ L, 0.316mmol) was added to a stirred solution of the β -diketone of Preparation 1 (75mg, 0.287mmol) in ethanol (2.9ml) at room temperature under nitrogen and the resulting orange solution was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (20ml) and washed with 2M hydrochloric acid (10ml) and brine (10ml) and then dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a viscous orange oil. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (10:1, by volume) then dichloromethane to provide the title compound (32mg) as a white powder, m.p. 114-115°C.


¹H-NMR (400MHz, CDCl₃): δ = 2.08 (s, 3H), 2.10 (s, 3H), 3.30 (t, 1H), 4.06 (m, 4H), 6.79 (s, 2H), 7.01 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 301.

Microanalysis: Found: C, 51.76; H, 4.64; N, 9.20. C₁₃H₁₄Cl₂N₂O₂ requires C, 5 51.85; H, 4.69; N, 9.30%.

EXAMPLE 2

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol



10

3,5-Dichlorophenol (501mg, 3.07mmol), potassium carbonate (467mg, 3.38mmol) and finally sodium iodide (461mg, 3.07mmol) were added sequentially to a stirred solution of the chloroketone of Preparation 2 (500mg, 3.07mmol) in acetone (15ml), at room temperature and under nitrogen, producing an orange/red suspension. The mixture was heated under reflux for 22½ hours producing a yellow suspension. After cooling the mixture was diluted with water (10ml) and the acetone was removed under reduced pressure in a fumehood (caution: possible residual lachrymator). The residue was diluted with 2M hydrochloric acid and extracted with dichloromethane (1x20ml, 2x10ml). The combined organic layers were washed with brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave crude 4-(3,5-dichlorophenoxy)-3,5-heptanedione as an orange oil (777mg). A portion of the crude 4-(3,5-dichlorophenoxy)-3,5-heptanedione (250mg, ca. 0.865mmol) 15 was dissolved in ethanol (8.6ml) and treated with 2-hydroxethyl hydrazine (65µL, 0.951mmol). The resulting solution was heated under reflux for 16 hours producing a red solution. After cooling, the mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20ml). The resulting solution was washed with 2M hydrochloric acid (10ml), 1N sodium 20 hydroxide solution (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange oil (102mg). The crude product was purified by flash chromatography on silica gel 25


eluting with methanol:dichloromethane (5:95, by volume) to provide the title compound (23mg) as an orange oil which solidified to a waxy solid on standing.

¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.38 (q, 2H), 2.48 (q, 2H), 3.69 (br.s, 1H), 4.02 (m, 4H), 6.76 (s, 2H), 6.97 (s, 1H).
 5 LRMS (thermospray): m/z [MH⁺] 329.

EXAMPLE 3

4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole

10



A mixture of the chloroketone of Preparation 2 (5g, 30.8mmol), 3,5-dichlorophenol (5g, 30.8mmol), caesium carbonate (10g, 30.8mmol) and acetone (40ml) was heated under reflux for 18 hours. After cooling, a solid was removed by filtration and washed with dichloromethane (100ml). The combined filtrates were concentrated under reduced pressure. The crude product was dissolved in ethanol (20ml), hydrazine hydrate (1.5ml, 30.8mmol) was added and the mixture was heated at 60°C for 30 minutes under nitrogen. After cooling, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with ether:pentane (1:1, by volume) to provide the title compound (5.5g) as a yellow oil which solidified on standing to leave a yellow solid, m.p. 114-115°C.


25 $^1\text{H-NMR}$ (300MHz, CDCl_3): δ = 1.15 (6H, t), 2.48 (4H, q), 6.78 (2H, s), 6.95 (1H, s).

LRMS (thermospray): m/z [MH⁺] 285.

Microanalysis: Found: C, 54.93; H, 5.05; N, 9.94. $C_{13}H_{14}Cl_2N_2O$ requires C, 54.75; H, 4.95; N, 9.82%.

30

EXAMPLE 4


[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetonitrile

5

Sodium hydride (60% dispersion in oil, 470mg, 11.8mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole (3g, 10.5mmol, Example 3) in dry N,N-dimethylformamide (20ml) at 0°C under nitrogen. The mixture was stirred for 5 minutes during which time hydrogen was evolved and 10 then bromoacetonitrile (0.81ml, 11.6mmol) was added. The yellow solution turned dark brown and a precipitate formed. Further dry N,N-dimethylformamide (5ml) was added to aid dissolution and after 45 minutes the reaction mixture was quenched by the addition of water (1ml). The mixture was partitioned between water (150ml) and diethyl ether (2x150ml). The combined organic layers were 15 washed with water (50ml) and brine (100ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane to provide the title compound (3.2g) as a yellow powder, m.p. 70-72°C.

20 ¹H-NMR (400MHz, CDCl₃): δ = 1.14 (6H, m), 2.38 (2H, q), 2.56 (2H, q), 4.92 (2H, s), 6.75 (2H, s), 7.00 (1H, s).

Microanalysis: Found: C, 55.43; H, 4.69; N, 12.71. C₁₅H₁₅Cl₂N₃O requires C, 55.57; H, 4.60; N, 12.96%.

EXAMPLE 5**5-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-1H-pyrazol-3-ol**


5

A mixture of the ester (120mg, 0.29mmol) of Preparation 3, hydrazine hydrate (16mg, 0.29mmol) and ethanol (5ml) was stirred and heated at 60°C for 2 hours under nitrogen. After cooling, the mixture was concentrated under reduced pressure and the resulting white solid was stirred in ethyl acetate and then 10 collected by filtration to give the title compound (60mg) as a white solid, m.p. 142-144°C.

¹H-NMR (400MHz, DMSO-d₆): δ = 0.89 (3H, t), 0.99 (3H, t), 2.26 (2H, q), 2.45 (2H, q), 5.01 (2H, s), 5.19 (1H, s), 6.88 (2H, s), 7.21 (1H, s).

15 LRMS (electrospray): m/z [M-H⁺] 379.

Microanalysis: Found: C, 55.39; H, 4.72; N, 14.69. C₁₇H₁₈Cl₂N₄O₂ requires C, 53.56; H, 4.76; N, 14.69%.

EXAMPLE 6**6-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl]-2-methyl-4(3H)-pyrimidinone**


A mixture of the ester (140mg, 0.34mmol) of Preparation 3, acetamidine hydrochloride (95mg, 1.0mmol), sodium ethoxide (68mg, 1.0mmol) and ethanol (5ml) was stirred and heated at 70°C for 1 hour under nitrogen. After cooling, the mixture was concentrated under reduced pressure. The resulting oil was dissolved in dichloromethane (50ml), washed with water (20ml), dried over magnesium sulphate and concentrated under reduced pressure to leave the title compound as a white foam (100mg).

10 $^1\text{H-NMR}$ (300MHz, CDCl_3): δ = 1.10 (3H, t), 1.19 (3H, t), 2.48 (7H, m), 5.08 (2H, s), 5.72 (1H, s), 6.82 (2H, s), 7.03 (1H, s).

15 LRMS (thermospray): m/z $[\text{MH}^+]$ 407.

EXAMPLE 7

15 2-Amino-6-[(4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl)methyl]-4(3*H*)-pyrimidinone




20 A mixture of the ester (150mg, 0.365mmol) from Preparation 3 and guanidine hydrochloride (104mg, 1.08mmol) and sodium ethoxide (73mg, 1.08mmol) in ethanol (5ml) was stirred and heated at 70°C for 3 hours under nitrogen. After cooling the mixture was concentrated under reduced pressure and the resulting oil was dissolved in dichloromethane (50ml), washed with water (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:10:1, by volume) to give the title compound as a white solid (30mg), m.p. 238-240°C.

25

¹H-NMR (400MHz, DMSO-d₆): δ = 0.91 (3H, t), 0.99 (3H, t), 2.29 (2H, q), 2.44 (2H, q), 4.75 (1H, s), 4.81 (2H, s), 6.58 (2H, br.s), 6.87 (2H, s), 7.22 (1H, s).
LRMS (thermospray): m/z [MH⁺] 408.

5 EXAMPLE 8

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-*N*-hydroxyethanimidamide



10


Hydroxylamine hydrochloride (1.1g, 15.8mmol) and potassium carbonate (2.1g, 15.2mmol) were added to a suspension of the nitrile (1g, 3.1mmol) of Example 4 in a mixture of methanol (25ml) and water (10ml) which was then heated under reflux for 3 days. After cooling, the mixture was extracted with dichloromethane (2x250ml) and the combined organic layers were washed with brine (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to afford the product as a white solid (1.1g), m.p. 128-130°C.

15 ¹H-NMR (300MHz, CD₃OD): δ = 1.10 (6H, m), 2.40 (2H, q), 2.60 (2H, q), 4.65 (2H, s), 6.90 (2H, s), 7.10 (1H, s).
20 LRMS (electrospray): m/z [MH⁺] 357.

EXAMPLE 9

Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate

25



Methyl bromoacetate (984 μ L, 10mmol) and then sodium hydride (60% dispersion in oil, 801mg, 20.1mmol) were added to a stirred solution of the pyrazole (2.6g, 9.12mmol) of Example 3 in dry N,N'-dimethylformamide (25ml) at 0°C under nitrogen. After stirring for 1 hour at 0°C ice-water (100ml) was added and the mixture was extracted with ether (3x50ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (20:80, by volume) to provide the title compound (780mg) as a yellow oil which partly crystallised on standing.


¹H-NMR (400MHz, CDCl₃): δ = 1.10 (6H, m), 2.44 (4H, m), 3.78 (3H, s), 4.80 (2H, s), 6.69 (2H, s), 6.99 (1H, s).

LRMS (thermospray): m/z [MH⁺] 357.

15

EXAMPLE 10

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide



20

1,1'-Carbonyl diimidazole (71mg, 0.44mmol) was added to stirred solution of the acid (125mg, 0.36mmol) of Preparation 4 in dry N,N-dimethylformamide at room temperature and the reaction mixture was stirred for 30 minutes. Concentrated aqueous ammonia ($d=0.880\text{g/cm}^3$, ca. 0.1ml, ca. 1.8mmol) was added and stirring was continued for 10 minutes. The solvent was removed under reduced pressure and the residue was partitioned between water (10ml) and ethyl acetate (10ml). The organic layer was concentrated under reduced pressure and the residue was purified by chromatography on silica gel, eluting with ethyl acetate, to give the title compound as a white solid (60mg), m.p. 164-166°C.

25

¹H-NMR (300MHz, CDCl₃): δ = 1.15 (6H, m), 2.50 (4H, m), 4.70 (2H, s), 5.50 (1H, br. s), 6.21 (1H, br. s), 6.78 (2H, s), 7.04 (1H, s).


30

LRMS (thermospray): m/z [MH⁺] 342.

EXAMPLE 11

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetohydrazide

5




Hydrazine hydrate (520µL, 10.9mmol) was added to a solution of the ester (780mg, 2.18mmol) of Example 9 in ethanol (25ml) and the resulting mixture was
 10 heated under reflux for 18 hours. After cooling, the precipitate was collected by filtration and washed with ether (50ml) to afford the title compound (550g) as a white solid, m.p. >250°C.

¹H-NMR (300MHz, CD₃OD): δ = 1.10 (6H, m), 2.39 (2H, q), 2.55 (2H, q), 4.72
 15 (2H, s), 6.93 (2H, s), 7.09 (1H, s).
 LRMS (electrospray): m/z [MH⁺] 357.

EXAMPLE 12

5-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1,3,4-oxadiazol-
 20 2(*3H*)-one



A stirred solution of the hydrazide (275mg, 0.77mmol) of Example 11 and 1,1'-carbonyl diimidazole 187mg, 1.16mmol) in dioxane (50ml) was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50ml) and washed with water (25ml). The organic layer was dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to afford the title compound (112mg) as a white solid m.p. 138-142°C.


5

10 $^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.10 (6H, m), 2.40 (2H, q), 2.55 (2H, q), 5.07 (2H, s), 6.76 (2H, s), 6.98 (1H, s), 10.45 (1H, br. s).

15 LRMS (electrospray): m/z $[\text{MH}^+]$ 383.

EXAMPLE 13

15 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethylamine




20 A mixture of the pyrazole (390mg, 1.37mmol) of Example 3 and chloroethylamine hydrochloride (238mg, 2.05mmol) was stirred and heated at 150°C for 24 hours. After cooling, the mixture was partitioned between saturated aqueous sodium bicarbonate solution (100ml) and dichloromethane (2x50ml). The combined organic layers were washed with brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting brown oil was

25 purified by flash chromatography on silica gel eluting with dichloromethane:methanol (90:10, by volume) to afford the title compound (244mg) as a brown oil.

30 $^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.09 (6H, m), 2.41 (2H, q), 2.52 (2H, q), 3.18 (2H, t), 4.02 (2H, t), 6.78 (2H, s), 6.99 (1H, s).

LRMS (electrospray): m/z $[\text{MH}^+]$ 330.

Microanalysis: Found: C, 52.28; H, 5.70; N, 11.75. $\text{C}_{15}\text{H}_{19}\text{Cl}_2\text{N}_3\text{O} \cdot \text{H}_2\text{O}$ requires C, 52.03; H, 6.11; N, 12.14%.

EXAMPLE 143-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1,2,4-oxadiazol-5-ol


5

Ethylchloroformate (0.30ml, 3.08mmol) was added to a stirred solution of the amidoxime of Example 8 (500mg, 1.39mmol) in pyridine (8ml) at 0°C under nitrogen and the resulting solution was stirred for 10 minutes. The mixture was 10 concentrated under reduced pressure and the residue was dissolved in a mixture of water (4ml), tetrahydrofuran (4ml) and 1M aqueous sodium hydroxide solution (2ml). The mixture was heated under reflux for 1 hour, cooled to room temperature and stirred for a further 2 days. The resulting solution was diluted with 2M aqueous hydrochloric acid (20ml) and extracted with ethyl acetate (2x50ml). The combined organic layers were washed with brine (50ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a yellow oil. The oil was purified by flash column chromatography on silica 15 gel eluting with pentane:ethyl acetate (50:50, by volume) to yield a white solid. The solid was dissolved in a mixture of tetrahydrofuran (1ml) and 1M aqueous sodium hydroxide solution (10ml) and then heated under reflux for 24 hours. The resulting solution was diluted with 2M hydrochloric acid (20ml) and extracted with dichloromethane (2x50ml). The combined organic layers were washed with brine 20 (50ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to give the title compound (113mg) as a white solid m.p. 94-96°C.

25

¹H-NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 2.56 (m, 4H), 5.06 (s, 2H), 6.75 (s, 2H), 7.03 (s, 1H).

LRMS (electrospray): m/z [M-(H⁺)] 381.

EXAMPLE 155-{{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,3,4-oxadiazol-2-amine}


5

Cyanogen bromide (49mg, 0.462mmol) was added to a stirred solution of the hydrazide of Example 11 (150mg, 0.420mmol) in ethanol (30ml), at room temperature, under nitrogen and the resulting solution was heated to reflux for 2.5 hours. After cooling, the mixture was concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (98:1.75:0.25, by volume) to provide the title compound (71mg) as a white powder, m.p. 226-228°C.

15 $^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.00 (m, 6H), 2.29 (m, 2H), 2.55 (m, 2H), 5.34 (s, 2H), 6.90 (s, 2H), 7.07 (s, 2H), 7.24 (s, 1H).
 LRMS (electrospray): m/z $[\text{MH}^+]$ 382.
 Microanalysis: Found: C, 49.82; H, 4.52; N, 17.81. $\text{C}_{16}\text{H}_{17}\text{Cl}_2\text{N}_5\text{O}_2 \cdot 0.25\text{H}_2\text{O}$ requires C, 49.69; H, 4.56; N, 18.11%.

20

EXAMPLE 16 N -{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-methoxyacetamide




A solution of the pyrazole of Example 13 (53mg, 0.161mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (34mg, 0.178mmol) and 4-(dimethylamino)pyridine (22mg, 0.178mmol) in dichloromethane (1ml) was added to a stirred solution of methoxyacetic acid (14.2 μ L, 0.178mmol) in dichloromethane (1ml) at room temperature. The reaction was stirred for 12 hours and then concentrated under a stream of nitrogen to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (54mg) as a brown solid, m.p. 75-76°C.



¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.18 (t, 3H), 2.42 (q, 2H), 2.52 (q, 2H), 3.39 (s, 3H), 3.75 (m, 2H), 3.90 (s, 2H), 4.13 (t, 2H), 6.79 (s, 2H), 6.99 (s, 1H), 7.21 (br s, 1H).
 LRMS (electrospray): m/z [MH⁺] 400; [M-(H⁺)] 398.
 Microanalysis: Found: C, 54.09; H, 5.79; N, 10.39. C₁₈H₂₃Cl₂N₃O₃ requires C, 54.01; H, 5.79; N, 10.50%.


20 EXAMPLES 17 AND 18

The compounds of the following tabulated Examples of the general formula:



were prepared by a similar method to that of Example 16 using the appropriate acid starting material and the pyrazole of Example 13.

Example No.	R	LRMS (thermospray)	Analytical Data
17		m/z [MH ⁺] 433	¹ H-NMR (400MHz, CDCl ₃): δ = 1.06 (t, 3H), 1.18 (t, 3H), 2.44 (q, 2H), 2.52 (q, 2H), 3.92 (m, 2H), 4.24 (t, 2H), 6.79 (s, 2H), 6.99 (s, 1H), 7.40 (m, 1H), 7.82 (m, 1H), 8.19 (m, 1H), 8.52 (br s, 2H), 8.55 (m, 1H). Microanalysis: Found: C, 57.01; H, 5.08; N, 11.94. C ₂₁ H ₂₂ Cl ₂ N ₄ O ₂ requires C, 58.21; H, 5.12; N, 12.03%.
18		m/z [MH ⁺] 434	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.18 (t, 3H), 2.42 (q, 2H), 2.52 (q, 2H), 3.96 (m, 2H), 4.24 (t, 2H), 6.79 (s, 2H), 7.01 (s, 1H), 8.22 (br s, 1H), 8.54 (d, 1H), 8.78 (d, 1H), 9.40 (s, 1H).

EXAMPLE 193-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]benzonitrile


5

A mixture of the chloroketone of Preparation 2 (243mg, 1.50mmol), 3-cyanophenol (155mg, 1.50mmol), cesium carbonate (488mg, 1.50mmol) and acetone (10ml) was heated under reflux for 2 hours. After cooling, the solid was removed by filtration and the filtrate was concentrated under reduced pressure to leave a brown oil. The oil was dissolved in ethanol (10ml), hydroxyethylhydrazine (114mg, 1.50mmol) was added and the mixture was heated at 60°C for 18 hours. After cooling, the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (10ml) was washed with 2M aqueous hydrochloric acid (5ml) and water (5ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate to provide the title compound (80mg) as a colourless oil.

20 $^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.50 (q, 2H), 3.68 (br s, 1H), 4.07 (m, 4H), 7.12 (s, 1H), 7.14 (d, 1H), 7.28 (d, 2H).
 LRMS (electrospray): m/z $[\text{MH}^+]$ 286; $[\text{MNa}^+]$ 308.




EXAMPLES 20 TO 38



The compounds of the following tabulated Examples of the general formula:











25



were prepared by a similar method to that of Example 19 using the appropriate phenols and the chloroketone of Preparation 2.

Example No.	R ⁴	LRMS (electrospray)	Analytical Data
20		m/z [MH ⁺] 314.	¹ H-NMR (400MHz, CDCl ₃): δ = 0.99 (t, 3H), 1.09 (t, 3H), 2.18 (s, 6H), 2.25 (q, 2H), 2.40 (q, 2H), 3.78 (br s, 1H), 4.00 (m, 4H), 7.34 (s, 2H).
21		m/z [MH ⁺] 320.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.53 (q, 2H), 3.56 (br s, 1H), 4.04 (m, 2H), 4.08 (m, 2H), 6.80 (d, 1H), 7.44 (d, 1H), 7.72 (s, 1H). Accurate Mass: Found: 320.1165 [MH ⁺]; C ₁₆ H ₁₈ ClN ₃ O ₂ requires 320.1161 [MH ⁺].
22		m/z [MH ⁺] 304.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.50 (q, 2H), 4.60 (m, 4H), 7.05 (m, 1H), 7.14 (m, 2H).


Example No.	R ⁴	LRMS (electrospray)	Analytical Data
23		m/z [MH ⁺] 295.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (m, 6H), 2.41 (m, 2H), 2.51 (m, 2H), 3.78 (br s, 1H), 4.06 (m, 4H), 6.81 (m, 2H), 7.21 (m, 2H). Microanalysis: Found: C, 60.88; H, 6.49; N, 9.40. C ₁₅ H ₁₉ ClN ₂ O ₂ requires C, 61.12; H, 6.50; N, 9.50%.
24		m/z [MH ⁺] 295.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41, (q, 2H), 2.52 (q, 2H), 3.79 (br s, 1H), 4.05 (m, 4H), 6.78 (d, 1H), 6.88 (s, 1H), 6.98 (d, 1H), 7.19 (t, 1H).
25		m/z [MH ⁺] 295.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.15 (t, 3H), 2.44 (q, 2H), 2.54 (q, 2H), 4.02 (m, 2H), 4.09 (m, 2H), 6.69 (d, 1H), 6.94 (t, 1H), 7.10 (t, 1H), 7.40 (d, 1H).
26		m/z [MH ⁺] 329.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.01 (t, 3H), 1.10 (t, 3H), 2.38 (q, 2H), 2.49 (q, 2H), 3.84 (br s, 1H), 3.99 (m, 4H), 7.01 (t, 1H), 7.30 (d, 2H). Accurate Mass: Found: 329.0822 [MH ⁺]; C ₁₅ H ₁₈ Cl ₂ N ₂ O ₂ requires 329.0818 [MH ⁺].

Example No.	R ⁴	LRMS (electrospray)	Analytical Data
27		m/z [M-(H ⁺)] 328.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 4.03 (m, 2H), 4.07 (m, 2H), 6.60 (d, 1H), 7.04 (t, 1H), 7.10 (t, 1H).
28		m/z [M(H ⁺)] 329.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 4.03 (m, 2H), 4.08 (m, 2H), 6.62 (d, 1H), 7.09 (d, 1H). Microanalysis: Found: C, 54.66; H, 5.54; N, 8.12. C ₁₅ H ₁₈ Cl ₂ N ₂ O ₂ requires C, 54.72; H, 5.51; N, 8.51%.
29		m/z [M(H ⁺)] 279.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (t, 3H), 1.14 (t, 3H), 2.44 (q, 2H), 2.55 (q, 2H), 3.79 (br s, 1H), 4.06 (m, 4H), 6.71 (m, 1H), 6.98 (m, 2H), 7.12 (m, 1H).
30		m/z [M(H ⁺)] 279.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.12 (t, 3H), 2.43 (q, 2H), 2.52 (q, 2H), 3.78 (br s, 1H), 4.04 (m, 4H), 6.59 (m, 1H), 6.75 (m, 2H), 7.20 (m, 2H).

Example No.	R ⁴	LRMS (electrospray)	Analytical Data
31		m/z [MH ⁺] 289.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (t, 3H), 1.17 (t, 3H), 2.25 (s, 6H), 2.42 (q, 2H), 2.52 (q, 2H), 3.90 (br s, 1H), 4.05 (m, 4H), 6.49 (s, 2H), 6.62 (s, 1H).
32		m/z [MH ⁺] 293.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.22 (s, 3H), 2.42 (q, 2H), 2.31 (q, 2H), 3.83 (br s, 1H), 4.03 (m, 4H), 6.60 (m, 1H), 6.70 (m, 1H), 6.88 (m, 1H).
33		m/z [MH ⁺] 329.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.11 (t, 3H), 1.17 (t, 3H), 2.42 (q, 2H), 2.54 (q, 2H), 4.06 (m, 4H), 6.69 (s, 1H), 6.94 (d, 1H), 7.34 (d, 1H). Microanalysis: Found: C, 54.84; H, 5.67; N, 8.48. C ₁₅ H ₁₈ Cl ₂ N ₂ O ₂ requires C, 54.72; H, 5.51; N, 8.51%.
34		m/z [MH ⁺] 297.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (3, 3H), 1.12 (t, 3H), 2.42 (q, 2H), 2.50 (q, 2H), 3.68 (br s, 1H), 4.01 (m, 4H), 6.47 (m, 1H), 6.77 (m, 1H), 6.86 (m, 1H). Microanalysis: Found: C, 60.57; H, 6.23; N, 9.52. C ₁₅ H ₁₈ F ₂ N ₂ O ₂ requires C, 60.80; H, 6.12; N, 9.45%.

Example No.	R ⁴	LRMS (electrospray)	Analytical Data
35		m/z [MH ⁺] 329.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 3.73 (br s, 1H), 4.08 (m, 4H), 6.75 (d, 1H), 6.98 (s, 1H), 7.31 (d, 1H). Microanalysis: Found: C, 54.70; H, 5.54; N, 8.50. C ₁₅ H ₁₈ Cl ₂ N ₂ O ₂ requires C, 54.72; H, 5.51; N, 8.51%.
36		m/z [MH ⁺] 297.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.49 (q, 2H), 2.60 (q, 2H), 3.81 (br s, 1H), 3.99 (m, 4H), 6.91 (m, 2H), 6.99 (m, 1H).
37		m/z [MH ⁺] 297.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.15 (t, 3H), 2.45 (q, 2H), 2.55 (q, 2H), 3.70 (br s, 1H), 4.06 (m, 4H), 6.46 (m, 1H), 6.62 (m, 1H), 7.08 (m, 1H).
38		m/z [MH ⁺] 297.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.53 (q, 2H), 3.72 (br s, 1H), 4.05 (m, 4H), 6.43 (m, 3H).

EXAMPLE 39

4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1*H*-pyrazole

5

Sodium hydride (60% dispersion in oil, 34mg, 0.850mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole of Example 3 (200mg, 0.701mmol) and methoxyethyl bromide (117mg, 0.850mmol) in dry *N,N*-dimethylformamide (2ml) at 0°C under nitrogen. The mixture was stirred at 0°C for 45 minutes during which time hydrogen was evolved and the yellow solution turned dark brown. The reaction mixture was quenched by the addition of water (5ml) and the mixture concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20ml) and washed with water (10ml) and brine (10ml) and then dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:diethyl ether (80:20, by volume) to provide the title compound (140mg) as a colourless oil.

20 ¹H-NMR (300MHz, CDCl₃): δ = 1.09 - 1.15 (m, 6H), 2.41 - 2.49 (q, 2H), 2.51 - 2.57 (q, 2H), 3.34 (s, 3H), 3.74 - 3.78 (t, 2H), 4.15 - 4.17 (t, 2H), 6.81 (s, 2H), 7.01 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 343.

Microanalysis: Found: C, 56.25; H, 5.94; N, 7.95. C₁₆H₂₀Cl₂N₂O₂ requires C, 55.99; H, 5.87; N, 8.16%.



25


EXAMPLES 40 AND 41

The compounds of the following tabulated Examples of the general formula:



5 were prepared by a similar method to that of Example 39 using the appropriate halides and the pyrazole of Example 3.


Example No.	R ²	LRMS (thermospray)	Analytical Data
40		m/z [MH ⁺] 329.	¹ H-NMR (300MHz, CDCl ₃): δ = 1.13 - 1.18 (m, 6H), 2.45 (q, 2H), 2.60 (q, 2H), 3.37 (s, 3H), 5.34 (s, 2H), 6.80 (s, 2H), 7.02 (s, 1H). Microanalysis: Found: C, 54.72; H, 5.46; N, 8.40. C ₁₅ H ₁₈ Cl ₂ N ₂ O ₂ requires C, 54.72; H, 5.51; N, 8.51%.
41		m/z [MH ⁺] 299.	¹ H-NMR (300MHz, CDCl ₃): δ = 1.15 (m, 6H), 2.48 (m, 4H), 3.79 (s, 3H), 6.82 (s, 2H), 7.01 (s, 1H). Microanalysis: Found: C, 56.08; H, 5.37; N, 9.29. C ₁₄ H ₁₆ Cl ₂ N ₂ O requires C, 56.20; H, 5.39; N, 9.36%.

EXAMPLE 424-(3,5-Dichlorophenoxy)-3-ethyl-1*H*-pyrazole

5

A solution of the enamine of Preparation 6 (2.88g, 10.0mmol) and hydrazine hydrate (0.49ml, 10.0mmol) in ethanol (10ml) was heated under reflux for 12 hours. After cooling further hydrazine hydrate (0.49ml, 10.0mmol) was added and the reaction was heated under reflux for 3 hours. After cooling the mixture was 10 concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) and then cyclohexane:ethyl acetate (60:40, by volume) to provide the title compound (620mg) as a yellow oil.

15 ¹H-NMR (400MHz, CDCl₃): δ = 1.23 (t, 3H), 2.66 (q, 2H), 6.87 (s, 2H), 7.02 (s, 1H), 7.40 (s, 1H).
 LRMS (electrospray): m/z [MH⁺] 257; [M-(H⁺)] 255.

EXAMPLE 434-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}morpholine


25 Osmium tetroxide (1.00ml of a 2.5% w/v solution in *tert*-butanol) was added dropwise to a stirred solution of the pyrazole of Example 64 (3.00g, 9.23mmol) and sodium periodate (4.93g, 23.1mmol) in acetone (90ml) and water (30ml) at

room temperature. A white precipitate formed after 5 minutes and the suspension was stirred for a further 3 hours. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (300ml) and water (100ml) and the organic phase was 5 separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure to yield an intermediate aldehyde. An aliquot of the aldehyde (100mg, 0.305mmol) was dissolved in dichloromethane (5ml) and morpholine (30mg, 0.344mmol) and glacial acetic acid (17.1 μ L, 0.305mmol) were added. After stirring at room temperature for 5 minutes sodium triacetoxyborohydride 10 (95mg, 0.451mmol) was added in one portion and the reaction was stirred for 1 hour. After this time the resultant mixture was diluted with dichloromethane (20ml) and partitioned between water (30ml) and dichloromethane (20ml). The organic phase was washed with 2M aqueous sodium hydroxide solution (10ml), dried over magnesium sulphate, filtered and concentrated under reduced 15 pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (125mg) as a colourless oil.





20 1 H-NMR (400MHz, CDCl₃): δ = 1.06 (m, 6H), 2.12 (m, 8H), 2.75 (t, 2H), 3.64 (m, 4H), 4.04 (t, 2H), 6.73 (s, 2H), 6.95 (s, 1H).
 LRMS (thermospray): m/z [MH⁺] 398.
 Microanalysis: Found: C, 57.18; H, 6.31; N, 10.36. C₁₉H₂₅Cl₂N₃O₂ requires C, 57.29; H, 6.33; N, 10.55%.

25 **EXAMPLES 44 TO 49**

The compounds of the following tabulated Examples of the general formula:




30 were prepared by a similar method to that of Example 43 using the appropriate amine starting material and the pyrazole of Example 64.

Example No.	R	LRMS (thermospray)	Analytical Data
44		m/z [MH ⁺] 386.	¹ H-NMR (300MHz, CDCl ₃): δ = 1.09 - 1.17 (m, 6H), 2.40 - 2.47 (q, 2H), 2.50 - 2.56 (q, 2H), 2.80 - 2.82 (t, 2H), 3.07 - 3.11 (t, 2H), 3.36 (s, 3H), 3.47 - 3.51 (t, 2H), 4.09 - 4.11 (t, 2H), 6.81 (s, 2H), 7.01 (s, 1H).
45		m/z [MH ⁺] 439.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.04 (m, 6H), 2.00 (s, 3H), 2.38 (m, 6H), 2.44 (q, 2H), 2.77 (q, 2H), 3.38 (m, 2H), 3.55 (m, 2H), 4.05 (m, 2H), 6.71 (s, 2H), 6.92 (s, 1H).
46		m/z [MH ⁺] 356.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.05 (m, 6H), 2.23 (s, 6H), 2.38 (q, 2H), 2.45 (q, 2H), 2.69 (m, 2H), 4.03 (m, 2H), 6.75 (s, 2H), 6.95 (s, 1H).
47		m/z [MH ⁺] 413.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (m, 6H), 1.59 (br s, 1H), 1.91 (s, 3H), 2.38 (q, 2H), 2.48 (q, 2H), 2.71 (m, 2H), 2.99 (m, 2H), 3.28 (m, 2H), 4.02 (m, 2H), 6.09 (br s, 1H), 6.71 (s, 2H), 6.95 (s, 1H). Microanalysis: Found: C, 54.86; H, 6.32; N, 13.33. C ₁₉ H ₂₆ Cl ₂ N ₄ O ₂ requires C, 55.21; H, 6.34; N, 13.55%. m.p. 69-70°C.


Example No.	R	LRMS (thermospray)	Analytical Data
48		m/z [MH ⁺] 342.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (m, 7H), 2.39 (m, 2H), 2.42 (s, 3H), 2.49 (q, 2H), 3.00 (m, 2H), 4.05 (m, 2H), 6.78 (s, 2H), 6.96 (s, 1H).
49		m/z [MH ⁺] 412.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.05 (m, 6H), 1.49 (m, 1H), 1.81 (m, 4H), 2.42 (q, 2H), 2.52 (q, 2H), 2.64 (m, 2H), 3.08 (t, 2H), 3.76 (m, 1H), 3.79 (m, 1H), 4.00 (m, 1H), 6.78 (s, 2H), 6.98 (s, 1H). Microanalysis: Found: C, 57.78; H, 6.68; N, 9.90. C ₂₀ H ₂₇ Cl ₂ N ₃ O ₂ requires C, 58.13; H, 6.61; N, 10.17%.

EXAMPLE 50

3-{{4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl}methyl}morpholine

Sodium hydride (60% dispersion in oil, 37mg, 0.925mmol) was added to a stirred solution of the mesylate of Preparation 11 (273mg, 0.925mmol) and the pyrazole of Example 3 (220mg, 0.772mmol) in dry *N,N*-dimethylformamide (4ml) at 0°C under nitrogen. The mixture was heated at 50°C for 3 hours during which time the yellow solution turned dark brown. The reaction mixture was quenched by the addition of water (5ml) and the mixture was concentrated under reduced pressure. A solution of the residue in ethyl acetate (20ml) was washed with water (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in dichloromethane (3ml), trifluoroacetic acid (1ml) was added and the reaction was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (10ml) and washed with 1M aqueous hydrochloric acid (2x5ml). The combined aqueous phases were neutralised with solid sodium carbonate and extracted with ethyl acetate (3x20ml). The combined ethyl acetate layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (3mg) as a colourless oil.


¹H-NMR (400MHz, CDCl₃): δ = 1.15 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 2.89 (m, 2H), 3.30 (m, 2H), 3.58 (m, 1H), 3.78 (m, 2H), 3.87 (d, 2H), 6.88 (s, 2H), 7.00 (1H, s).
 LRMS (thermospray): m/z [MH⁺] 384.

EXAMPLE 511-(3-Azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole

Sodium hydride (60% dispersion in oil, 30mg, 0.750mmol) was added to a stirred solution of the pyrazole of Example 3 (200mg, 0.702mmol) and 1-benzhydryl-3-azetidinyl methanesulfonate (222mg, 0.702mmol) (see *J. Org. Chem.*, **1972**, *37*, 3953) in *N,N*-dimethylformamide (5ml) at 0°C under nitrogen. The mixture was heated at 50°C for 4 hours and then cooled to room temperature. The reaction mixture was quenched by the addition of water (30ml) and the aqueous mixture was extracted with ether (2x50ml). The combined organic phases were washed with water (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The oil was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the intermediate (60mg) as a yellow oil. The oil was dissolved in dichloromethane (5ml) and 1-chloroethylchloroformate (20µL, 0.182mmol) was added at room temperature under nitrogen. The mixture was heated under reflux for 4 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (5ml) and the resulting solution was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (17mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.16 (t, 3H), 2.48 (m, 4H), 3.87 (t, 2H), 4.40 (t, 2H), 5.07 (q, 1H), 6.79 (s, 2H), 7.01 (m, 1H).


LRMS (thermospray): m/z [MH⁺] 340.

EXAMPLE 527-(3,5-Dichlorophenoxy)-6-ethyl-2,3-dihydropyrazolo[5,1-*b*][1,3]oxazole

The triflate of Preparation 15 (282mg, 0.500mmol), tributylvinyltin (175 μ L, 0.600mmol), palladium dibenzylidene acetone (23mg, 0.025mmol), triphenyl arsine (12mg, 0.040mmol) and lithium chloride (64mg, 1.50mmol) were heated in *N,N*-dimethylformamide (3ml) at 80°C under nitrogen for 12 hours. The reaction was cooled to room temperature and partitioned between water (20ml) and ethyl acetate (20ml). The organic layer was washed with brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (34mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.16 (t, 3H), 2.45 (q, 2H), 4.29 (t, 2H), 5.03 (t, 2H), 6.89 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 299.

EXAMPLE 534-(3,5-Dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazole

A mixture of 3-chloro-2,4-pentanedione (5.00g, 37.0mmol), 3,5-dichlorophenol (6.03g, 37.0mmol), cesium carbonate (12.0g, 37.0mmol) and acetone (40ml) was heated under reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate concentrated under reduced pressure. The intermediate was dissolved in ethanol (30ml) and hydrazine hydrate (1.85g, 37.0mmol) was added and the mixture heated at 60°C for 30 minutes. After cooling the mixture was concentrated under reduced pressure and the residue purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (3.00g) as a yellow oil which solidified on standing to leave a yellow solid, m.p. 85-87°C.


¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 6H), 5.24 (br s, 1H), 6.81 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 257.

Microanalysis: Found: C, 49.58; H, 4.06; N, 11.05. C₁₁H₁₀Cl₂N₂O·0.4H₂O requires C, 49.98; H, 4.12; N, 10.60%.

EXAMPLE 54

1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-2-propanol




Osmium tetroxide (1.00ml of a 2.5% w/v solution in *tert*-butanol) was added dropwise to a stirred solution of the pyrazole of Example 64 (3.00g, 9.23mmol) and sodium periodate (4.93g, 23.1mmol) in acetone (90ml) and water (30ml) at room temperature. A white precipitate formed after 5 minutes and the suspension was stirred for a further 3 hours. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (300ml) and water (100ml) and the organic phase was separated, dried over

magnesium sulphate, filtered and concentrated under reduced pressure to yield the intermediate aldehyde. An aliquot of the aldehyde (250mg, 0.765mmol) was dissolved in tetrahydrofuran (5ml) and stored under nitrogen. In a separate flask, anhydrous cerium trichloride (377mg, 1.53mmol) was added to a stirred solution of methyl magnesium bromide (0.51ml of a 3M solution in ether, 1.53mmol) in tetrahydrofuran (5ml) at room temperature under nitrogen. The mixture was stirred at room temperature for 1.5 hours and the aldehyde in tetrahydrofuran was added dropwise. The mixture was stirred for 12 hours and the reaction was then quenched with 1M aqueous acetic acid at room temperature. The mixture was diluted with dichloromethane (20ml), washed with water (5ml) and brine (5ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (70:30, by volume) to provide the title compound (30mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.05 (t, 3H), 1.10 (t, 3H), 1.21 (d, 2H), 2.40 (q, 2H), 2.47 (q, 2H), 3.79 (dd, 1H), 3.97 (dd, 1H), 4.24 (s, 1H), 6.76 (s, 2H), 6.98 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 343.

EXAMPLE 55

2-[2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethoxy]ethanamine



Sodium hydride (60% dispersion in oil, 24mg, 0.600mmol) was added to a stirred solution of the pyrazole of Example 2 (100mg, 0.303mmol) in dry *N,N*-dimethylformamide (4ml) at 0°C under nitrogen. The mixture was stirred at 0°C for 30 minutes and 2-chloroethylamine hydrochloride (53mg, 0.455mmol) was added.


The reaction mixture was stirred at 0°C for 30 minutes and then stirred at room temperature for 30 minutes. The reaction was cooled to 0°C, further sodium hydride (60% dispersion in oil, 24mg, 0.600mmol) and 2-chloroethylamine hydrochloride (53mg, 0.455mmol) were added and the reaction was stirred for 1 hour. The reaction was quenched by the addition of water (5ml) and extracted with ether (10ml). The organic layer was washed with 2M aqueous hydrochloric acid (30ml). The acid was neutralised with solid sodium carbonate and extracted with ether (3x20ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (21mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.19 (m, 6H), 2.42 (q, 2H), 2.58 (q, 2H), 2.80 (t, 2H), 3.38 (t, 2H), 3.81 (t, 2H), 4.18 (t, 2H), 6.78 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 372.

EXAMPLE 56

4-{{4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}morpholine




Morpholine (140µL, 1.59mmol) was added in one portion to a stirred solution of the bromide of Preparation 8 (200mg, 0.531mmol) in isopropanol (4ml) at room temperature. The mixture was heated at 50°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate to provide the title compound (60mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 2.13 (s, 3H), 2.42 (m, 4H), 3.38 (s, 2H), 3.64 (m, 4H), 6.79 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 342.

EXAMPLE 57


4-(3,5-Dichlorophenoxy)-3-methyl-5-[(2-methyl-1*H*-imidazol-1-yl)methyl]-1*H*-pyrazole



Sodium hydride (60% dispersion in oil, 32mg, 0.800mmol) was added to a stirred solution of 2-methylimidazole (65mg, 0.800mmol) in *N,N*-dimethylformamide (5ml) at 0°C under nitrogen. The mixture was stirred for 10 minutes and then the bromide of Preparation 8 (100mg, 0.261mmol) was added and the reaction was stirred at room temperature for 1 hour. The reaction mixture was quenched by the addition of 1M aqueous sodium hydroxide solution (5ml) and the mixture was concentrated under reduced pressure. A solution of the residue in ethyl acetate (20ml) was washed with water (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (10mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 2.35 (s, 3H), 4.89 (s, 2H), 6.68 (s, 2H), 6.78 (s, 1H), 6.82 (s, 1H), 7.03 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 337.

EXAMPLE 582-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1*H*-pyrazol-1-yl]ethanol

The triflate of Preparation 15 (282mg, 0.500mmol) was dissolved in methanol (3ml) and 1,1'-bis(diphenylphosphino)ferrocenepalladium(II)chloride (18mg, 0.025mmol) was added in one portion at room temperature. The mixture was heated at 50°C under an atmosphere of carbon monoxide (345 kPa, 50 psi) for 10 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in a mixture of tetrahydrofuran (0.5ml), glacial acetic acid (1.0ml) and water (0.5ml) and stirred at room temperature for 12 hours. The solvent was removed under a stream of nitrogen to leave a yellow solid and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:acetonitrile (95:5, by volume) and then dichloromethane:acetonitrile (90:10, by volume) to provide the title compound (6mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 1.13 (t, 3H), 2.41 (q, 2H), 3.44 (br s, 1H), 3.94 (s, 3H), 4.23 (m, 4H), 6.87 (s, 2H), 7.09 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 331.

EXAMPLE 591-{[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}-1*H*-1,2,4-triazole

A suspension of the bromide of Preparation 8 (100mg, 0.264mmol), 1,2,4-triazole (92mg, 1.32mmol) and sodium carbonate (140mg, 1.32mmol) in toluene (5ml) was heated at 100°C for 12 hours. The suspension was cooled to room temperature and 1M aqueous sodium hydroxide solution (5ml) was added. The mixture was extracted with ethyl acetate (3x20ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (62mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.16 (s, 3H), 5.25 (s, 2H), 6.70 (s, 2H), 7.04 (s, 1H), 7.89 (s, 1H), 8.04 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 324.

EXAMPLE 603-[(3,5-Diethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

Hydrazine hydrate (153 μ L, 3.14mmol) was added to a stirred solution of the β -diketone of Preparation 9 (771mg, 3.14mmol) in ethanol (16ml) and the resulting solution was heated under reflux for 12 hours. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (75:25, by volume) to provide the title compound (712mg) as a yellow solid, m.p. 81-84°C.


1 H-NMR (400MHz, CDCl₃): δ = 1.15 (t, 6H), 2.47 (q, 4H), 7.11 (m, 2H), 7.24 (d, 1H), 7.35 (t, 1H).

LRMS (thermospray): m/z [MH⁺] 242.

Microanalysis: Found: C, 69.03; H, 6.43; N, 17.20. C₁₄H₁₅N₃O₃.0.13H₂O requires C, 69.02; H, 6.31; N, 17.25%.

EXAMPLE 61

3-[(1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy]benzonitrile




The pyrazole of Example 60 (200mg, 0.829mmol) and 2-chloroethylamine hydrochloride (144mg, 1.24mmol) were heated as a melt at 150°C for 17 hours. After cooling the solid was dissolved in saturated aqueous sodium hydrogencarbonate (15ml) and extracted with dichloromethane (2x10ml). The combined organic phases were washed with 2M aqueous hydrochloric acid (20ml) and the aqueous layer was neutralised with solid sodium carbonate and extracted with dichloromethane (3x10ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange gum. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (90:10) then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (124mg) as a pale yellow oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.41 (q, 2H), 2.52 (q, 2H), 3.18 (t, 2H), 4.04 (t, 2H), 7.15 (m, 2H), 7.29 (d, 1H), 7.38 (t, 1H).

LRMS (thermospray): m/z [MH⁺] 285.

EXAMPLE 62

2-[4-(3-Cyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide



A saturated solution of ammonia in methanol (2.3ml) was added to the ester of Example 63 (75mg, 0.229mmol) in a vial at room temperature then the vial was sealed and heated at 75°C for 17 hours. After cooling to room temperature the mixture was concentrated under reduced pressure to leave a cream solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane then dichloromethane:methanol (99:1, by volume) to provide the title compound (49mg) as a white solid, m.p. 159-160°C.


¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.17 (t, 3H), 2.44 (q, 2H), 2.53 (q, 2H), 4.69 (s, 2H), 5.44 (br s, 1H), 6.22 (br s, 1H), 7.14 (m, 2H), 7.31 (d, 1H), 7.40 (t, 1H).
LRMS (thermospray): m/z [MH⁺] 299.

Microanalysis: Found: C, 64.20; H, 6.12; N, 18.79. C₁₆H₁₈N₄O₂ requires C, 64.41; H, 6.08; N, 18.78%.

EXAMPLE 63

Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate

65




A solution of ethylhydrazinoacetate (88mg, 0.571mmol) in ethanol (2.0ml) was added to a stirred solution of the β -diketone of Preparation 9 (140mg, 0.571mmol) and triethylamine (88 μ L, 0.628ml) in ethanol (1.0ml) and the resulting solution was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20ml) and water (10ml). The organic layer was separated, washed with brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (75:25, by volume) and then ethyl acetate to provide the title compound (131mg) as a yellow oil.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.08 (m, 6H), 1.25 (t, 3H), 2.40 (m, 4H), 4.20 (q, 2H), 4.77 (s, 2H), 7.12 (m, 2H), 7.23 (d, 1H), 7.34 (t, 1H).

LRMS (thermospray): m/z [MH $^+$] 328.

EXAMPLE 64

1-Allyl-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole



Sodium hydride (60% dispersion in oil, 770mg, 19.2mmol) was added to a stirred solution of allyl bromide (1.70ml, 19.2mmol) and the pyrazole of Example 3 (5.00g,


17.5mmol) in *N,N*-dimethylformamide (20ml) at 0°C under nitrogen. The reaction was warmed to room temperature and stirred for 1 hour. The reaction mixture was quenched by the addition of water (100ml) and the aqueous phase was extracted with ether (2x50ml). The combined organic phases were washed with water (30ml) and brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (5.00g) as a yellow oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.46 (m, 4H), 4.65 (d, 2H), 5.04 (d, 1H), 5.22 (d, 1H), 5.99 (m, 1H), 6.79 (s, 2H), 6.99 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 325.

EXAMPLE 65

N-(4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl)-*N*-(4-methoxybenzyl)amine




4-Methoxybenzylamine (0.104ml, 0.800mmol) was added in one portion to a stirred solution of the bromide of Preparation 8 (100mg, 0.265mmol) in isopropanol (2ml) at room temperature. The mixture was heated at 50°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was diluted with diethyl ether (20ml), washed with saturated aqueous sodium hydrogen carbonate (5ml) and water (5ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (50mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.13 (s, 3H), 3.68 (s, 2H), 3.71 (s, 2H), 3.80 (s, 3H), 6.83 (m, 4H), 7.03 (s, 1H), 7.17 (m, 2H).





LRMS (thermospray): m/z [MH⁺] 392.

EXAMPLES 66 TO 75


The compounds of the following tabulated Examples of the general formula:



were prepared by a similar method to that of Example 65 using the appropriate amine starting material and the bromide of Preparation 8.

Example No.	R	LRMS (thermospray)	Analytical Data
66		m/z [MH ⁺] 326.	¹ H-NMR (300MHz, CDCl ₃): δ = 0.09 (m, 2H), 0.49 (q, 2H), 0.90 (m, 1H), 2.34 (s, 3H), 2.47 (d, 2H), 3.73 (s, 2H), 6.82 (s, 2H), 7.03 (s, 1H).
67		m/z [MH ⁺] 300.	¹ H-NMR (400MHz, CDCl ₃): δ = 2.08 (s, 3H), 2.20 (s, 6H), 3.31 (s, 2H), 6.76 (s, 2H), 6.97 (s, 1H).
68		m/z [MH ⁺] 286.	¹ H-NMR (400MHz, CDCl ₃): δ = 2.12 (s, 3H), 2.42 (s, 3H), 3.65 (s, 2H), 6.80 (s, 2H), 7.02 (s, 1H).
69		m/z [MH ⁺] 355.	¹ H-NMR (400MHz, CDCl ₃): δ = 2.08 (s, 3H), 2.22 (s, 3H), 2.31 (m, 8H), 3.36 (s, 2H), 6.76 (s, 2H), 6.97 (s, 1H).
70		m/z [MH ⁺] 385.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.50 (m, 2H), 1.60 (m, 2H), 1.90 (m, 4H), 2.41 (m, 2H), 3.25 (s, 2H), 3.75 (m, 2H), 5.52 (s, 1H), 5.80 (s, 1H), 6.67 (s, 2H), 6.86 (s, 1H).
71		m/z [MH ⁺] 330.	¹ H-NMR (400MHz, CDCl ₃): δ = 2.08 (s, 3H), 2.74 (m, 2H), 3.30 (s, 3H), 3.44 (m, 2H), 3.68 (s, 2H), 6.76 (s, 2H), 6.98 (s, 1H).
72		m/z [MH ⁺] 383.	¹ H-NMR (400MHz, CDCl ₃): δ = 2.02 (s, 3H), 2.10 (s, 3H), 2.38 (m, 4H), 3.34 (m, 2H), 3.38 (s, 2H), 3.51 (m, 2H), 6.76 (s, 2H), 6.98 (s, 1H).

73		m/z [MH ⁺] 357. ¹ H-NMR (400MHz, CDCl ₃): δ = 1.92 (s, 3H), 2.09 (s, 3H), 2.70 (m, 2H), 3.29 (m, 2H), 3.65 (s, 2H), 6.01 (s, 1H), 6.76 (s, 2H), 6.99 (s, 1H).
74		m/z [MH ⁺] 397. ¹ H-NMR (400MHz, CDCl ₃): δ = 1.30 (m, 2H), 1.80 (m, 2H), 1.92 (s, 3H), 2.09 (m, 5H), 2.70 (m, 2H), 3.34 (s, 2H), 3.71 (m, 1H), 6.76 (s, 2H), 6.98 (s, 1H).
75		m/z [MH ⁺] 370. ¹ H-NMR (300MHz, CDCl ₃): δ = 1.60 (m, 2H), 1.80 (m, 2H), 2.13 (s, 3H), 2.20 (m, 2H), 2.71 (m, 2H), 3.22 (m, 1H), 3.33 (s, 3H), 3.39 (s, 2H), 6.81 (s, 2H), 7.03 (s, 1H).


EXAMPLE 763-Chloro-5-[(3,5-dimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

Hydrazine hydrate (1.10ml, 21.9mol) was added to a stirred solution of the β -diketone of Preparation 16 (5.50g, 21.9mmol) in glacial acetic acid (22ml) and the resulting solution was stirred at room temperature for 14 hours. The mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:ethyl acetate (85:15, by volume) to provide the title compound (4.80g) as a yellow solid, m.p. 136-140°C.

¹H-NMR (400MHz, CDCl₃): δ = 2.09 (s, 6H), 7.02 (m, 1H), 7.10 (m, 1H), 7.25 (m, 1H).

LRMS (electrospray): m/z [MH⁺] 248.

Microanalysis: Found: C, 57.91; H, 4.03; N, 16.79. C₁₂H₁₀N₃OCl requires C, 58.19; H, 4.07; N, 16.97%.

EXAMPLE 773-[(5-(Aminomethyl)-3-methyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile


The bromide of Preparation 18 (300mg, 0.800mmol) was added to a saturated solution of ammonia in isopropanol (50ml) at 0°C. The reaction was stirred for 2 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (50ml). The dichloromethane solution was washed with 1M aqueous sodium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (220mg) as a white foam.

¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 3.79 (s, 2H), 7.08 (1H, s), 7.16 (1H, s), 7.31 (1H, s).

LRMS (thermospray): m/z [MH⁺] 263.

EXAMPLE 78

3-Chloro-5-[(3-methyl-5-(1-piperazinylmethyl)-1*H*-pyrazol-4-yl]oxy}benzonitrile




t-Butyl-1-piperazinecarboxylate (1.17g, 6.30mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (500mg, 1.40mmol) in isopropanol (20ml) at room temperature. The mixture was heated at 60°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in dichloromethane (100ml) and the resulting solution was washed with 1M aqueous sodium carbonate (20ml) and brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide a yellow foam. The foam was dissolved in dichloromethane (10ml), the resulting solution was cooled to 0°C and trifluoroacetic acid (2ml) was added. The reaction was allowed to warm to room temperature and stirred for 24 hours. The mixture was diluted with

dichloromethane (50ml), washed with 1M aqueous sodium carbonate (20ml) and brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (400mg) as a white foam.

¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 2.40 (m, 4H), 2.83 (m, 4H), 3.38 (s, 2H), 7.09 (s, 1H), 7.16 (s, 1H), 7.30 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 332.

EXAMPLE 79

3-Chloro-5-[(5-[(4-cyanobenzyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile




A mixture of 4-cyanobenzaldehyde (60mg, 0.460mmol), the amine of Example 77 (120mg, 0.460mmol), magnesium sulphate (500mg) and dichloromethane (5ml) was stirred under nitrogen at room temperature for 3 days. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with methanol:ethyl acetate (5:95, by volume) to provide a foam. The foam was dissolved in methanol (5ml), sodium borohydride (50mg, 1.31mmol) was added in one portion at room temperature and the reaction was stirred for 30 minutes. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20ml). The resulting solution was washed with 1M aqueous sodium carbonate solution (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (35mg) as a white foam.

¹H-NMR (300MHz, CDCl₃): δ = 2.15 (s, 3H), 3.69 (s, 2H), 3.84 (s, 2H), 7.06 (s, 1H), 7.15 (s, 1H), 7.31 (s, 1H), 7.38 (d, 2H), 7.60 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 378.

EXAMPLE 80


3-Chloro-5-[(3-methyl-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1*H*-pyrazol-4-yl)oxy]benzonitrile



Methanesulphonyl chloride (19μl, 0.240mmol) was added dropwise to a stirred solution of the amine of Example 78 (80mg, 0.240mmol) and triethylamine (45μL, 0.288mmol) in dichloromethane (3ml) at room temperature under nitrogen. The reaction was stirred for 30 minutes and then concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (65mg) as a white foam.

¹H-NMR (400MHz, CDCl₃): δ = 2.14 (s, 3H), 2.51 (m, 4H), 2.72 (s, 3H), 3.12 (m, 4H), 3.39 (s, 2H), 7.08 (m, 1H), 7.13 (m, 1H), 7.26 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 410.

EXAMPLE 813-Chloro-5-[(5-[(4-(methoxyacetyl)-1-piperazinyl]methyl]-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

N-Benzyl-*N*-cyclohexylcarbodiimide polymer bound (624mg of 1.3mmol/g, 0.480mmol) was added in one portion to a stirred solution of methoxyacetic acid (37μL, 0.480mmol) and the amine of Example 78 (80mg, 0.240mmol) in dichloromethane (5ml) at room temperature under nitrogen. The reaction was stirred for 1 hour and the polymer bound reagent was removed by filtration. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (45mg) as a white foam.

¹H-NMR (400MHz, CDCl₃): δ = 2.11 (s, 3H), 2.38 (m, 4H), 3.37 (m, 7H), 3.51 (m, 2H), 4.04 (s, 2H), 7.04 (m, 1H), 7.10 (m, 1H), 7.26 (m, 1H).

LRMS (thermospray): m/z [MH⁺] 404.

EXAMPLE 82Methyl 4-[(4-(3-chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]-1-piperazinecarboxylate


Methyl chloroformate (19 μ l, 0.240mmol) was added dropwise to a stirred solution of the amine of Example 78 (80mg, 0.240mmol) and triethylamine (45 μ l, 0.288mmol) in dichloromethane (5ml) at room temperature under nitrogen. The reaction was stirred for 90 minutes and then concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (55mg) as a white foam.

1 H-NMR (400MHz, CDCl₃): δ = 2.09 (s, 3H), 2.34 (m, 4H), 3.36 (m, 6H), 3.64 (s, 3H), 7.02 (m, 1H), 7.10 (m, 1H), 7.25 (m, 1H).

LRMS (thermospray): m/z [MH⁺] 390.

EXAMPLE 83

4-[(4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]amino]methyl]benzenesulfonamide




Triethylamine (125 μ l, 0.860mmol) was added in one portion to a stirred suspension of 4-aminomethylbenzenesulphonamide hydrochloride (144mg, 0.590mmol) and the bromide of Preparation 18 (100mg, 0.270mmol) in isopropanol (5ml) at room temperature under nitrogen. The reaction was heated at 70°C for 1 hour and then cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide a foam. The foam was further purified using a Phenomenex Luna C18 column eluting with diethylamine:methanol (0.1:99.1, by volume) to provide the title compound (8mg) as a white foam.

¹H-NMR (400MHz, CD₃OD): δ = 2.06 (s, 3H), 3.27 (s, 2H), 3.62 (s, 2H), 3.79 (s, 2H), 7.17 (s, 1H), 7.21 (s, 1H), 7.40 (m, 3H), 7.77 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 432.

EXAMPLE 84


4-(3,5-Dichlorophenoxy)-5-(methoxymethyl)-3-methyl-1*H*-pyrazole



Tetrakis(triphenylphosphine)palladium (60mg) was added in one portion to a stirred solution of the bromide of Preparation 8 (590mg, 1.56mmol) in methanol (20ml) and tetrahydrofuran (20ml) at room temperature. The mixture was heated at 80°C under an atmosphere of carbon monoxide (690kPa, 100psi) for 18 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in dichloromethane (100ml) and the resulting solution was washed with water (50ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with ether to provide the title compound (110mg) as a colourless oil.


¹H-NMR (400MHz, CDCl₃): δ = 2.15 (s, 3H), 3.34 (s, 3H), 4.35 (s, 2H), 6.83 (s, 2H), 7.03 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 287.

EXAMPLE 853-*tert*-Butyl-4-(3,5-dichlorophenoxy)-5-methyl-1*H*-pyrazole

A mixture of the dione of Preparation 19 (1.00g, 5.68mmol), 3,5-dichlorophenol (930mg, 5.68mmol), cesium carbonate (1.85g, 5.68mmol) and acetone (20ml) was heated at reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The intermediate was dissolved in ethanol (20ml), hydrazine hydrate (284mg, 5.68mmol) was added and the mixture was heated at 60°C for 1 hour. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (25:75, by volume) to provide the title compound (200mg) as a yellow oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.30 (s, 9H), 2.06 (s, 3H), 6.81 (s, 2H), 7.02 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 299.

EXAMPLE 864-(3,5-Dichlorophenoxy)-3-ethyl-5-methyl-1*H*-pyrazole


A mixture of the dione of Preparation 50 (4.50g, 30.8mmol), 3,5-dichlorophenol (5.00g, 30.8mmol), caesium carbonate (10.0g, 30.8mmol) and acetone (40ml) was heated at reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The intermediate was dissolved in ethanol (40ml), hydrazine hydrate (1.00ml, 30.8mmol) was added and the mixture was heated at 60°C for 1 hour. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (20:80, by volume) to provide the title compound (1.50g) as an orange oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.18 (t, 3H), 2.11 (s, 3H), 2.53 (q, 2H), 6.79 (s, 2H), 7.01 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 271.

EXAMPLE 87

4-Cyano-N-[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}benzamide




1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide (93mg, 0.490mmol) was added in one portion to a stirred solution of the amine of Example 109 (120mg, 0.440mmol) and 4-cyanobenzoic acid (71mg, 0.490mmol) in dichloromethane (5ml) at room temperature under nitrogen. The reaction was stirred for 20 minutes and then washed with 1M aqueous sodium hydroxide solution (10ml), 1M aqueous hydrochloric acid (10ml) and water (10ml). The organic layer was dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a yellow foam. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (110mg) as a white foam.

¹H-NMR (400MHz, CDCl₃): δ = 2.09 (s, 3H), 4.91 (d, 2H), 6.74 (s, 2H), 6.95 (s, 1H), 6.98 (d, 1H), 7.65 (d, 2H), 7.77 (d, 2H).

LRMS (thermospray): m/z [MNH₄⁺] 418.

EXAMPLE 88


3-Cyano-N-[(4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]benzamide



1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide (93mg, 0.490mmol) was added in one portion to a stirred solution of the amine of Example 109 (120mg, 0.440mmol) and 3-cyanobenzoic acid (71mg, 0.490mmol) in dichloromethane (5ml) at room temperature under nitrogen. The reaction was stirred for 10 minutes and then washed with 1M aqueous sodium hydroxide solution (10ml), 1M aqueous hydrochloric acid (10ml) and brine (10ml). The organic layer was dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a cream foam. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (100mg) as a white foam.

¹H-NMR (400MHz, CDCl₃): δ = 2.14 (s, 3H), 4.53 (d, 2H), 6.78 (s, 2H), 6.98 (m, 2H), 7.54 (dd, 1H), 7.76 (d, 1H), 7.95 (d, 1H), 7.99 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 401.

EXAMPLE 89*N-[(4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]-N-(3-pyridinylmethyl)amine*

A mixture of 3-pyridinecarboxaldehyde (55mg, 0.514mmol), the amine of Example 109 (140mg, 0.514mmol), magnesium sulphate (500mg) and dichloromethane (5ml) was stirred under nitrogen at room temperature for 18 hours. Sodium triacetoxyborohydride (163mg, 0.771mmol) was added in one portion and then acetic acid (3 drops) was added. After 5 minutes the mixture was filtered. The filtrate was washed with 1M aqueous sodium carbonate solution (10ml), water (10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (60mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 2.09 (s, 3H), 3.66 (s, 2H), 3.74 (s, 2H), 6.75 (s, 2H), 6.97 (s, 1H), 7.17 (m, 1H), 7.55 (d, 1H), 8.49 (m, 2H).


LRMS (electrospray): m/z [MH⁺] 363.

EXAMPLE 903-((5-[(4-Acetyl-1-piperazinyl)methyl]-3-methyl-1*H*-pyrazol-4-yl)oxy)-5-chlorobenzonitrile

N-Acetyl

¹H-NMR (300MHz, CDCl₃): δ = 2.08 (s, 3H), 2.16 (s, 3H), 2.43 (m, 4H), 3.42 (m, 4H), 3.55 (m, 2H), 7.08 (s, 1H), 7.16 (s, 1H), 7.31 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 374.


EXAMPLE 913-Chloro-5-[(5-[(4-cyanobenzyl)(methyl)amino]methyl]-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

The amine of Preparation 20 (127mg, 0.870mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (100mg, 0.271mmol) in isopropanol (5ml) at room temperature. The mixture was heated at 50°C for 12 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in 1M hydrochloric acid and the aqueous solution was washed with ethyl acetate (10ml). Solid sodium carbonate was added until effervescence ceased and the mixture was extracted with ethyl acetate (3x20ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (45mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 2.17 (s, 3H), 3.45 (s, 2H), 3.55 (s, 2H), 7.05 (s, 1H), 7.14 (s, 1H), 7.31 (m, 3H), 7.59 (d, 2H).
LRMS (thermospray): m/z [MH⁺] 392.

EXAMPLE 92

3-Chloro-5-[(5-[(4-cyanobenzyl)(2-hydroxyethyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile



The amine of Preparation 21 (153mg, 0.870mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (100mg, 0.271mmol) in isopropanol (5ml) at room temperature. The mixture was heated at 50°C for 12 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in 1M aqueous sodium hydroxide solution and the resulting solution was stirred at room temperature for 1 hour. The aqueous was extracted with ethyl acetate (3x20ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The


residue was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (20mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 2.71 (m, 2H), 3.50 (s, 1H), 3.58 (s, 2H), 3.67 (m, 2H), 3.72 (s, 2H), 6.99 (s, 1H), 7.09 (s, 1H), 7.31 (s, 1H), 7.41 (d, 2H), 7.58 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 422.

EXAMPLE 93


3-Chloro-5-((3-methyl-5-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-pyrazol-4-yl)oxy)benzonitrile



A suspension of the bromide of Preparation 18 (100mg, 0.264mmol), 2-methylimidazole (111mg, 1.35mmol) and sodium carbonate (143mg, 1.35mmol) in toluene (5ml) was heated at 100°C for 12 hours. The suspension was cooled to room temperature, 1M aqueous sodium hydroxide solution (5ml) was added and the mixture was stirred for 1 hour. The mixture was extracted with ethyl acetate (3x20ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a white solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (77mg) as a white solid, m.p. 212-214°C.


¹H-NMR (300MHz, CDCl₃): δ = 2.14 (s, 3H), 2.33 (s, 3H), 4.92 (s, 2H), 6.76 (s, 1H), 6.79 (s, 1H), 6.86 (s, 1H), 7.27 (s, 2H).

LRMS (thermospray): m/z [MH⁺] 328.

EXAMPLE 942-(4-(3,5-Dichlorophenoxy)-3-methyl-5-[(3-pyridinylmethyl)amino]methyl)-1*H*-pyrazol-1-yl)ethanol

Tetrabutylammonium fluoride (0.58ml of a 1.0M solution in tetrahydrofuran, 0.580mmol) was added in one portion to a stirred solution of the amine of Preparation 22 (150mg, 0.290mmol) in dichloromethane (5ml) at room temperature. The reaction was stirred for 12 hours and concentrated under reduced pressure to leave a colourless oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (100mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 2.07 (s, 3H), 3.65 (s, 2H), 3.76 (s, 2H), 3.96 (m, 2H), 4.24 (m, 2H), 6.76 (s, 2H), 7.02 (s, 1H), 7.26 (m, 1H), 7.59 (d, 1H), 8.50 (m, 2H).
LRMS (thermospray): m/z [MH⁺] 407.

EXAMPLE 955-[(3-Isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile


Hydrazine hydrate (110 μ l, 2.24mmol) was added to a stirred solution of the β -diketone of Preparation 24 (550mg, 2.04mmol) in glacial acetic acid (5ml) and the resulting solution was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (60:40, by volume) to provide the title compound (350mg) as a yellow solid, m.p. 142-144°C.

1 H-NMR (300MHz, CDCl₃): δ = 1.21 (d, 6H), 2.09 (s, 3H), 2.90 (sept, 1H), 7.40 (s, 2H), 7.60 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 267.

EXAMPLE 96

5-{[1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



Tetrabutylammonium fluoride (0.28ml of a 1.0M solution in tetrahydrofuran, 0.280mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 25 (60mg, 0.140mmol) in dichloromethane (5ml) at room temperature. The reaction was stirred for 12 hours and concentrated under reduced pressure to leave a colourless oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (20:80, by volume) to provide the title compound (30mg) as a white solid.


1 H-NMR (400MHz, CDCl₃): δ = 1.17 (d, 6H), 2.08 (s, 3H), 2.76 (sept, 1H), 3.52 (m, 2H), 4.10 (m, 2H), 7.40 (s, 2H), 7.59 (s, 1H).

LRMS (electrospray): m/z [MH⁺] 311.

Microanalysis: Found: C, 65.44; H, 5.87; N, 17.91. $C_{17}H_{18}N_4O_2$ requires C, 65.79; H, 5.85; N, 18.05%.

EXAMPLE 97

3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihdropyrazolo[1,5-*a*]pyrazin-4(5*H*)-one



Lithium diisopropylamide (18.0ml of a 1.5M solution in cyclohexane, 27.0mmol) was added dropwise to a stirred solution of the pyrazole of Preparation 26 (12.3g, 24.6mmol) in tetrahydrofuran (120ml) at -78°C under nitrogen. The reaction was stirred for 14 hours, slowly warming to room temperature, and cautiously quenched with saturated aqueous ammonium chloride solution (20ml). The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (200ml). The resulting solution was washed with saturated aqueous ammonium chloride solution (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a white solid. The solid was triturated with a mixture of dichloromethane and pentane (100ml and 100ml) to give the title compound (2.63g) as a white solid, m.p. 220-223°C.

1H -NMR (400MHz, D_6 DMSO): δ = 1.08 (t, 3H), 2.44 (q, 2H), 3.60 (m, 2H), 4.24 (t, 2H), 7.00 (s, 2H), 7.26 (s, 1H), 8.15 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 343.

Microanalysis: Found: C, 51.52; H, 3.98; N, 12.74. $C_{14}H_{31}Cl_2N_3O_2$ requires C, 51.55; H, 4.02; N, 12.88%.


EXAMPLE 983-(3,5-Dichlorophenoxy)-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

Borane (2.00ml of a 1.0M solution in tetrahydrofuran, 2.00mmol) was added to a stirred solution of the pyrazole of Example 97 (326mg, 1.00mmol) in tetrahydrofuran (10ml) at room temperature under nitrogen. The reaction was heated under reflux for 5 hours and further borane (3.00ml of a 1.0M solution in tetrahydrofuran, 3.00mmol) was added. The reaction was heated under reflux for 14 hours and further borane (2.00ml of a 1.0M solution in tetrahydrofuran, 2.00mmol) was added. The reaction was heated under reflux for 3 hours and further borane (2.00ml of a 1.0M solution in tetrahydrofuran, 2.00mmol) was added. The mixture was cooled to room temperature, 2M hydrochloric acid (10ml) was added and the mixture was heated under reflux for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in dichloromethane (40ml), washed with 1M aqueous potassium carbonate solution (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume), then dichloromethane:methanol (95:5, by volume) and then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (219mg) as a white solid, m.p. 76-77°C.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 2.42 (q, 2H), 3.24 (t, 2H), 3.80 (s, 2H), 4.05 (t, 2H), 6.76 (s, 2H), 6.95 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 312.

Microanalysis: Found: C, 53.79; H, 4.88; N, 13.14. C₁₄H₁₅Cl₂N₃O requires C, 53.86; H, 4.84; N, 13.46%.

EXAMPLE 993-(3,5-Dichlorophenoxy)-2-ethyl-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

Methyl iodide (11 μ l, 0.176mmol) was added to a stirred solution of potassium carbonate (24mg, 0.176mmol) and the amine of Example 98 (50mg, 0.160mmol) in *N,N*-dimethylformamide (2ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20ml), washed with 1M aqueous potassium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (18mg) as a colourless oil.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.11 (t, 3H), 2.42 (m, 5H), 2.84 (t, 2H), 3.37 (s, 2H), 4.11 (t, 2H), 6.77 (s, 2H), 6.98 (s, 1H).
 LRMS (thermospray): m/z [MH $^+$] 326.


EXAMPLE 1004-[(3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methyl]benzonitrile

4-Cyanobenzylbromide (35mg, 0.176mmol) was added to a stirred solution of potassium carbonate (24mg, 0.176mmol) and the amine of Example 98 (50mg, 0.160mmol) in *N,N*-dimethylformamide (2ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (15ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (66mg) as a white solid, m.p. 149-150°C.

¹H-NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 2.44 (q, 2H), 2.92 (t, 2H), 3.42 (s, 2H), 3.71 (s, 2H), 4.13 (t, 2H), 6.74 (s, 2H), 6.97 (s, 1H), 7.42 (d, 2H), 7.60 (d, 2H).
LRMS (thermospray): m/z [MH⁺] 427.

EXAMPLE 101

3-(3,5-Dichlorophenoxy)-2-ethyl-5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine



4-Methoxybenzylchloride (24μl, 0.176mmol) was added to a stirred solution of potassium carbonate (24mg, 0.176mmol) and the amine of Example 98 (50mg, 0.160mmol) in *N,N*-dimethylformamide (6ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then potassium carbonate (12mg, 0.088mmol) and 4-methoxybenzylchloride (12μl, 0.088mmol) added. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified


by flash column chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (50mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 2.45 (q, 2H), 2.92 (t, 2H), 3.44 (s, 2H), 3.60 (s, 2H), 3.80 (s, 3H), 4.10 (t, 2H), 6.77 (s, 2H), 6.85 (d, 2H), 7.00 (s, 1H), 7.23 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 432.

EXAMPLE 102

[1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-yl]methanol




Hydrogen chloride (0.50ml of a 4.0M solution in dioxane, 2.00mmol) was added to a stirred solution of the pyrazole of Example 135 (86mg, 0.200mmol) in dioxane (0.5ml) at room temperature under nitrogen. The reaction was stirred for 24 hours and concentrated under reduced pressure. The residue was dissolved in dichloromethane (20ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (40mg) as a white solid, m.p. 105-107°C.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 2.42 (q, 2H), 2.55 (s, 2H), 3.13 (t, 2H), 4.13 (t, 2H), 4.37 (s, 2H), 6.79 (s, 2H), 6.98 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 330.

Microanalysis: Found: C, 50.61; H, 5.23; N, 12.31. C₁₄H₁₇Cl₂N₃O₂ requires C, 50.92; H, 5.19; N, 12.73%.

EXAMPLE 1032-[4-(3,5-Dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine


Hydrogen chloride (0.50ml of a 4.0M solution in dioxane, 2.00mmol) was added to a stirred solution of the pyrazole of Example 136 (60mg, 0.130mmol) in dioxane (0.5ml) at room temperature under nitrogen. The reaction was stirred for 2 days and concentrated under reduced pressure. The residue was dissolved in dichloromethane (20ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (99:9:1, by volume) to provide the title compound (32mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.42 (q, 2H), 3.15 (t, 2H), 3.40 (q, 2H), 4.11 (t, 2H), 4.29 (s, 2H), 6.79 (s, 2H), 6.98 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 358.


EXAMPLES 104 TO 106

The compounds of the following tabulated Examples of the general formula:



were prepared by a similar method to that of Example 103 using the appropriate starting material.


Example No. (Starting material)	R	LRMS (thermospray)	Analytical Data
104 (Example 140)		m/z [MH ⁺] 380.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (t, 3H), 2.40 (q, 2H), 2.97 (t, 2H), 4.15 (t, 2H), 5.20 (s, 2H), 6.16 (s, 1H), 6.71 (d, 2H), 6.97 (s, 1H), 7.15 (s, 1H), 7.42 (s, 1H). Microanalysis: Found: C, 52.78; H, 5.09; N, 17.86. C ₁₇ H ₁₉ Cl ₂ N ₅ O.0.12CH ₂ Cl ₂ requires C, 52.66; H, 4.97; N, 17.94%.
105 (Example 142)		m/z [MH ⁺] 449.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (t, 3H), 2.42 (q, 2H), 3.11 (t, 2H), 3.55 (s, 2H), 3.60 (s, 2H), 3.75 (s, 3H), 4.07 (t, 2H), 6.73 (s, 2H), 6.79 (d, 2H), 6.97 (s, 1H), 7.10 (d, 2H). Microanalysis: Found: C, 56.88; H, 5.67; N, 11.88. C ₂₂ H ₂₆ Cl ₂ N ₄ O ₂ .0.23CH ₂ Cl ₂ requires C, 56.94; H, 5.69; N, 11.95%.
106 (Example 143)		m/z [MH ⁺] 444.	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (t, 3H), 2.41 (q, 2H), 3.15 (t, 2H), 3.60 (s, 2H), 3.74 (s, 2H), 4.10 (d, 2H), 6.73 (s, 2H), 6.97 (s, 1H), 7.29 (d, 2H), 7.53 (d, 2H). Microanalysis: Found: C, 57.53; H, 5.09; N, 15.05. C ₂₂ H ₂₃ Cl ₂ N ₅ O.0.22CH ₂ Cl ₂ requires C, 57.64; H, 5.10; N, 15.12%.

EXAMPLE 107**2-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine**

Trifluoroacetic acid (1ml) was added to a stirred solution of the pyrazole of Example 139 (150mg, 0.28mmol) in dichloromethane (2ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (20ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (103mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 2.05 (s, 3H), 2.32 (m, 4H), 2.42 (q, 2H), 3.13 (m, 2H), 3.33 (s, 2H), 3.34 (m, 2H), 3.52 (m, 2H), 4.15 (t, 2H), 6.73 (s, 2H), 6.97 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 440.

EXAMPLE 108 N -(2-((1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-yl)methyl)amino)ethyl]acetamide

Trifluoroacetic acid (1ml) was added to a stirred solution of the pyrazole of Example 141 (122mg, 0.24mmol) in dichloromethane (2ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (50ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (64mg) as a colourless oil.


$^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.15 (t, 3H), 1.95 (s, 3H), 2.45 (q, 2H), 2.69 (t, 2H), 3.20 (t, 2H), 3.27 (m, 2H), 3.65 (s, 2H), 4.15 (t, 2H), 6.31 (s, 1H), 6.81 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z $[\text{MH}^+]$ 414.

EXAMPLE 109[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methanamine hydrobromide

The bromide of Preparation 8 (500mg, 1.30mmol) was added portionwise to a saturated solution of ammonia in isopropanol (50ml) at 0°C. The reaction was stirred for 2 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting solid was triturated with diethyl ether to provide the title compound (340mg) as a white solid.

¹H-NMR (400MHz, CDCl₃): δ = 2.38 (s, 3H), 4.78 (s, 2H), 6.88 (s, 2H), 7.19 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 272.

EXAMPLE 110*N*-{[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}-*N*-(4-fluorobenzyl)amine

Sodium triacetoxyborohydride (36mg, 0.160mmol) was added in one portion to a stirred solution of the pyrazole of Example 109 (150mg, 0.400mmol), 4-fluorobenzaldehyde (11mg, 0.080mmol) and acetic acid (3 drops) in dichloromethane (15ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The crude


product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (6mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.17 (s, 3H), 3.67 (s, 2H), 3.73 (s, 2H), 6.81 (s, 2H), 6.99 (s, 2H), 7.02 (s, 1H), 7.22 (s, 2H).

LRMS (electrospray): m/z [M-H⁺] 378.

EXAMPLE 111


4-[(4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]amino)methyl]benzonitrile



Sodium triacetoxyborohydride (216mg, 1.09mmol) was added in one portion to a stirred solution of the pyrazole of Example 109 (300mg, 0.850mmol), 4-cyanobenzaldehyde (111mg, 0.850mmol) and acetic acid (3 drops) in dichloromethane (25ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then washed with 1M aqueous sodium carbonate solution (2x10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (10mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.16 (s, 3H), 3.70 (s, 2H), 3.85 (s, 2H), 6.78 (s, 2H), 7.01 (s, 2H), 7.35 (d, 2H), 7.58 (d, 2H).

LRMS (electrospray): m/z [MH⁺] 387.


EXAMPLE 1123-Chloro-5-[(1,3,5-trimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

Methyl hydrazine (250mg, 5.17mol) was added to a stirred solution of the β -diketone of Preparation 16 (1.00g, 3.97mmol) in glacial acetic acid (10ml) and the resulting solution was stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure and the resulting orange oil was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (500mg) as a white solid, m.p. 114-116°C.

$^1\text{H-NMR}$ (300MHz, CDCl_3): δ = 1.85 (s, 3H), 1.87 (s, 3H), 3.61 (s, 3H), 6.88 (s, 1H), 6.98 (s, 1H), 7.11 (s, 1H).

LRMS (thermospray): m/z $[\text{MH}^+]$ 262.

Microanalysis: Found: C, 59.48; H, 4.60; N, 15.88. $\text{C}_{13}\text{H}_{12}\text{N}_3\text{OCl}$ requires C, 59.66; H, 4.62; N, 16.06%.


EXAMPLE 1133-Chloro-5-[(5-[(4-cyanobenzyl)amino]methyl)-1,3-dimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

4-Cyanobenzylamine (155mg, 1.17mmol) was added in one portion to a stirred solution of the bromide of Example 144 (100mg, 0.300mmol) in isopropanol (10ml) at room temperature. The mixture was heated at 50°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (97mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.03 (s, 3H), 3.66 (s, 2H), 3.79 (s, 2H), 3.84 (s, 3H), 7.02 (s, 1H), 7.13 (s, 1H), 7.31 (s, 1H), 7.37 (d, 2H), 7.58 (d, 2H).
LRMS (thermospray): m/z [MH⁺] 392.

EXAMPLE 114


3-Chloro-5-[(1-(2-hydroxyethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]oxy}benzonitrile



2-Hydroxyethyl hydrazine (1.80g, 24.0mol) was added to a stirred solution of the β -diketone of Preparation 16 (5.80g, 23.0mmol) in glacial acetic acid (30ml) and the resulting solution was stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure and the resulting brown oil was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (4.80g) as a yellow solid, m.p. 114-116°C.


¹H-NMR (300MHz, CDCl₃): δ = 2.04 (s, 3H), 2.12 (s, 3H), 3.24 (s, 1H), 4.08 (m, 4H), 7.03 (s, 1H), 7.15 (s, 1H), 7.28 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 292.

Microanalysis: Found: C, 57.40; H, 4.86; N, 14.14. C₁₄H₁₄N₃O₂Cl requires C, 57.69; H, 4.84; N, 14.40%.

EXAMPLE 1153-Chloro-5-{{5-[(4-cyanobenzyl)amino]methyl}-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazol-4-yl}oxy}benzonitrile

4-Cyanobenzylamine (131mg, 0.910mmol) was added to a stirred solution of the pyrazole of Preparation 30 (120mg, 0.240mmol) in *N*-methylpyrrolidine (10ml) and the resulting solution was heated at 60°C for 3 hours. The mixture was concentrated under reduced pressure and the resulting brown oil was dissolved in acetic acid (10ml) and heated at 40°C for 6 hours. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (5mg) as a white solid.

¹H-NMR (300MHz, CDCl₃): δ = 2.05 (s, 3H), 3.04 (s, 2H), 3.91 (s, 2H), 3.99 (t, 2H), 4.32 (m, 2H), 7.06 (s, 1H), 7.11 (s, 1H), 7.33 (s, 1H), 7.46 (d, 2H), 7.62 (d, 2H).
LRMS (thermospray): m/z [MNa⁺] 444.


EXAMPLE 1164-{{[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}amino}methyl]benzamide

The amine of Preparation 55 (150mg, 0.800mmol) was added to a stirred solution of the pyrazole of Preparation 18 (100mg, 0.270mmol) and triethylamine (81mg, 0.800mmol) in isopropanol (10ml) and *N,N*-dimethylformamide (5ml) and the resulting solution was heated at 60°C for 3 hours. The mixture was concentrated under reduced pressure and the resulting brown oil was dissolved in ethyl acetate (20ml). The solution was washed with 1M aqueous sodium carbonate solution (2x10ml) and brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (5mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 2.16 (s, 3H), 3.68 (s, 2H), 3.82 (s, 2H), 7.05 (s, 1H), 7.13 (s, 1H), 7.28 (s, 1H), 7.32 (d, 2H), 7.76 (d, 2H).
LRMS (electrospray): m/z [MH⁺] 396.

EXAMPLES 117 TO 120

The compounds of the following tabulated Examples of the general formula:




were prepared by a similar method to that of Example 114 using the appropriate diketone starting material and 2-hydroxyethylhydrazine.

Example No. (Diketone No.)	R	LRMS	Analytical Data
117 (Preparation 43)	F	m/z [MH ⁺] 303. (thermospray)	¹ H-NMR (300MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.49 (q, 2H), 4.04 (m, 4H), 6.85 (dd, 1H), 6.99 (s, 1H), 7.00 (dd, 1H). Microanalysis: Found: C, 62.96; H, 5.94; N, 13.75. C ₁₆ H ₁₈ N ₃ O ₂ F requires C, 63.35; H, 5.98; N, 13.85%.
118 (Preparation 44)	Me	m/z [MH ⁺] 300. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.12 (t, 3H), 2.34 (s, 3H), 2.39 (q, 2H), 2.50 (q, 2H), 3.70 (s, 1H), 4.60 (m, 4H), 6.91 (s, 1H), 6.97 (s, 1H), 7.10 (s, 1H).
119 (Preparation 45)	CN	m/z [MH ⁺] 311. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.13 (m, 6H), 2.40 (q, 2H), 2.53 (q, 2H), 3.53 (m, 1H), 4.11 (m, 4H), 7.40 (s, 2H), 7.58 (s, 1H). Microanalysis: Found: C, 65.64; H, 5.84; N, 18.05. C ₁₇ H ₁₈ N ₄ O ₂ requires C, 65.79; H, 5.85; N, 18.05%.
120 (Preparation 46)	Cl	m/z [MH ⁺] 320. (thermospray)	m.p. 120-121°C. ¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (m, 6H), 2.39 (q, 2H), 2.50 (q, 2H), 4.01 (m, 2H), 4.08 (m, 2H), 7.03 (s, 1H), 7.13 (s, 1H), 7.24 (s, 1H). Microanalysis: Found: C, 59.67; H, 5.71; N, 12.99. C ₁₆ H ₁₈ N ₃ O ₂ Cl requires C, 60.09; H, 5.67; N, 13.14%.

EXAMPLES 121 TO 124

The compounds of the following tabulated Examples of the general formula:




were prepared by a similar method to that of Example 76 using the appropriate diketone starting material and hydrazine.

Example No. (Diketone No.)	R	LRMS	Analytical Data
121 (Preparation 43)	F	m/z [MH ⁺] 260. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.18 (t, 6H), 2.47 (q, 4H), 6.85 (dd, 1H), 6.98 (s, 1H), 7.01 (dd, 1H).
122 (Preparation 45)	CN	m/z [MH ⁺] 267. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.20 (6H, m), 2.47 (q, 4H), 7.39 (s, 2H), 7.59 (s, 1H).
123 (Preparation 44)	Me	m/z [MH ⁺] 256. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.17 (t, 6H), 2.34 (s, 3H), 2.48 (q, 4H), 6.92 (s, 1H), 6.96 (s, 1H), 7.10 (s, 1H).
124 (Preparation 46)	Cl	m/z [MH ⁺] 276. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.18 (t, 6H), 2.49 (q, 4H), 7.07 (s, 1H), 7.13 (s, 1H), 7.27 (s, 1H).

EXAMPLES 125 TO 128

The compounds of the following tabulated Examples of the general formula:




were prepared by a similar method to that of Example 13 using the appropriate pyrazole starting material and chloroethylamine hydrochloride.

Example No. (Starting pyrazole No.)	R	LRMS	Analytical Data
125 (Example 123)	Me	m/z [MH ⁺] 299. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.34 (s, 3H), 2.39 (q, 2H), 2.43 (q, 2H), 3.17 (t, 2H), 4.04 (t, 2H), 6.91 (s, 1H), 6.96 (s, 1H), 7.09 (s, 1H).
126 (Example 124)	Cl	m/z [MH ⁺] 319. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (m, 6H), 2.40 (q, 2H), 2.51 (q, 2H), 3.15 (m, 2H), 4.02 (m, 2H), 7.04 (s, 1H), 7.12 (s, 1H), 7.28 (s, 1H).
127 (Example 122)	CN	m/z [MH ⁺] 310. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (m, 6H), 2.38 (q, 2H), 2.50 (q, 2H), 3.15 (m, 2H), 4.03 (m, 2H), 7.39 (s, 2H), 7.57 (s, 1H).
128 (Example 121)	F	m/z [MH ⁺] 303. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.06 (m, 6H), 2.37 (q, 2H), 2.48 (q, 2H), 3.13 (t, 2H), 4.03 (t, 2H), 6.84 (d, 1H), 6.94 (s, 1H), 6.97 (d, 1H).


EXAMPLES 129 TO 131

The compounds of the following tabulated Examples of the general formula:



were prepared by a similar method to that of Example 76 using the appropriate diketone starting material and hydrazine.

Example No. (Diketone No.)	R	R'	LRMS	Analytical Data
129 (Preparation 52)	cycloPr	Et	m/z [MH ⁺] 279. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): 0.73 (m, 2H), 0.81 (m, 2H), 1.16 (t, 3H), 1.58 (m, 1H), 2.46 (q, 2H), 7.42 (s, 2H), 7.58 (s, 1H). m.p. 136-141°C.
130 (Preparation 53)	tBu	Me	m/z [MH ⁺] 281. (electrospray)	¹ H-NMR (300MHz, CDCl ₃): 1.21 (s, 9H), 1.94 (s, 3H), 7.34 (s, 2H), 7.56 (s, 1H). Microanalysis: Found: C, 68.18; H, 5.74; N, 19.72. C ₁₆ H ₁₆ N ₄ O requires C, 68.55; H, 5.75; N, 19.99%. m.p. 61-63°C.
131 (Preparation 54)	iPr	Et	m/z [MH ⁺] 281. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): 1.15 (m, 9H), 2.41 (q, 2H), 2.82 (m, 1H), 7.36 (s, 2H), 7.58 (s, 1H). m.p. 136-141°C.


EXAMPLE 1324-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(1-methyl-3-azetidinyl)-1*H*-pyrazole

Paraformaldehyde (30mg, 0.330mmol) was added in one portion to a stirred solution of the pyrazole of Example 51 (120mg, 0.330mmol) in formic acid (2ml) at room temperature. The mixture was heated at 100°C for 5 hours, cooled to room temperature and concentrated under reduced pressure to leave a colourless oil. The oil was dissolved in ethyl acetate (50ml) and the resulting solution was washed with saturated aqueous sodium hydrogencarbonate (20ml), water (20ml) and brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (85mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 1.08 (t, 3H), 1.16 (t, 3H), 2.49 (m, 7H), 3.63 (m, 2H),

3.81 (m, 2H), 4.79 (m, 1H), 6.79 (s, 2H), 7.00 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 354.

EXAMPLES 133-1342-[4-(3,5-Dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine (Example 133) and2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1*H*-pyrazol-1-yl]ethylamine (Example 134)


A mixture of the pyrazole (1.03g, 4.00mmol) of Example 42 and chloroethylamine hydrochloride (510mg, 4.40mmol) was stirred and heated at 150°C for 24 hours. After cooling the mixture was partitioned between 1M aqueous potassium carbonate solution (30ml) and dichloromethane (30ml). The organic layer was washed with brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting brown oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (93:6:1, by volume) to afford the title compounds (768mg) in a 85:15 ratio of regioisomers as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.16 (major, t, 3H), 1.16 (minor, t, 3H), 2.48 (major, q, 2H), 2.60 (minor, q, 2H), 3.13 (major, t, 2H), 3.19 (minor, t, 2H), 4.10 (major, t, 2H), 4.10 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.02 (major, s, 1H), 7.02 (minor, s, 1H), 7.27 (major, s, 1H), 7.31 (minor, s, 1H).

LRMS (thermospray): m/z [MH⁺] 300.

EXAMPLE 135

tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethylcarbamate




A solution of the pyrazole of Example 97 (1.96g, 6.00mmol) in concentrated hydrochloric acid (50ml) was heated under reflux for 20 hours. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in dioxane (80ml) and water (60ml), di-*t*-butyldicarbonate (1.44g, 6.60mmol) and sodium hydrogencarbonate (1.26g, 15.0mmol) were added and the

reaction was stirred at room temperature for 3 days. The reaction was concentrated under reduced pressure. A solution of the residue in dichloromethane (300ml) was washed with 2M aqueous hydrochloric acid (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. A solution of the crude product in tetrahydrofuran (50ml) was cooled to -40°C under nitrogen and triethylamine (0.79ml, 5.68mmol) and isopropylchloroformate (5.68ml of a 1.0M solution in toluene, 5.68mmol) were added dropwise. The reaction was stirred at -40°C for 40 minutes and then warmed to 0°C. Sodium borohydride (537mg, 14.2mmol) was added in one portion and then water (3 drops) was added and the reaction was stirred at 0°C for 1 hour and at room temperature for 14 hours. The mixture was concentrated under reduced pressure and a solution of the residue in dichloromethane (100ml) was washed with water (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (1.37g) as a white foam.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.37 (s, 9H), 2.40 (q, 2H), 3.00 (s, 1H), 3.56 (m, 2H), 4.20 (t, 2H), 4.48 (d, 2H), 5.00 (m, 1H), 6.80 (s, 2H), 6.97 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 430.

EXAMPLE 136

tert-Butyl 2-[4-(3,5-dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate




Silver(I)oxide (210mg, 0.900mmol) was added in one portion to a stirred solution of the alcohol of Example 135 (129mg, 0.300mmol) in ethyl iodide (1.75ml) at room

temperature under nitrogen. The reaction was heated at 40°C for 1 day and then cooled to room temperature. The mixture was filtered and the residual solid was washed with dichloromethane (10ml). The filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (60mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.15 (m, 6H), 1.44 (s, 9H), 2.45 (q, 2H), 3.45 (q, 2H), 3.58 (m, 2H), 4.18 (m, 2H), 4.29 (s, 2H), 5.26 (m, 1H), 6.92 (s, 2H), 7.00 (s, 1H).
LRMS (electrospray): m/z [MNa⁺] 480.

EXAMPLE 137

tert-Butyl 2-[5-(bromomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate



Bromine (160μl, 3.12mmol) was added dropwise to a stirred solution of triphenylphosphine (820mg, 3.12mmol) and imidazole (213mg, 3.12mmol) in dichloromethane (15ml) at room temperature under nitrogen. A solution of the alcohol of Example 135 (1.12g, 2.60mmol) in dichloromethane (5ml) was then added to the reaction. The reaction was stirred at room temperature for 2 hours, diluted with dichloromethane (50ml), washed with brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (969mg) as a white foam.


¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.40 (s, 9H), 2.40 (q, 2H), 3.60 (m, 2H), 4.18 (t, 2H), 4.27 (s, 2H), 4.95 (s, 1H), 6.82 (s, 2H), 7.00 (s, 1H).

LRMS (electrospray): m/z [MH⁺] 494.

Microanalysis: Found: C, 46.22; H, 4.89; N, 8.44. C₁₉H₂₄BrCl₂N₃O₃ requires C, 46.27; H, 4.90; N, 8.52%.

EXAMPLE 138

tert-Butyl 2-[5-(aminomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate




The bromide of Example 137 (444mg, 0.900mmol) was added to a saturated solution of ammonia in isopropanol (25ml) and diisopropylethylamine (173μl, 1.00mmol) at room temperature. The reaction was stirred for 5 hours and then concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (359mg) as a white solid, m.p. 112-114°C.

¹H-NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 1.40 (s, 9H), 2.40 (q, 2H), 3.55 (m, 2H), 3.73 (s, 2H), 4.18 (t, 2H), 5.60 (s, 1H), 6.77 (s, 2H), 6.98 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 429.

EXAMPLE 139

tert-Butyl 2-[5-[(4-acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate




N-AcetylN,N-dimethylformamide (1ml) was added to a stirred solution of the bromide of Example 137 (148mg, 0.300mmol) and diisopropylethylamine (57µL, 0.330mmol) in *N,N*-dimethylformamide (2ml) at room temperature. The reaction was stirred for 5 hours and the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (30ml) was washed with 1M aqueous potassium carbonate solution (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (150mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.15 (t, 3H), 1.42 (s, 9H), 2.06 (s, 3H), 2.44 (m, 6H), 3.32 (s, 2H), 3.47 (m, 2H), 3.60 (m, 2H), 3.65 (m, 2H), 4.23 (m, 2H), 5.89 (s, 1H), 6.76 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 540.

EXAMPLE 140

tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1*H*-pyrazol-1-ylmethyl)-1*H*-pyrazol-1-yl]ethylcarbamate




Pyrazole (23mg, 0.330mmol) was added in one portion to a stirred solution of the bromide of Example 137 (148mg, 0.300mmol) and sodium hydride (60% dispersion in oil, 13.2mg, 0.330mmol) in *N,N*-dimethylformamide (2ml) at room temperature under nitrogen. The reaction was stirred for 5 hours, quenched with water (1.00ml) and concentrated under reduced pressure. The residue was dissolved in dichloromethane (30ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (125mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 1.44 (s, 9H), 2.42 (q, 2H), 3.52 (m, 2H), 4.26 (t, 2H), 5.18 (s, 2H), 5.48 (s, 1H), 6.16 (s, 1H), 6.73 (s, 2H), 7.00 (s, 1H), 7.18 (s, 1H), 7.45 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 480.

EXAMPLE 141


tert-Butyl 2-[5-({[2-(acetylamino)ethyl]amino}methyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate



N-Acetylenediamine (153mg, 1.50mmol) in isopropanol (1ml) was added to a stirred solution of the bromide of Example 137 (148mg, 0.300mmol) and diisopropylethylamine (57µl, 0.330mmol) in isopropanol (2ml) at room temperature. The reaction was stirred for 5 hours and the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (50ml) was washed with 1M aqueous potassium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (90:10, by volume) then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (122mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 1.42 (s, 9H), 1.94 (d, 3H), 2.44 (q, 2H), 2.74 (m, 2H), 3.35 (m, 2H), 3.58 (m, 4H), 4.19 (m, 2H), 5.68 (s, 1H), 6.77 (s, 2H), 7.00 (s, 1H), 7.65 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 514.

EXAMPLE 142**tert-Butyl 2-(4-(3,5-dichlorophenoxy)-3-ethyl-5-[(4-methoxybenzyl)amino]methyl}-1*H*-pyrazol-1-yl)ethylcarbamate**


4-Methoxybenzaldehyde (46 μ l, 0.380mmol), the amine of Example 138 (172mg, 0.400mmol) and magnesium sulphate (200mg) were stirred in dichloromethane (4ml) at room temperature for 4 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (4ml) and sodium borohydride (18mg, 0.480mmol) was added with vigorous stirring. Once the addition was complete the reaction was stirred for 4 hours and then water (2ml) was added. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50ml). The resulting solution was washed with 1M aqueous potassium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) and then dichloromethane:methanol (95:5, by volume) to provide the title compound (142mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.40 (s, 9H), 2.42 (m, 2H), 3.55 (m, 5H), 3.66 (s, 2H), 3.77 (s, 2H), 4.15 (m, 2H), 6.11 (s, 1H), 6.74 (s, 2H), 6.80 (d, 2H), 7.00 (s, 1H), 7.11 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 549.

EXAMPLE 143


tert-Butyl 2-[5-[(4-cyanobenzyl)amino]methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate



A mixture of 4-cyanobenzaldehyde (50mg, 0.380mmol), the amine of Example 138 (172mg, 0.400mmol), magnesium sulphate (200mg) and dichloromethane (4ml) was stirred at room temperature for 4 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (4ml) and sodium borohydride (18mg, 0.480mmol) was added with vigorous stirring. Once the addition was complete the reaction was stirred for 4 hours and then water (2ml) was added. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50ml). The resulting solution was washed with 1M aqueous potassium carbonate solution (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) then dichloromethane:methanol (95:5, by volume) to provide the title compound (120mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.35 (s, 9H), 2.40 (q, 2H), 3.55 (m, 2H), 3.58 (s, 2H), 3.76 (s, 2H), 4.16 (m, 2H), 5.45 (s, 1H), 6.73 (s, 2H), 6.98 (s, 1H), 7.32 (d, 2H), 7.55 (d, 2H).


LRMS (thermospray): m/z [MH⁺] 544.

EXAMPLE 1443-[(5-(Bromomethyl)-1,3-dimethyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile

N-Bromosuccinimide (340mg, 1.90mmol) was added to a stirred solution of the pyrazole of Example 112 (500mg, 1.90mmol) in carbon tetrachloride (10ml) and azobisisobutyronitrile (20mg) at room temperature under nitrogen. The reaction was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (340mg) as a white solid, m.p. 76-78°C.

¹H-NMR (300MHz, CDCl₃): δ = 2.03 (s, 3H), 3.45 (s, 3H), 4.32 (s, 2H), 7.12 (s, 1H), 7.19 (s, 1H), 7.34 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 342.

EXAMPLE 1453-[(3,5-Diethyl-1-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile

Sodium hydride (60% dispersion in oil, 22mg, 0.53mmol) was added to a solution of the pyrazole from Example 60 (100mg, 0.41mmol) and methyl iodide (34 μ l, 0.53mmol) in dimethylformamide (1.5ml) at 0°C under nitrogen. The reaction was allowed to warm to room temperature and was stirred for 4 hours. The reaction was quenched with water and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (20ml) and water (10ml) and the organic phase was washed with water (2x10ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of 100% pentane changing to 100% ethyl acetate and finally ethyl acetate:methanol (10:1, by volume) to provide the title compound (65mg) as a colourless oil.


1 H NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.12 (t, 3H), 2.41 (q, 2H), 2.50 (q, 2H), 3.77 (s, 3H), 7.12-7.38 (m, 4H).

LRMS (electrospray) : m/z [MH⁺] 256, [MNa⁺] 278.

Microanalysis: Found C, 70.15; H, 6.78; N, 16.42. C₁₅H₁₅N₃O.0.08H₂O requires C, 70.17; H, 6.74; N, 16.37%.

EXAMPLE 146

3-[(3,5-Diethyl-1-(2-methoxyethyl)-1*H*-pyrazol-4-yl)oxy]benzonitrile



Sodium hydride (60% dispersion in oil, 22mg, 0.54mmol) was added to a solution of the pyrazole from Example 60 (100mg, 0.41mmol) and 1-bromo-2-methoxy-ethane (51 μ l, 0.54mmol) in dimethylformamide (1.5ml) at 0°C under nitrogen. The reaction was allowed to warm to room temperature and was stirred for 4 hours. The reaction was quenched with water and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (20ml) and water (10ml) and the

organic phase was washed with water (2x10ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of 100% pentane changing to 100% ethyl acetate and finally ethyl acetate:methanol (90:10, by volume) to provide the title compound (66mg) as a colourless oil.


¹H NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.12 (t, 3H), 2.42 (q, 2H), 2.54 (q, 2H), 3.34 (s, 3H), 3.75 (t, 2H), 4.16 (t, 2H), 7.11-7.38 (m, 4H).

LRMS (electrospray) : m/z [MH⁺] 300, [MNa⁺] 322.

Microanalysis: Found C, 68.21; H, 7.07; N, 14.04. C₁₇H₂₁N₃O₂ requires C, 67.85; H, 7.12; N, 14.09%.

EXAMPLE 147

3-({5-[2-(Benzyl)ethoxy]ethyl}-3-ethyl-1*H*-pyrazol-4-yl)oxy)-5-fluorobenzonitrile




Hydrazine hydrate (390μl, 8.00mmol) was added to a solution of the enol from Preparation 60 (2.47g, 6.69mmol) in acetic acid (5ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (70:30 changing to 50:50, by volume) to provide the title compound (5.8g) as a yellow oil.

¹H NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 2.41 (q, 2H), 2.67 (t, 2H), 3.62 (t, 2H), 4.48 (s, 2H), 6.79 (m, 1H), 6.98 (m, 2H), 7.24 (m, 5H).

LRMS (electrospray) : m/z [M-H⁺] 364.

Microanalysis: Found C, 66.96; H, 5.62; N, 11.25. $C_{21}H_{20}N_3O_2F \cdot 0.60H_2O$ requires C, 67.04; H, 5.68; N, 11.17%.


EXAMPLE 1483-{{3-Ethyl-5-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-fluorobenzonitrile

Iron(III)chloride (9.30g, 57.5mmol) was added to a solution of the pyrazole from Example 147 (2.10g, 5.75mmol) in dichloromethane (90ml) under nitrogen at room temperature. After stirring for 20 minutes the mixture was diluted with dichloromethane (50ml), washed with water (100ml) then saturated aqueous sodium ethylenediaminetetraacetate solution (70ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 95:5, by volume) to provide the title compound (1.2g) as a brown oil which solidified on standing.

1H NMR (400MHz, $CDCl_3$): δ = 1.16 (t, 3H), 2.44 (q, 2H), 2.63 (t, 2H), 3.82 (t, 2H), 6.82 (m, 1H), 6.98 (m, 2H).

LRMS (electrospray) : m/z $[MH^+]$ 276.

Microanalysis: Found C, 60.69; H, 5.12; N, 15.08. $C_{14}H_{14}N_3O_2F$ requires C, 61.08; H, 5.13; N, 15.26%.

EXAMPLE 1493-({5-[2-(4-Cyanophenoxy)ethyl]-3-ethyl-1*H*-pyrazol-4-yl}oxy)-5-fluorobenzonitrile


4-Hydroxy-benzonitrile (49mg, 0.41mmol), triphenylphosphine (106mg, 0.41mmol) and diethylazodicarboxylate (65 μ l, 0.41mmol) were added sequentially to a solution of the alcohol from Example 148 (74mg, 0.27mmol) in tetrahydrofuran (2ml) under nitrogen at 0°C. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (75:25, by volume) to provide the title compound (50mg) as a yellow oil.

¹H NMR (400MHz, CDCl₃): δ = 1.18 (t, 3H), 2.49 (q, 2H), 2.98 (t, 2H), 4.21 (t, 2H), 6.82 (m, 3H), 6.99 (m, 2H), 7.56 (m, 2H).




LRMS (electrospray) : m/z [MH⁺] 377.

EXAMPLES 150-152

The preparations of the following tabulated Examples of the general formula




were performed by a similar method to that of Example 149 using the appropriate aryl alcohol as the starting material.

Example No.	Starting Material Example No.	R	Analytical Data
150 ¹	148		¹ H NMR (400MHz, CDCl ₃): δ = 1.18 (t, 3H), 2.42 (s, 3H), 2.52 (q, 2H), 2.99 (t, 2H), 4.18 (t, 2H), 6.83 (m, 1H), 6.99 (m, 4H), 8.04 (m, 1H). LRMS (thermospray) : m/z [MH ⁺] 367.
151 ¹	148		¹ H NMR (400MHz, CDCl ₃): δ = 1.19 (t, 3H), 2.50 (q, 2H), 2.98 (t, 2H), 4.22 (t, 2H), 6.85 (m, 1H), 6.99 (m, 2H), 7.12 (m, 1H), 7.18 (m, 1H), 8.22 (m, 2H). LRMS (thermospray) : m/z [MH ⁺] 353.
152 ¹	148		¹ H NMR (400MHz, CDCl ₃): δ = 1.20 (t, 3H), 2.53 (q, 2H), 2.98 (t, 2H), 4.19 (t, 2H), 4.85 (brs, 2H), 6.58 (m, 1H), 6.83 (m, 2H), 6.99 (m, 2H), 7.63 (d, 1H). LRMS (thermospray) : m/z [MH ⁺] 368.

¹ These compounds were purified on silica gel eluting with a solvent gradient of cyclohexane:ethyl acetate (75:25 then 66:34 then 50:50, by volume) changing to ethyl acetate and finally ethyl acetate:methanol (90:10, by volume).


EXAMPLE 153

5-({5-[2-(benzyloxy)ethyl]-3-ethyl-1*H*-pyrazol-4-yl}oxy)isophthalonitrile

Hydrazine hydrate (177 μ l, 3.66mmol) was added to a solution of the crude enol from Preparation 61 (917mg, 2.40mmol) in acetic acid (10ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:cyclohexane (75:25, by volume) changing to toluene:ethyl acetate (50:50, by volume) to give the product which was further purified by preparative HPLC using a Develosil combi-rp C30 50x4.6mm 3 μ m column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in water:acetonitrile to provide the title compound (5mg) as a colourless oil.

1 H NMR (400MHz, CDCl₃): δ = 1.18 (t, 3H), 2.44 (q, 2H), 2.77 (t, 2H), 3.63 (t, 2H), 4.52 (s, 2H), 7.30 (m, 7H), 7.55 (s, 1H).


LRMS (electrospray) : m/z [M H^+] 231, [MNa $^+$] 253.

EXAMPLE 1545-{{3-Ethyl-5-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile

Iron(III)Chloride (217mg, 1.30mmol) was added to a solution of the pyrazole from Example 153 (50mg, 0.13mmol) in dichloromethane (5ml) under nitrogen at room temperature. After stirring for 30 minutes the mixture was diluted with dichloromethane (20ml), washed with water (100ml) then saturated aqueous sodium ethylenediaminetetraacetate solution (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 95:5, by volume) to provide the title compound (20mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.19 (t, 3H), 2.51 (q, 2H), 2.69 (t, 2H), 3.88 (t, 2H), 7.40 (s, 2H), 7.59 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 283.

EXAMPLE 1553-{{[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazol-4-yl}oxy}-5-chlorobenzonitrile

The protected alcohol from Preparation 31 (100mg, 0.23mmol) and *tert*-butyl-ammonium fluoride (360 μ l of a 1M solution in tetrahydrofuran, 0.36mmol) were stirred in dichloromethane (5ml) at room temperature under nitrogen for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in methanol (2ml) and purified on a BondElut® SCX polymer supported sulphonic acid column washing with methanol (2x3ml) to remove impurities and 2N aqueous ammonia to remove the product. This procedure was repeated twice to provide the title compound (40mg) as a colourless oil.


1 H NMR (400MHz, CD₃OD): δ = 1.99 (s, 3H), 3.85 (t, 2H), 4.02 (s, 2H), 4.32 (t, 2H), 7.22 (s, 1H), 7.28 (s, 1H), 7.47 (s, 1H).

LRMS (thermospray) : m/z [MH $^+$] 309.

Microanalysis: Found C, 53.32; H, 5.17; N, 16.38. C₁₄H₁₅CIN₄O₂·0.85CH₃OH requires C, 53.40; H, 5.55; N, 16.77%.

EXAMPLE 156

5-[(1-Allyl-3-*tert*-butyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile



Sodium hydride (60% dispersion in oil, 120mg, 3.15mmol) was added to a solution of the pyrazole from Example 130 (800mg, 2.80mmol) and allyl bromide (345mg, 2.80mmol) in dimethylformamide (30ml) at room temperature under nitrogen and the reaction was stirred for 3 hours. The reaction was diluted with ethyl acetate (50ml), washed with water (2x50ml) then brine (50ml) and the organic phase was concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of pentane changing to

ethyl acetate:pentane (20:80, by volume) to provide the title compound (600mg) as a colourless oil.


¹H NMR (400MHz, CDCl₃): δ = 1.21 (s, 9H), 1.96 (s, 3H), 4.66 (s, 2H), 5.04 (d, 1H), 5.24 (d, 1H), 5.98 (m, 1H), 7.37 (s, 2H), 7.57 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 322.

Microanalysis: Found C, 70.79; H, 6.29; N, 17.11. C₁₉H₂₀N₄O.0.05CH₂Cl₂ requires C, 70.48; H, 6.24; N, 17.26%.

EXAMPLE 157

5-{[3-*tert*-Butyl-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



Sodium periodate (1.00g, 4.60mmol), osmium tetroxide (1.5% solution in *tert*-butanol, 190mg, 0.02mmol) and the pyrazole from Example 156 (600mg, 1.86mmol) were dissolved in acetone (9ml) and water (3ml) under nitrogen at room temperature, and the reaction was stirred for 5 hours. The acetone was removed under reduced pressure and the residue was extracted with ethyl acetate (30ml). The organic phase was washed with water (2x30ml) then brine (30ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude aldehyde was then dissolved in methanol (15ml) and sodium borohydride (84mg, 2.22mmol) was added portionwise at room temperature under nitrogen. The reaction was stirred for 3 hours and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (10ml) and water (10ml) and the organic phase was washed with water (2x10ml) then brine (10ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent

gradient of pentane changing to ethyl acetate:pentane (50:50, by volume) to provide the title compound (250mg) as a colourless oil.


^1H NMR (400MHz, CDCl_3): δ = 1.17 (s, 9H), 1.98 (s, 3H), 3.67 (s, 1H), 4.04 (m, 4H), 7.35 (s, 2H), 7.54 (s, 1H).

LRMS (thermospray) : m/z $[\text{MH}^+]$ 325.

Microanalysis: Found C, 64.30; H, 6.10; N, 16.35. $\text{C}_{18}\text{H}_{20}\text{N}_4\text{O}_2 \cdot 0.20\text{CH}_2\text{Cl}_2$ requires C, 64.04; H, 6.02; N, 16.41%.

EXAMPLE 158

5-{{[1-(2-Aminoethyl)-3-*tert*-butyl-5-methyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



Diphenylphosphorylazide (305mg, 1.10mmol) was dissolved in tetrahydrofuran (5ml) and added to a solution of the pyrazole from Example 157 (180mg, 0.55mmol), triphenylphosphine (291mg, 1.10mmol) and diethylazodicarboxylate (193mg, 1.10mmol) in tetrahydrofuran (20ml) under nitrogen at room temperature. The reaction was stirred for 18 hours then triphenylphosphine (291mg, 1.10mmol) was added, and the reaction was stirred for a further 18 hours. Water (180 μ l, 10.0mmol) was then added and the reaction was stirred for 64 hours. The solvent was removed under reduced pressure and the residual white paste was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:4.5:0.5, by volume) to provide the title compound (55mg) as a colourless oil.


^1H NMR (300MHz, CDCl_3): δ = 1.22 (s, 9H), 1.78 (s, 2H), 2.03 (s, 3H), 3.18 (t, 2H), 4.05 (m, 2H), 7.38 (s, 2H), 7.58 (s, 1H).

LRMS (thermospray) : m/z $[\text{MH}^+]$ 324.

Microanalysis: Found C, 64.46; H, 6.48; N, 20.47. $C_{18}H_{21}N_5O.0.20CH_2Cl_2$ requires C, 64.22; H, 6.34; N, 20.57%.

EXAMPLE 159

3-[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}-5-(1*H*-1,2,4-triazol-1-yl)benzonitrile



Cesium carbonate (179mg, 0.55mmol) was added to a solution of 1*H*[1,2,4]triazole (38mg, 0.55mmol) in dimethylsulfoxide (1ml) under nitrogen at room temperature and the reaction was stirred for 10 minutes. The aryl fluoride from Preparation 62 (210mg, 0.5mmol) dissolved in dimethylsulfoxide (1ml) was then added and the reaction was heated to 100°C for 18 hours. After cooling to room temperature the reaction was diluted with water (15ml) and extracted with ethyl acetate (25ml). The organic phase was washed with brine (15ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (98:2 changing to 90:10, by volume) to provide the title compound (67.5mg) as a white solid, m.p. 122-124°C.


¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.61 (brs, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.10 (s, 1H), 7.52 (s, 1H), 7.60 (s, 1H), 8.07 (s, 1H), 8.54 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 353.

Microanalysis: Found C, 60.69; H, 5.83; N, 22.98. $C_{18}H_{20}N_6O_2.0.08CH_2Cl_2$ requires C, 60.46; H, 5.66; N, 23.40%.

EXAMPLES 160-162

The preparation of the following tabulated Examples of the general formula



were performed by a similar method to that of Example 159 using the appropriate heterocycle as the starting material.


Example No. (Starting Material Preparation No)	R	Analytical Data
160 (62)		<p>¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.52 (q, 2H), 3.62 (brs, 1H), 4.02 (t, 2H), 4.08 (t, 2H), 6.44 (d, 2H), 7.14 (s, 1H), 7.16 (s, 1H), 7.25 (s, 1H), 7.49 (d, 2H). m.p. 169-170°C. LRMS (thermospray) : m/z [MH⁺] 379. Microanalysis: Found C, 65.68; H, 5.98; N, 14.31. C₂₁H₂₂N₄O₃.0.09CH₂Cl₂ requires C, 65.61; H, 5.79; N, 14.51%.</p>
161 ¹ (62)		<p>¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.51 (q, 2H), 3.56 (t, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.20 (s, 1H), 7.65 (s, 2H), 7.85 (s, 1H), 7.98 (s, 1H). LRMS (thermospray) : m/z [MH⁺] 353. HRMS: [MH⁺] 353.1722. C₁₈H₂₀N₆O₂ requires 353.1720.</p>

162 ¹ (62)		¹ H NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 3.62 (t, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.08 (s, 1H), 7.80 (s, 2H), 7.87 (s, 1H), 8.02 (s, 1H). LRMS (thermospray) : m/z [MH ⁺] 353. HRMS: [MH ⁺] 353.1719. C ₁₈ H ₂₀ N ₆ O ₂ requires 353.1720.
-----------------------	---	---

¹ Both of these compounds were isolated from a single reaction starting from 1,2,3-triazole with Example 161 being the most polar.

EXAMPLE 163

3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}-5-fluorobenzamide




The protected alcohol from Preparation 64 (432mg, 1.07mmol) and p-toluene-sulphonic acid (30.3mg, 0.11mmol) were dissolved in methanol (4ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20ml) and dichloromethane (20ml). The aqueous phase was extracted with dichloromethane (10ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 93:7, by volume) to provide the title compound (241mg) as a white foam.

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.49 (q, 2H), 3.68 (brs, 1H), 4.04 (m, 4H), 5.59 (brs, 1H), 5.88 (brs, 1H), 6.71 (d, 1H), 7.11 (m, 2H).
LRMS (thermospray) : m/z [MH⁺] 322.

Microanalysis: Found C, 57.91; H, 6.32; N, 12.56. $C_{16}H_{20}FN_3O_3$.0.13CH₂Cl₂.0.12H₂O requires C, 57.91; H, 6.18; N, 12.56%.



EXAMPLES 164-167

The preparation of the following tabulated Examples of the general formula



were performed by a similar method to that of Example 163 using the appropriate protected alcohol as the starting material.

Example No. (Starting Material Preparation No.)	R	Analytical Data
164 ¹ (65)		¹ H NMR (400MHz, CDCl ₃): δ = 1.13 (m, 6H), 2.44 (q, 2H), 2.54 (q, 2H), 3.65 (brs, 1H), 4.07 (t, 2H), 4.11 (t, 2H), 6.51 (s, 1H), 7.00 (s, 1H), 7.56 (s, 1H), 7.63 (s, 1H), 7.74 (s, 1H), 7.90 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 352, [MNa ⁺] 374. HRMS: [MH ⁺] Found 352.1770. C ₁₉ H ₂₂ N ₅ O ₂ requires 352.1768.
165 ¹ (66)		¹ H NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.40(q, 2H), 2.50 (q, 2H), 4.00 (t, 2H), 4.06 (t, 2H), 6.24 (t, 1H), 6.60 (d, 1H), 7.18 (d, 2H), 7.24 (d, 1H), 7.30 (s, 1H), 7.38 (t, 1H). LRMS (electrospray) : m/z [MH ⁺] 379, [MNa ⁺] 401. HRMS: [MH ⁺] Found 379.1766. C ₂₁ H ₂₃ N ₄ O ₃ requires 379.1765 [MNa ⁺] Found 401.1585. C ₂₁ H ₂₂ N ₄ O ₃ Na requires 401.1584.


166 ¹ (67)		¹ H NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 4.01 (t, 2H), 4.06 (t, 2H), 7.07 (d, 1H), 7.13 (s, 1H), 7.22 (m, 1H), 7.52 (s, 1H), 7.65 (s, 1H), 7.88 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 380, [MNa ⁺] 402. HRMS: [MH ⁺] Found 380.1722. C ₂₀ H ₂₂ N ₅ O ₃ requires 380.1717.
167 ² (68)		¹ H NMR (400MHz, CDCl ₃): δ = 1.11 (m, 6H), 2.27 (s, 3H), 2.41 (q, 2H), 2.50 (q, 2H), 3.70 (s, 3H), 4.04 (t, 1H), 4.08 (t, 2H), 5.64 (s, 1H), 6.81 (s, 1H), 6.91 (s, 1H), 6.99 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 396, [MNa ⁺] 418. HRMS: [MH ⁺] Found 396.2027. C ₂₁ H ₂₆ N ₅ O ₃ requires 396.2030.

¹ The eluent used for flash column chromatography purification of these compounds was dichloromethane:methanol (99:1 changing to 80:20, by volume).

² The eluent used for flash column chromatography purification of this compound was dichloromethane:methanol (99:1 changing to 98:2, by volume).

EXAMPLE 168


5-{[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



and

EXAMPLE 169

5-{[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



Potassium carbonate (91mg, 0.66mmol) and 2-(2-bromoethoxy)-tetrahydropyran (91 μ l, 0.61mmol) were sequentially added to a solution of the pyrazole from Example 129 (152mg, 0.55mmol) dissolved in dimethylformamide (4ml) and the reaction was heated to 35°C under nitrogen for 5 hours. Starting material still remained, so the temperature was increased to 80°C and the reaction was stirred for a further 18 hours. The reaction was cooled to room temperature, sodium hydride (60% dispersion in oil, 24mg, 0.60mmol) was added and the reaction was stirred at room temperature for 1hour. The mixture was diluted with water (50ml) and extracted with ethyl acetate (2x50ml). The combined organic extracts were washed with brine (30ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:cyclohexane (75:25, by volume) to provide a mixture of regioisomers (239mg). The regioisomers (239mg, 0.55mmol) and p-toluenesulphonic acid (10mg, 0.05mmol) were dissolved in methanol (5ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20ml) and dichloromethane (30ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (50:50, by volume) to yield two products as colourless oils.

Least Polar Fraction (Example 168) – 34mg


¹H NMR (400MHz, CDCl₃): δ = 0.76 (m, 4H), 1.05 (t, 3H), 1.45 (m, 1H), 2.48 (q, 2H), 3.39 (brs, 1H), 4.02 (m, 4H), 7.39 (s, 2H), 7.56 (s, 1H).

LRMS (electrospray) : m/z [M-H⁺] 321.

Most Polar Fraction (Example 169) – 9mg

¹H NMR (400MHz, CDCl₃): δ = 0.62 (m, 2H), 0.78 (m, 2H), 1.18 (t, 3H), 1.46 (m, 1H), 2.38 (q, 2H), 3.42 (brs, 1H), 4.02 (m, 2H), 4.21 (t, 2H), 7.38 (s, 2H), 7.57 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 323, [MH] 321.

EXAMPLE 1705-[(5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile

2-(2-Bromoethoxy)-tetrahydropyran (91μl, 0.60mmol) was added to a solution of the pyrazole from Example 131 (153mg, 0.55mmol) dissolved in dimethylformamide (4ml) at room temperature under nitrogen, then sodium hydride (60% dispersion in oil, 24mg, 0.60mmol) was added and the reaction was stirred at room temperature for 3 hours. The mixture was diluted with water (50ml) and extracted with ethyl acetate (2x50ml). The combined organic extracts were washed with brine (30ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (85:15, by volume) to provide the separated isomers as colourless oils (83mg of Isomer 1, 55mg of Isomer 2).


The least polar isomer (isomer 1) (83mg, 0.20mmol) and p-toluene-sulphonic acid (4mg, 0.02mmol) were dissolved in methanol (5ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (30ml) and dichloromethane (30ml). The aqueous phase was extracted with dichloromethane (20ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (66:34, by volume) to provide the title compound (39mg) as an oil.

¹H NMR (400MHz, CDCl₃): δ = 1.05 (t, 3H), 1.14 (d, 6H), 2.44 (q, 2H), 2.68 (sept, 1H), 3.77 (brs, 1H), 4.06 (m, 4H), 7.38 (s, 2H), 7.58 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 325.

EXAMPLE 171


5-{{3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile



The most polar isomer (isomer 2) from Example 170 (55mg, 0.13mmol) and p-toluene-sulphonic acid (3mg, 0.01mmol) were dissolved in methanol (5ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (30ml) and dichloromethane (30ml). The aqueous phase was extracted with dichloromethane (20ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate 66:33, by volume) to provide the title compound (39mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.13 (d, 6H), 2.49 (q, 2H), 2.97 (sept, 1H), 3.59 (t, 1H), 4.06 (m, 4H), 7.37 (s, 2H), 7.57 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 325.


EXAMPLE 1722-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl carbamate

Trichloroacetyl-isocyanate (46 μ l, 0.38mmol) was added to a solution of the alcohol from Example 119 (100mg, 0.32mmol) dissolved in dichloromethane (3.2ml) under nitrogen at 0°C. After stirring for 2 hours the dichloromethane was removed under reduced pressure and methanol (1.6ml), water (1.6ml) and potassium carbonate (134mg, 0.96mmol) were added and the reaction was stirred for a further 2 hours. The methanol was removed under reduced pressure and the residue was extracted with dichloromethane (3x10ml). The combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual solid was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (60mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.48 (q, 2H), 4.26 (m, 2H), 4.44 (m, 2H), 4.62 (brs, 2H), 7.41 (s, 2H), 7.58 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 354.

Microanalysis: Found C, 60.00; H, 5.55; N, 19.82. C₁₈H₁₉N₅O₃·0.23EtOAc requires C, 60.30; H, 5.67; N, 18.58%.


EXAMPLE 173N-[2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}sulfamide

Sulfamide (31mg, 0.32mmol) was added to a solution of the amine from Example 127 (100mg, 0.32mmol) dissolved in dioxan (0.5ml) under nitrogen at room temperature. The reaction was heated to 100°C for 18 hours, cooled to room temperature and partitioned between ethyl acetate (15ml) and water (15ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residual brown oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (25mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.12 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.61 (m, 2H), 4.20 (m, 2H), 4.78 (s, 2H), 5.42 (s, 1H), 7.40 (s, 2H), 7.59 (s, 1H).

Microanalysis: Found C, 50.33; H, 5.07; N, 20.60. C₁₇H₂₀N₆O₃S.0.95H₂O requires C, 50.35; H, 5.44; N, 20.72%.

EXAMPLE 174


N-[2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl]-2-methoxyacetamide

The amine from Example 127 (100mg, 0.32mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (68mg, 0.35mmol) and *N,N*-dimethylaminopyridine (43mg, 0.35mmol) were added to a solution of 1-methoxyacetic acid (27 μ l, 0.35mmol) dissolved in dichloromethane (10ml) under nitrogen at room temperature. The reaction was stirred for 18 hours, concentrated under reduced pressure and the residual yellow oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (32mg) as a colourless oil.

¹H NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 1.16 (t, 3H), 2.38 (q, 2H), 2.47 (q, 2H), 3.41 (s, 3H), 3.77 (dd, 2H), 3.89 (s, 2H), 4.15 (m, 2H), 7.19 (brs, 1H), 7.40 (s, 2H), 7.59 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 382.

Microanalysis: Found C, 61.26; H, 6.18; N, 17.59. C₂₀H₂₃N₅O₃·0.60H₂O requires C, 61.24; H, 6.22; N, 17.85%.


EXAMPLE 175**5-[(1-(3-Azetidinyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile**

The protected amine from Preparation 69 (178mg, 0.42mmol) was dissolved in 4M hydrochloric acid in dioxan solution (1ml) and dioxan (1ml) and the reaction was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between dichloromethane (20ml) and saturated aqueous sodium bicarbonate solution (20ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 then 98:2:0 then 95:5:0 then 95:5:0.5 then 90:10:1 then 80:20:1, by volume) to provide the title compound (33mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.05 (t, 3H), 1.11 (t, 3H), 2.44 (m, 4H), 3.85 (m, 2H), 4.38 (m, 2H), 5.05 (m, 1H), 7.37 (s, 2H), 7.56 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 322.

Microanalysis: Found C, 65.87; H, 5.94; N, 20.98. C₁₈H₁₉N₅O.0.38H₂O requires C, 65.87; H, 6.07; N, 21.04%.


EXAMPLE 1765-[(3,5-Diethyl-1-(3-hydroxypropyl)-1*H*-pyrazol-4-yl)oxy]isophthalonitrile

The protected alcohol from Preparation 70 (215mg, 0.53mmol) and p-toluenesulphonic acid (10mg, 0.05mmol) were dissolved in methanol (2ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (10ml) and dichloromethane (10ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (148mg) as a pale yellow solid, m.p. 93-95°C.

¹H NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.04 (tt, 2H), 2.37 (q, 2H), 2.53 (q, 2H), 3.06 (t, 1H), 3.69 (dt, 2H), 4.18 (t, 2H), 7.38 (s, 2H), 7.58 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 325, [MNa⁺] 347.

Microanalysis: Found C, 66.27; H, 6.27; N, 17.00. C₁₈H₂₀N₄O₂ requires C, 66.28; H, 6.24; N, 17.18%.

EXAMPLE 1775-[(3,5-Diethyl-1-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile

Sodium hydride (60% dispersion in oil, 33mg, 0.82mmol) was added to a solution of the pyrazole from Example 122 (200mg, 0.75mmol) in dimethylformamide (3ml) at 0°C under nitrogen and the reaction was stirred for 10 minutes. Methyl iodide (117mg, 0.82mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was quenched with water (0.2ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5ml) and water (5ml) and the organic phase was isolated using a 5µM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80, by volume) changing to ethyl acetate:methanol (90:10, by volume) then dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (170mg) as a yellow solid.


¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.49 (q, 2H), 3.80 (s, 3H), 7.40 (s, 2H), 7.56 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 281.




Microanalysis: Found C, 68.41; H, 5.71; N, 19.93. C₁₆H₁₆N₄O requires C, 68.55; H, 5.75; N, 19.99%.

EXAMPLES 178-180

The preparation of the following tabulated Examples of the general formula



were performed by a similar method to that of Example 177 using the appropriate alkyl halide as the starting material.

Example No. (Starting Material Example No.)	R	Analytical Data
178 (122)		¹ H NMR (400MHz, CDCl ₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.40 (q, 2H), 2.54 (q, 2H), 3.34 (s, 3H), 3.75 (t, 2H), 4.17 (t, 2H), 7.38 (s, 2H), 7.56 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 325, [MNa ⁺] 347. Microanalysis: Found C, 65.73; H, 6.17; N, 17.08. C ₁₈ H ₂₀ N ₄ O ₃ .0.25H ₂ O requires C, 65.74; H, 6.28; N, 17.04%.
179 ^{1,2} (122)		¹ H NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 1.98 (tt, 2H), 2.38 (q, 2H), 2.51 (q, 2H), 2.76 (t, 2H), 4.09 (t, 2H), 7.38 (s, 2H), 7.57 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 324. Microanalysis: Found C, 64.86; H, 6.51; N, 20.79. C ₁₈ H ₂₁ N ₅ O.0.57H ₂ O requires C, 64.79; H, 6.69; N, 20.99%.
180 ³ (122)		¹ H NMR (400MHz, CDCl ₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.47 (q, 2H), 3.79 (s, 3H), 4.82 (s, 2H), 7.40 (s, 2H), 7.57 (s, 1H). LRMS (electrospray) : m/z [MH ⁺] 339. Microanalysis: Found C, 63.58; H, 5.35; N, 16.35. C ₁₈ H ₁₈ N ₄ O ₃ .0.10H ₂ O requires C, 63.56; H, 5.39; N, 16.47%.

¹ The two reagents were heated together as a melt at 160°C for 24 hours, and the reaction was worked up by partitioning between dichloromethane and saturated sodium bicarbonate solution, extracting the organic phase with 2M aqueous hydrochloric acid and basifying the aqueous phase with sodium carbonate. After extraction with dichloromethane the organic phase was dried and concentrated to give the crude product.


² The eluent used for flash column chromatography purification of this compound was dichloromethane:methanol:0.88 ammonia (95:5:0.5 changing to 80:20:1, by volume).

³ The eluent used for flash column chromatography purification of this compound was pentane:ethyl acetate (75:25 changing to 66:34 then 50:50, by volume).

⁴ The hydrochloride salt of the starting alkyl halide was used.

EXAMPLE 181

2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide




The ester from Example 180 (200mg, 0.59mmol) was dissolved in 2M methanolic ammonia solution (5ml) and the reaction was stirred under nitrogen at 75°C for 18 hours. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (6mg).

¹H NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.15 (t, 3H), 2.44 (q, 2H), 2.54 (q, 2H), 4.69 (s, 2H), 5.55 (brs, 1H), 6.22 (brs, 1H), 7.38 (s, 2H), 7.59 (s, 1H).

LRMS (electrospray) : m/z [M-H⁺] 322.

Microanalysis: Found C, 68.41; H, 5.71; N, 19.93. C₁₆H₁₆N₄O requires C, 68.55; H, 5.75; N, 19.99%.


EXAMPLE 182**5-[[3,5-Diethyl-1-(hydroxymethyl)-1*H*-pyrazol-4-yl]oxy]isophthalonitrile**

Formaldehyde (37% solution in water, 253 μ l, 3.14mmol) was added to a solution of the pyrazole from Example 122 (440mg, 1.65mmol) in ethanol (5ml) and the reaction was stirred at 80°C for 18 hours. After cooling to room temperature the solvent was removed under reduced pressure and the residual yellow solid was partitioned between ethyl acetate (15ml) and water (10ml) and the organic phase was removed. The aqueous phase was washed with ethyl acetate (2x15ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (490mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 1.14 (t, 3H), 2.39 (q, 2H), 2.61 (q, 2H), 5.49 (s, 2H), 5.68 (brs, 1H), 7.40 (s, 2H), 7.56 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 267.

Microanalysis: Found C, 64.28; H, 5.52; N, 18.47. C₁₆H₁₆N₄O₂.0.15H₂O requires C, 64.27; H, 5.49; N, 18.24%.

EXAMPLE 183**3-[(4-(3-cyano-5-fluorophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]amino)methyl]benzamide**


The pyrazole from Preparation 75 (320mg, 0.91mmol) and the amine from Preparation 80 (680mg, 4.61mmol) were refluxed in isopropanol (5ml) for 1.5 hours. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to give the product which was further purified by preparative HPLC using a Develosil combi-rp C30 50x4.6mm 3 μ m column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-6min 95:5 changing to 50:50; 6-7min 50:50; 7-7.1min 50:50 changing to 5:95; 7.1-8min 5:95) to provide the title compound (38mg).

¹H NMR (400MHz, CD₃OD): δ = 2.14 (s, 3H), 4.10 (s, 2H), 4.34 (s, 2H), 7.03 (m, 1H), 7.10 (s, 1H), 7.25 (m, 1H), 7.54 (t, 1H), 7.64 (d, 1H), 7.92 (d, 1H), 7.97 (s, 1H).
LRMS (electrospray) : m/z [MH⁺] 380.

Microanalysis: Found C, 51.32; H, 3.91; N, 13.69.
C₂₀H₁₈N₅O₂F.1.00CF₃CO₂H1.10H₂O requires C, 51.49; H, 4.16; N, 13.65%.

EXAMPLES 184-188

The preparation of the following tabulated Examples of the general formula



were performed by a similar method to that of Example 183 using as the starting materials the appropriate pyrazole (P) and amine (A).

Ex. no.	P prep. no.	A prep. no.	X	R	Analytical Data
184 ¹	75	55	F		¹ H NMR (400MHz, CDCl ₃): δ = 2.09 (s, 3H), 3.65 (s, 2H), 3.79 (s, 2H), 6.80 (d, 1H), 6.93 (s, 1H), 6.97 (d, 1H), 7.31 (d, 2H), 7.72 (d, 2H). LRMS (thermospray) : m/z [MH ⁺] 380.
185 ¹	76	55	CN		m.p. 114-116°C ¹ H NMR (400MHz, CDCl ₃): δ = 2.08 (s, 3H), 3.62 (s, 2H), 3.77 (s, 2H), 7.34 (d, 2H), 7.55 (s, 1H), 7.77 (d, 2H), 7.79 (s, 1H). LRMS (thermospray) : m/z [MH ⁺] 387.

186 ¹	18	80	Cl		<p>m.p. 98-101°C ¹H NMR (400MHz, CDCl₃): δ = 2.04 (s, 3H), 3.62 (s, 2H), 3.74 (s, 2H), 6.97 (s, 1H), 7.07 (s, 1H), 7.20 (s, 1H), 7.22 (d, 1H), 7.29 (t, 1H), 7.62 (s, 1H), 7.81 (s, 1H). LRMS (thermospray) : m/z [MH⁺] 396. Microanalysis: Found C, 56.98; H, 4.58; N, 17.69. C₂₀H₁₈ClN₅O₂·0.40CH₂Cl₂ requires C, 57.01; H, 4.41; N, 16.29%.</p>
187 ^{1,2,3}	77	55	Me		<p>¹H NMR (400MHz, CDCl₃): δ = 2.10 (s, 3H), 2.30 (s, 3H), 3.65 (s, 2H), 3.80 (s, 2H), 6.85 (s, 1H), 6.95 (s, 1H), 7.10 (s, 1H), 7.30 (d, 2H), 7.70 (d, 2H). LRMS (electrospray) : m/z [MH⁺] 376, [M-H⁺] 374. Microanalysis: Found C, 65.59; H, 5.65; N, 18.19. C₂₁H₂₁N₅O₂·0.50H₂O requires C, 65.51; H, 5.77; N, 18.22%.</p>
188 ⁴	78	55	H		<p>¹H NMR (400MHz, CD₃OD): δ = 2.15 (s, 3H), 4.10 (s, 2H), 7.20 (m, 2H), 7.40 (m, 1H), 7.50 (m, 1H), 7.55 (d, 2H), 7.90 (d, 2H). Microanalysis: Found C, 53.51; H, 4.13; N, 13.59. C₂₀H₁₉N₅O₂. 1.25 TFA requires C, 53.63; H, 4.05; N, 13.90%.</p>

¹ No preparative HPLC was required for purification of this compound.


² The eluent used for flash column chromatography purification of this compound was dichloromethane:methanol:0.88 ammonia (95:5:0.5 changing to 90:10:1, by volume).

³ The product was triturated with dichloromethane containing a trace of methanol – a solid crystallised out which was an impurity. This was filtered off and the filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to give the title compound.

⁴ The column used for preparative HPLC was a LUNA C18 10μm 150x21.2mm.

EXAMPLE 189

5-[(3,5-Dicyclopropyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile



Hydrazine hydrate (133μl, 2.75mmol) was added to a solution of the diketone from Preparation 82 (735mg, 2.50mmol) in acetic acid (25ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (25ml) and saturated aqueous sodium bicarbonate solution (25ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 96:4, by volume) to provide the title compound (473mg) as a white solid, m.p. 168-170°C.


¹H NMR (400MHz, CDCl₃): δ = 0.77 (m, 4H), 0.85 (m, 4H), 1.59 (m, 2H), 7.44 (s, 2H), 7.59 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 291.

Microanalysis: Found C, 69.90; H, 4.85; N, 19.18. C₁₇H₁₄N₄O.0.10H₂O requires C, 69.90; H, 4.90; N, 19.18%.

150

EXAMPLE 190


5-{{3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile

2-Hydroxyethylhydrazine (84mg, 1.10mmol) was added to a solution of the diketone from Preparation 82 (294mg, 1.00mmol) in acetic acid (10ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (25ml) and saturated aqueous sodium bicarbonate solution (25ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1 changing to 95:5, by volume) to provide the title compound (137mg) as a white solid, m.p. 115-117°C.

¹H NMR (400MHz, CDCl₃): δ = 0.67 (m, 2H), 0.80 (m, 4H), 0.85 (m, 2H), 1.52 (m, 2H), 3.39 (brs, 1H), 4.05 (m, 2H), 4.22 (t, 2H), 7.42 (s, 2H), 7.58 (s, 1H).


LRMS (thermospray) : m/z [MH⁺] 355.

Microanalysis: Found C, 67.63; H, 5.55; N, 16.35. C₁₉H₁₈N₄O₂·0.17H₂O requires C, 67.63; H, 5.48; N, 16.60%.

EXAMPLE 1915-{{1-(2-Aminoethyl)-3,5-dicyclopropyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile

2-Chloroethylamine hydrochloride (192mg, 1.65mmol) and the pyrazole from Example 189 (440mg, 1.50mmol) were heated as a melt at 160°C for 18 hours and the residue was partitioned between dichloromethane (25ml) and 10% aqueous potassium carbonate solution (25ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0 changing to 95:5:0.5, by volume) to provide the title compound (9.2mg) as a white solid, m.p. 175-177°C.


¹H NMR (400MHz, CDCl₃): δ = 0.70 (m, 2H), 0.79 (m, 4H), 0.88 (m, 2H), 1.57 (m, 1H), 1.66 (m, 1H), 3.46 (t, 2H), 4.41 (t, 2H), 7.62 (s, 2H), 7.58 (s, 1H).

EXAMPLE 1923-{{3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazol-4-yl}oxy}-5-methylbenzonitrile

and

EXAMPLE 193

3-{{[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile



2-Hydroxy-ethyl-hydrazine (326 μ l, 4.80mmol) was added to a solution of the diketone from Preparation 86 (1.00g, 4.37mmol) in acetic acid (10ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and the residual orange oil was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (50:50 changing to 100:0, by volume) to provide two pale yellow oils.

Least Polar Fraction (Example 192) – 419mg

^1H NMR (400MHz, CDCl_3): δ = 0.69 (m, 2H), 0.82 (m, 2H), 1.54 (m, 1H), 2.00 (s, 3H), 2.35 (s, 3H), 3.46 (brs, 1H), 4.05 (t, 2H), 4.22 (t, 2H), 6.88 (s, 1H), 6.94 (s, 1H), 7.08 (s, 1H).

LRMS (thermospray) : m/z [MH $^+$] 298.

Microanalysis: Found C, 68.29; H, 6.51; N, 13.92. $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}_2$ requires C, 68.67; H, 6.44; N, 14.13%.


Most Polar Fraction (Example 193) – 201mg

^1H NMR (400MHz, CDCl_3): δ = 0.75 (m, 4H), 1.58 (m, 1H), 2.07 (s, 3H), 2.35 (s, 3H), 3.45 (brs, 1H), 4.00 (m, 4H), 6.92 (s, 1H), 7.00 (s, 1H), 7.10 (s, 1H).

LRMS (thermospray) : m/z [MH $^+$] 298.

Microanalysis: Found C, 68.44; H, 6.49; N, 13.95. $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}_2$ requires C, 68.67; H, 6.44; N, 14.13%.

EXAMPLE 194


3-[3-Cyclopropyl-1-(2-amino-ethyl)-5-methyl-1H-pyrazol-4-yl]oxy]-5-methylbenzonitrile

The alcohol from Example 192 (140mg, 0.47mmol), triphenylphosphine (309mg, 1.18mmol) and phthalimide (174mg, 1.18mmol) were dissolved in tetrahydrofuran (9ml) at 0°C under nitrogen and diisopropylazodicarboxylate (232μl, 1.18mmol) dissolved in tetrahydrofuran (2ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (11ml) and hydrazine hydrate (114μl, 2.35mmol) was added. The thick white slurry was stirred for 18h at room temperature under nitrogen, methanol (10ml) was added and the mixture was filtered. The filtrate was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20ml). The organic phase was extracted with 2M aqueous hydrochloric acid (20ml) and the aqueous phase was washed with dichloromethane (5x10ml), basified with 1M aqueous sodium hydroxide and extracted with dichloromethane (50ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (135mg) as a yellow oil.

¹H NMR (400MHz, CDCl₃): δ = 0.70 (m, 4H), 1.56 (m, 1H), 2.06 (s, 3H), 2.30 (s, 3H), 3.10 (t, 2H), 3.97 (t, 2H), 6.87 (s, 1H), 6.92 (s, 1H), 7.05 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 297.

Microanalysis: Found C, 63.81; H, 6.51; N, 17.30. C₁₇H₂₀N₄O.0.36CH₂Cl₂ requires C, 63.78; H, 6.39; N, 17.14%.


EXAMPLE 1953-[(3-Cyclopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile

Hydrazine hydrate (31 μ l, 0.64mmol) was added to a solution of the diketone from Preparation 86 (150mg, 0.58mmol) in acetic acid (1.3ml) under nitrogen at room temperature. After stirring for 24 hours, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (60:40 changing to 40:60, by volume) to provide the title compound (140mg).

1 H NMR (400MHz, CDCl₃): δ = 0.60 (m, 4H), 1.69 (m, 1H), 2.09 (s, 3H), 2.34 (s, 3H), 6.95 (s, 1H), 6.99 (s, 1H), 7.10 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 254.

Microanalysis: Found C, 68.35; H, 6.13; N, 15.10. C₁₅H₁₅N₃O.0.29EtOAc requires C, 68.72; H, 6.32; N, 14.88%.

EXAMPLE 1963-{{[1-(3-Aminopropyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile

3-Chloropropylamine hydrochloride (62mg, 0.48mmol) and the pyrazole from Example 123 (113mg, 0.44mmol) were heated as a melt at 150°C for 18 hours. After cooling the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (98:2:0 changing to 95:5:0.5, by volume). An impurity remained so the oil was dissolved in acetone (3ml) and (L)-tartaric acid (54mg, 0.44mmol) was added, the mixture was heated to effect dissolution and cooled. The resultant precipitate was isolated by filtration washing with acetone (10ml) to provide the title compound (127mg) as a white solid which was the tartrate salt.


¹H NMR (400MHz, CD₃OD): δ = 1.05 (m, 6H), 2.07 (m, 2H), 2.37 (q, 2H), 2.53 (s, 3H), 2.57 (q, 2H), 2.99 (t, 2H), 4.15 (t, 2H), 4.38 (s, 2H), 6.89 (s, 1H), 7.01 (s, 1H), 7.19 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 313.

Microanalysis: Found C, 56.81; H, 6.57; N, 12.06. C₂₂H₃₀N₄O₇ requires C, 57.13; H, 6.54; N, 12.11%.

EXAMPLE 197

3-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-4-methoxybenzonitrile



Cesium carbonate (700mg, 2.14mmol) was added to a stirred solution of 2-methoxy-5-cyanophenol (285mg, 2.15mmol) and the dione of Preparation 2 (348mg, 2.15mmol) in acetone (20ml) at room temperature. The reaction was heated at 50°C for 3 hours and then cooled to room temperature. The mixture was concentrated under reduced pressure, dissolved in dichloromethane (5ml) and washed with water (5ml). The organic phase was isolated using a 5μM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was dissolved in acetic acid (5.4ml) and 2-hydroxy-ethyl-hydrazine (160μl, 2.15mmol) added under nitrogen at


room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and the residual orange oil was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (25:75 changing to 50:50, by volume) to provide the title compound (182mg).

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.71 (brs, 1H), 4.00 (s, 3H), 4.08 (m, 2H), 4.09 (m, 2H), 6.89 (s, 1H), 6.99 (d, 1H), 7.32 (d, 1H). LRMS (thermospray) : m/z [MH⁺] 316.

Microanalysis: Found C, 64.57; H, 6.73; N, 13.15. C₁₇H₂₁N₃O₃ requires C, 64.74; H, 6.71; N, 13.32%.

Examples 198-199


The preparation of the following tabulated Examples of the general formula



were performed by a similar method to that of Example 197 using the β-diketone of Preparation 2 and the appropriate aryl alcohol as the starting materials.

Example No.	R	Analytical Data
198		¹ H NMR (400MHz, CDCl ₃): δ = 1.04 (m, 6H), 2.42 (q, 2H), 2.51 (q, 2H), 4.07 (m, 2H), 4.12 (m, 2H), 6.60 (d, 1H), 7.25 (t, 1H), 7.49 (d, 1H), 7.53 (m, 2H), 7.82 (m, 1H), 8.41 (m, 1H). LRMS (thermospray) : m/z [MH ⁺] 311.
199		¹ H NMR (400MHz, CDCl ₃): δ = 1.19 (m, 6H), 2.48 (q, 2H), 2.51 (q, 2H), 4.03 (m, 2H), 4.10 (m, 2H), 7.06 (s, 1H), 7.22 (m, 1H), 7.38 (t, 1H), 7.42 (m, 1H), 7.69 (d, 1H), 7.79 (s, 1H), 7.80 (s, 1H). LRMS (thermospray) : m/z [MH ⁺] 311. Microanalysis: Found C, 72.16; H, 7.20; N, 8.95. C ₁₉ H ₂₂ N ₂ O ₂ ·0.10EtOAc requires C, 72.45; H, 7.19;

		N, 8.63%.
--	--	-----------

EXAMPLE 2002-[4-[3,5-Di(1*H*-pyrazol-1-yl)phenoxy]-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol


The protected alcohol from Preparation 88 (254mg, 0.53mmol) and p-toluene-sulphonic acid (10mg, 0.05mmol) were dissolved in methanol (4ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20ml) and dichloromethane (20ml). The aqueous phase was extracted with dichloromethane (10ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 93:7, by volume) to provide the title compound (56mg) as a white solid, m.p. 108-110°C.

¹H NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.46 (q, 2H), 2.53 (q, 2H), 4.01 (t, 2H), 4.07 (t, 2H), 6.44 (s, 2H), 7.16 (s, 2H), 7.68 (s, 3H), 7.92 (s, 2H).

LRMS (electrospray) : m/z [MH⁺] 393, [MNa⁺] 415.

Microanalysis: Found C, 63.62; H, 6.11; N, 21.11. C₂₁H₂₄N₆O₂·0.06CH₂Cl₂ requires C, 63.63; H, 6.12; N, 21.14%.

EXAMPLE 201


2-[3,5-Diethyl-4-[3-fluoro-5-(1*H*-pyrazol-1-yl)phenoxy]-1*H*-pyrazol-1-yl]ethanol

The protected alcohol from Preparation 89 (38.6mg, 0.09mmol) and p-toluene-sulphonic acid (3.5mg, 0.01mmol) were dissolved in methanol (1ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between 10% aqueous potassium carbonate solution (4ml) and dichloromethane (4ml). The aqueous phase was extracted with dichloromethane (10ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (99:1 changing to 98:2, by volume) to provide the title compound (23mg) as a white solid, m.p. 120-122°C.

¹H NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 2.46 (q, 2H), 2.55 (q, 2H), 4.06 (m, 2H), 4.09 (m, 2H), 6.47 (s, 1H), 6.49 (s, 1H), 7.09 (s, 1H), 7.12 (s, 1H), 7.71 (s, 1H), 7.86 (s, 1H).

LRMS (electrospray) : m/z [MNa⁺] 367.

HRMS: [MH⁺] Found 345.1717. C₁₈H₂₂FN₄O₂ requires 345.1722.


EXAMPLE 2023-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-methoxybenzonitrile

The protected alcohol from Preparation 90 (400mg, 1.00mmol) and p-toluene-sulphonic acid (19mg, 0.10mmol) were dissolved in methanol (10ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20ml) and dichloromethane (20ml). The aqueous phase was extracted with dichloromethane (40ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (174mg) as an oil.

¹H NMR (400MHz, CDCl₃): δ = 1.09 (m, 6H), 2.40 (q, 2H), 2.49 (q, 2H), 3.78 (s, 3H), 4.04 (m, 2H), 4.08 (m, 2H), 6.66 (s, 1H), 6.71 (s, 1H), 6.79 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 316.

Microanalysis: Found C, 63.63; H, 6.76; N, 13.06. C₁₇H₂₁N₃O₃.0.08CH₂Cl₂ requires C, 63.68; H, 6.68; N, 13.04%.


EXAMPLE 2032-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethylamine

The alcohol from Example 38 (371mg, 1.25mmol), triphenylphosphine (984mg, 3.75mmol) and phthalimide (552mg, 3.75mmol) were dissolved in tetrahydrofuran (20ml) at 0°C under nitrogen and diisopropylazodicarboxylate (738μl, 3.75mmol) dissolved in tetrahydrofuran (2ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (25ml) and hydrazine hydrate (303μl, 6.25mmol) was added. The slurry was stirred for 4 hours at 45°C under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M methanolic ammonia solution to elute the product. The product was then purified by flash chromatography on alumina eluting with dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (212mg) as an oil.

¹H NMR (400MHz, CDCl₃): δ = 1.12 (m, 6H), 2.43 (q, 2H), 2.54 (q, 2H), 3.21 (t, 2H), 4.07 (t, 2H), 6.43 (m, 3H).


Microanalysis: Found C, 59.78; H, 6.50; N, 14.35. C₁₅H₁₉F₂N₃O_{0.26}H₂O requires C, 60.05; H, 6.56; N, 14.01%.

EXAMPLE 204

3-{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-fluorobenzamide

The alcohol from Example 163 (142mg, 0.44mmol), triphenylphosphine (346mg, 1.32mmol) and phthalimide (194mg, 1.32mmol) were dissolved in tetrahydrofuran (8ml) at 0°C under nitrogen and diisopropylazodicarboxylate (260µl, 1.32mmol) dissolved in tetrahydrofuran (1ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (9ml) and hydrazine hydrate (107µl, 2.2mmol) was added. The slurry was stirred for 4 hours at 45°C under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through a polymer supported sulphonic acid column eluting with methanol to remove impurities, then 2M methanolic ammonia solution to elute the product. The product was then purified by flash chromatography on alumina eluting with dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (60mg) as an oil.


¹H NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.43 (q, 2H), 2.53 (q, 2H), 3.17 (t, 2H), 4.05 (t, 2H), 6.01 (brs, 1H), 6.25 (brs, 1H), 6.75 (d, 1H), 7.16 (m, 2H).
 HRMS: [MH⁺] Found 321.1718. C₁₆H₂₁FN₄O₂ requires 321.1722.

EXAMPLE 2053-[(3-Isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile

Hydrazine hydrate (100 μ l, 2.10mmol) was added to a solution of the diketone from Preparation 91 (544mg, 2.10mmol) in acetic acid (10ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (66:34, by volume) to provide the title compound (308mg) as a pale yellow oil.

^1H NMR (400MHz, CDCl_3): δ = 1.22 (d, 6H), 2.09 (s, 3H), 2.56 (s, 3H), 2.84 (m, 1H), 6.91 (s, 1H), 6.94 (s, 1H), 7.11 (s, 1H).

LRMS (thermospray) : m/z $[\text{MH}^+]$ 256.


EXAMPLE 2063-[(1-(2-Aminoethyl)-3-isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile

The pyrazole from Example 205 (70mg, 0.27mmol) and 2-chloroethylamine hydrochloride (38mg, 0.33mmol) were heated as a melt at 150°C for 18 hours. The residue was cooled and purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to give the title compound (25mg).

¹H NMR (400MHz, CDCl₃): δ = 1.18 (m, 6H), 2.06 (s, 3H), 2.35 (s, 3H), 2.79 (m, 1H), 3.19 (m, 2H), 4.04 (m, 2H), 6.89 (s, 1H), 6.97 (s, 1H), 7.12 (s, 1H).
LRMS (electrospray) : m/z [MH⁺] 300.

EXAMPLE 207

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-*N*-(2-pyridinylmethyl)acetamide




Standard solutions: The acid of Preparation 4 (800mg, 2.33mmol), 1*H*-benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (822mg, 3.50mmol) and diisopropylethylamine (603mg, 4.66mmol) were separately dissolved in *N,N*-dimethylformamide (3x13ml). 2-(Methylamino)pyridine (3mg, 0.029mmol) was treated with the standard solutions of the acid and coupling reagents (3x170μl) in a 96 well plate and the mixture was shaken for 14 hours at room temperature. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500μl) and purified by HPLC (Magellen C₈(2) 150x10mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water)).

Retention time: 5.69 minutes.

LRMS (electrospray) : m/z [MH⁺] 434.

EXAMPLE 208

[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetonitrile




The pyrazole of Preparation 8 (1.00g, 2.60mmol) in tetrahydrofuran (10ml) was added in one portion to a solution of sodium cyanide (284mg, 5.20mmol) in water (10ml) at room temperature. The reaction was heated at 80°C for 14 hours and cooled to room temperature. The solvent was removed under reduced pressure and the resulting brown solid was dissolved in dichloromethane (50ml) and water (50ml). The organic layer was separated, washed with water (50ml), brine (30ml), dried over magnesium sulphate, filtered and the solvent removed under reduced pressure to give a brown solid. The product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to give the title compound as a yellow solid (500mg), m.p. 150-152°C.

¹H NMR (400MHz, CDCl₃): δ = 2.17 (s, 3H), 3.56 (s, 2H), 6.77 (s, 2H), 7.02 (s, 1H).

LRMS (thermospray) : m/z [MH⁺] 282.

EXAMPLE 209

1-{{[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetyl}piperidine



Standard solutions: The acid of Preparation 92 (680mg, 2.16mmol) and 1*H*-benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (761mg, 3.23mmol) were separately dissolved in *N,N*-dimethylacetamide:triethylamine (96:4) (2x17ml).


Piperidine (3mg, 0.031mmol) was treated with the standard solutions of the acid and coupling reagents (250 μ l of each) in a 96 well plate and the mixture was shaken for 14 hours at 80°C. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500 μ l) and purified by HPLC (Magellen C₁₈(2) 150x10mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water).

Retention time: 4.7 minutes.

LRMS (electrospray) : m/z [MH⁺] 368.







EXAMPLES 210-217

The compounds of the following tabulated Examples of the general formula:




were performed by a similar method to that of Example 209 using the appropriate amine.

Example No.	X	HPLC retention times / min	LRMS (electrospray) m/z [MH ⁺]
210		3.9	384
211		5.5	459

212		5.4	476
213		5.3	458
214		5.1	424
215		5.3	458
216		4.9	408
217		5.2	404

EXAMPLE 218

3-chloro-5-[(5-[(2-chlorobenzyl)amino]methyl]-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile



Standard solutions: The bromide of Preparation 18 (850mg, 2.30mmol) was dissolved in *N*-methylpyrrolidinone (43ml).

2-Chlorobenzylamine (19mg, 0.13mmol) in a 96 well plate was treated with the solution of the bromide of Preparation 18 (500 μ l) and the mixture was shaken for 14 hours at 80°C. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500 μ l) and purified by HPLC (Magellen C₈(2)


150x10mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water).

Retention time: 5.3 minutes.

LRMS (electrospray) : m/z [MH⁺] 386.












EXAMPLES 219-249

The compounds of the following tabulated Examples of the general formula:






were performed by a similar method to that of Example 218 using the appropriate amine.

Example No.	X	HPLC retention times / min	LRMS (electrospray) m/z [MH ⁺]
219		4.2	367
220		4.1	366
221		3.8	374
222		3.2	353
223		4.2	366

224		3.7	334
225		3.7	445
226		4.1	366
227		4.3	387
228		4.2	380
229		3.6	328
230		3.5	347
231		4.3	387
232		4.5	438
233		3.8	353
234		3.7	370

235		4.1	370
236		4.1	396
237		4.1	352
238		4.1	382
239		4.4	420
240		4.0	362
241		4.1	382
242		4.2	372
243		3.2	353
244		4.2	420
245		4.4	421
246		3.7	353
247		4.4	421

248		4.1	382
249		4.1	382


EXAMPLE 2503-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}-5-(methylsulfonyl)benzonitrile

The protected alcohol from Preparation 93 (687mg, 1.65mmol) and p-toluene-sulphonic acid (32mg, 0.17mmol) were dissolved in methanol (16ml) and stirred under nitrogen at room temperature. After 4 hours a second portion of p-toluene-sulphonic acid (32mg, 0.17mmol) was added. After 18 hours the solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20ml) and dichloromethane (20ml). The aqueous phase was extracted with dichloromethane (40ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (487mg) as a white solid. m.p. 72 °C.

¹H NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 2.44 (q, 2H), 2.49 (s, 3H), 2.53 (q, 3H), 4.08 (m, 2H), 4.14 (m, 2H), 6.84 (s, 1H), 7.00 (s, 1H), 7.10 (s, 1H).

LRMS (electrospray) : m/z [MH⁺] 332.


Microanalysis: Found C, 61.36; H, 6.43; N, 12.55. C₁₇H₂₁N₃O₂S requires C, 61.61; H, 6.39; N, 12.68%.

EXAMPLE 2513-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-(methylsulfinyl)benzonitrile

Wet alumina was prepared by adding water (1ml) to Brockman grade I alumina (5g). To a stirred solution of the sulphide from Example 250 (134mg, 0.40mmol) in dichloromethane (2ml) was added of wet alumina (400mg) followed by Oxone® (123mg, 0.4mmol) and the mixture was heated at reflux. After 1 hour a second portion of oxone (123mg, 0.40mmol) was added and the mixture was heated for a further 2 hours. After cooling to room temperature the reaction mixture was filtered and the resulting solids were washed with dichloromethane (20ml). The filtrate was concentrated and was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 90:10, by volume) to provide the title compound (92mg) as an oil.

¹H NMR (400MHz, CDCl₃): δ = 1.12 (m, 6H), 2.44 (q, 2H), 2.53 (q, 2H), 2.73 (s, 3H), 4.06 (m, 2H), 4.18 (m, 2H), 7.24 (s, 1H), 7.45 (s, 1H), 7.49 (s, 1H).

LRMS (electrospray) : m/z [M+Na⁺] 370.

EXAMPLE 2523-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-(methylsulfonyl)benzonitrile

To a stirred solution of the sulphide from Example 250 (133mg, 0.4mmol) in dichloromethane (2ml) at -78°C was added a solution of meta-chloroperoxybenzoic acid (138mg of 50% by weight mixture, 0.4mmol) in dichloromethane (2ml). The cooling bath was removed and the solution was stirred at room temperature for 4 hours. The mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (6ml) and extracted with dichloromethane (3x5ml). The combined organic components were dried over magnesium sulphate and concentrated. Analysis of the ^1H NMR (400MHz, CDCl_3) suggested a mixture of the desired product and the sulphoxide from Example 251. The crude product mixture was dissolved in dichloromethane (2ml), cooled to -78°C and to this was added meta-chloroperoxybenzoic acid (138mg of 50% by weight mixture, 0.4mmol) in dichloromethane (2ml). The cooling bath was removed and the mixture was stirred at room temperature for 1 hour. The mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (6ml) and extracted with dichloromethane (3x5ml). The combined organic components were dried over magnesium sulphate and concentrated. The crude product mixture was purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound contaminated with meta-chloroperoxybenzoic acid. To a solution of this crude product in dichloromethane at -78°C was added dimethylsulphoxide (30 μl , 0.4mmol). The cooling bath was removed and the mixture was stirred at room temperature for 15 minutes. The mixture was quenched by addition of 10% aqueous potassium carbonate solution (10ml) and the dichloromethane was evaporated. The remaining aqueous mixture was then extracted with diethyl ether (2x10ml) and ethyl acetate (10ml). The organic components were combined, dried over magnesium

sulphate and concentrated to give the crude product mixture which was purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (26mg) as a white solid. m.p. 133 °C.


¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.06 (s, 3H), 4.05 (m, 2H), 4.10 (m, 2H), 7.39 (s, 1H), 7.67 (s, 1H), 7.84 (s, 1H).

LRMS (electrospray) : m/z [M+Na⁺] 385.

HRMS: [MH⁺] 364.1329. C₁₈H₂₀N₆O₂ requires 364.1326.

EXAMPLE 253

3-[{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy]-5-[2-(dimethylamino)ethoxy]benzonitrile



To a stirred solution of the protected alcohol from Preparation 94 (180mg, 0.39mmol) in methanol (4ml) was added para-toluenesulphonic acid (89mg, 0.47mmol). After 18 hours at room temperature the solvent was evaporated under reduced pressure and the residue was partitioned between dichloromethane (5ml) and 10% aqueous potassium carbonate solution (5ml). The aqueous phase was separated and extracted with a dichloromethane (3ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) followed by dichloromethane:methanol:ammonia (80:20:1, by volume) to provide the title compound (63mg) as an oil.


¹H NMR (400MHz, CDCl₃): δ = 1.13 (m, 6H), 2.43 (m, 8H), 2.52 (q, 2H), 2.85 (m, 2H), 3.81 (broad s, 1H), 4.08 (m, 6H), 6.70 (s, 1H), 6.78 (s, 1H), 6.81 (s, 1H).

LRMS (APCI) : m/z [MH⁺] 373.

HRMS: $[\text{MH}^+]$ 373.2234. $\text{C}_{20}\text{H}_{29}\text{N}_4\text{O}_3$ requires 373.2234.

EXAMPLES 254-256


The compounds of the following tabulated Examples of the general formula:



were performed by a similar method to that of Example 253 using as starting material the appropriate protected alcohol (PA) from Preparations 95-97.

Example No.	PA prep No.	R	Analytical Data
254	95	$\text{CH}_2\text{CH}_2\text{NHMe}$	<p>^1H NMR (400MHz, CDCl_3): δ = 1.13 (m, 6H), 2.42 (q, 2H), 2.53 (q, 2H), 2.59 (s, 3H), 3.12 (t, 2H), 4.05 (m, 2H), 4.09 (m, 2H), 4.16 (t, 2H), 6.75 (s, 1H), 6.81 (s, 1H), 6.82 (s, 1H).</p> <p>LRMS (APCI): m/z $[\text{MH}^+]$ 359</p> <p>HRMS: $[\text{MH}^+]$ 359.2083. $\text{C}_{19}\text{H}_{27}\text{N}_4\text{O}_3$ requires 359.2078.</p>
255	96	CH_2CONH_2	<p>^1H NMR (400MHz, CDCl_3): δ = 1.11 (m, 6H), 2.41 (q, 2H), 2.52 (q, 2H), 4.05 (t, 2H), 4.09 (t, 2H), 4.46 (s, 2H), 5.74 (broad s, 1H), 6.42 (broad s, 1H), 6.69 (s, 1H), 6.85 (s, 2H).</p> <p>LRMS (APCI): m/z 359 (MH^+)</p>

256	97	CH ₂ CH ₂ OCH ₃	¹ H NMR (400MHz, CDCl ₃): δ = 1.12 (m, 6H), 2.42 (q, 2H), 2.51 (q, 2H), 3.44 (s, 3H), 3.73 (t, 2H), 4.09 (m, 6H), 6.71 (s, 1H), 6.77 (s, 1H), 6.83 (s, 1H). LRMS (electrospray): m/z 360 (MH ⁺) HRMS: [MH ⁺] 360.1920. C ₁₉ H ₂₆ N ₃ O ₄ requires 360.1918.
-----	----	--	--

EXAMPLE 2573-[(1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methoxybenzonitrile

The alcohol from Example 202 (87mg, 0.28mmol), triphenylphosphine (220mg, 0.84mmol) and phthalimide (124mg, 0.84mmol) were dissolved in tetrahydrofuran (5ml) at 0°C under nitrogen and diisopropylazodicarboxylate (165μl, 0.84mmol) dissolved in tetrahydrofuran (1ml) was added dropwise. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (6ml) and hydrazine hydrate (68μl, 1.40mmol) was added. The slurry was stirred for 48 hours at room temperature under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M ammonia in methanol solution to elute the product. The product was then purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5) then dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (67mg) as an oil.


¹H NMR (400MHz, CDCl₃): δ = 1.13 (m, 6H), 2.19 (broad s, 2H), 2.43 (q, 2H), 2.54 (q, 2H), 3.19 (t, 2H), 3.60 (s, 3H), 4.06 (t, 2H), 6.68 (s, 1H), 6.73 (s, 1H), 6.80 (s, 1H).

LRMS (electrospray): m/z 315 (MH⁺)

HRMS: [MH⁺] 315.1819. C₁₇H₂₃N₄O₂ requires 315.1816.

EXAMPLE 258

3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-(1*H*-pyrazol-1-yl)benzonitrile



The alcohol from Example 164 (162mg, 0.46mmol), triphenylphosphine (362mg, 1.38mmol) and phthalimide (203mg, 1.38mmol) were dissolved in tetrahydrofuran (8ml) at 0°C under nitrogen and diisopropylazodicarboxylate (272 μ l, 1.38mmol) dissolved in tetrahydrofuran (1ml) was added dropwise. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (9ml) and hydrazine hydrate (112 μ l, 2.3mmol) was added. The slurry was stirred for 48 hours at room temperature under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M ammonia in methanol solution to elute the product. The product was then purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5) then dichloromethane:methanol:0.880 ammonia (90:10:1, by volume) to provide the title compound (62mg) as an oil.


¹H NMR (400MHz, CD₃OD): δ = 1.15 (m, 6H), 2.46 (q, 2H), 2.63 (q, 2H), 3.13 (t, 2H), 4.13 (t, 2H), 6.54 (s, 1H), 7.17 (s, 1H), 7.69 (s, 1H), 7.72 (s, 1H), 7.82 (s, 1H), 8.32 (s, 1H).

LRMS (APCI): m/z 351 (MH⁺)

HRMS: [MH⁺] 351.1929. C₁₉H₂₂N₄O₂ requires 351.1928.

EXAMPLE 259


3,5-Dichlorophenyl-3-methyl-5-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1*H*-pyrazol-4-yl ether



To a stirred solution of the acid (100mg, 0.33mmol) from Preparation 92 in dimethylformamide (2ml) was added carbonyldiimidazole (59mg, 0.36mmol) in one portion. After 30 minutes at room temperature (1*Z*)-*N*-hydroxyethanimidamide (27mg, 0.36mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. A second portion of carbonyldiimidazole (59mg, 0.36mmol) was added and the mixture was heated at 100°C for 12 hours. After cooling to room temperature water (30ml) was added and the mixture was extracted with ethyl acetate (3 x 20ml). The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure to give a brown oil. The crude product mixture was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (40mg) as a pale yellow oil.

¹H NMR (400MHz, CDCl₃): δ = 2.12 (s, 3H), 2.29 (s, 3H), 4.08 (s, 2H), 6.74 (s, 2H), 6.98 (s, 1H).

LRMS (electrospray): m/z 339 (MH⁺)


EXAMPLE 2603-Fluoro-5-[(1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-4-yl)oxy]benzonitrile

To a stirred solution of the protected alcohol (85mg, 0.21mmol) from Preparation 99 in methanol (0.5ml) was added para-toluenesulphonic acid (4mg, 0.02mmol). After 5 hours the reaction mixture was concentrated under reduced pressure, dissolved in dichloromethane (20ml), washed with saturated sodium bicarbonate solution (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (60:40 followed by 40:60, by volume) to provide the title compound (54mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 2.19 (s, 3H), 2.45 (t, 1H), 4.10 (m, 2H), 4.20 (m, 2H), 6.87 (d, 1H), 6.96 (s, 1H), 7.05 (d, 1H).

LRMS (APCI): m/z 330 (MH⁺)

Microanalysis: Found C, 51.38; H, 3.52; N, 12.37. C₁₄H₁₁F₄N₃O₂ requires C, 51.07; H, 3.37; N, 12.76%.

EXAMPLE 2615-[(3,5-Diethyl-1-[2-[(2-methoxyethoxy)methoxy]ethyl]-1*H*-pyrazol-4-yl)oxy]isophthalonitrile

To a stirred solution of the alcohol (5.0g, 16.11mmol) from Example 119 in tetrahydrofuran (65ml) at 0°C was added 2-methoxyethoxymethylchloride (2.39ml, 20.94mmol) followed by sodium hydride (838mg of a 60% by weight dispersion in oil, 20.94mmol). After 10 minutes the reaction mixture was heated at 50°C for 18 hours. After cooling to room temperature, the mixture was diluted with saturated aqueous ammonium chloride solution dropwise (3ml). The mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (250ml) and water (200ml). The aqueous phase was separated and extracted with dichloromethane (150ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane, followed by dichloromethane:methanol (99:1, by volume) to provide the title compound (5.38g) as a colourless oil.


¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.39 (q, 2H), 2.55 (q, 2H), 3.38 (s, 3H), 3.51 (m, 2H), 3.56 (m, 2H), 3.93 (t, 2H), 4.20 (t, 2H), 4.66 (s, 2H), 7.38 (s, 2H), 7.56 (s, 1H).

LRMS (APCI): m/z 399 (MH⁺)

Microanalysis: Found C, 62.11; H, 6.67; N, 13.51. C₂₁H₂₆N₄O₄+0.43H₂O requires C, 62.09; H, 6.67; N, 13.79%.

EXAMPLE 262

3-Cyano-5-[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}benzamide



To a stirred solution of the pyrazole (60mg) from Preparation 100 in dichloromethane (4ml) was added aluminium trichloride (134mg, 1mmol). After 18 hours, ice was added, the mixture was neutralised using saturated aqueous sodium


bicarbonate solution, diluted with water (30ml) and extracted with dichloromethane (2x40ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (27mg) as a colourless glass.

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.52 (q, 2H), 4.07 (m, 4H), 7.25 (s, 1H), 7.60 (s, 1H), 7.65 (s, 1H).

LRMS (APCI): m/z 329 (MH⁺)

EXAMPLE 263

5-{{[5-Ethyl-3-(1-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile




To a stirred solution of the pyrazole from Preparation 102 (219mg, 0.57mmol) in tetrahydrofuran (2.5ml) was added saturated aqueous sodium carbonate solution (0.5ml). The reaction mixture was stirred at room temperature for 4 hours and then heated at reflux for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20ml) and water (20ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 90:10, by volume) to provide the title compound (68mg) as a white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.21 (t, 3H), 1.51 (d, 3H), 2.54 (q, 2H), 4.89 (q, 1H), 7.25 (s, 2H), 7.43 (s, 1H).

LRMS (APCI): m/z 283 (MH⁺)


EXAMPLE 264

5-{{5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile

To a stirred solution of the pyrazole from Preparation 103 (80mg, 0.19mmol) in methanol (1ml) was added para-toluenesulphonic acid (4mg, 0.02mmol). After 5 hours at room temperature the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20ml) and water (20ml). The organic component was dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 95:5, by volume) to provide the title compound (44mg) white solid.

¹H NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 1.46 (d, 3H), 2.54 (q, 2H), 4.10 (q, 2H), 4.17 (q, 2H), 4.79 (q, 1H), 7.44 (s, 2H), 7.57 (s, 1H).

LRMS (APCI): m/z 327 (MH⁺)

EXAMPLE 265**3-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile**


To a stirred solution of the pyrazole from Preparation 105 (235mg, 0.46mmol) in dichloromethane (2ml) was added aluminium trichloride (373mg, 2.8mmol). The reaction mixture was stirred at room temperature for 48 hours, diluted with water (6ml) and extracted with dichloromethane (6ml). The organic component was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 80:20, by volume) followed by dichloromethane:methanol:0.88 ammonia (80:20:1, by volume) to provide an impure sample of the title compound (44mg) as a white solid. The product was further purified by HPLC using a Phenomenex Luna C₁₈ 150x21.2mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-1min 80:20; 1-7min 80:20 changing to 0:100; 7-12min 0:100; 12-12.1min 0:100 changing to 80:20; 12.1-15min 80:20) to provide the title compound (38mg) as a white solid.

Retention time 5.7minutes.

LRMS (electrospray): m/z 422 (MH⁺)

EXAMPLES 266-268

The compounds of the following tabulated Examples of the general formula:




were prepared by a similar method to that of Example 265 using the appropriate protected alcohol (PA) from Preparation 106-108.

Example No.	PA prep No.	R	Analytical Data
266	106	Me	Retention time 4.8 minutes LRMS (electrospray): m/z [MH ⁺] 368
267	107	Et	Retention time 5.3 minutes LRMS (electrospray): m/z [MH ⁺] 382
268	108	ⁱ Pr	Retention time 5.7 minutes LRMS (electrospray): m/z 396 (MH ⁺)

EXAMPLE 269

5-[(4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl]amino)methyl]nicotinamide




To a stirred solution of the amine from Preparation 111 (650mg, 1.70mmol) in isopropyl alcohol (6ml) was added the pyrazole from Preparation 18 (210mg, 0.57mmol) followed by potassium carbonate (240mg, 1.70mmol). The reaction mixture was heated at reflux for 1.5 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5 then 90:10:1 then 80:20:1, by volume) which gave an impure sample of the desired product. Flash chromatography was repeated eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 95:5:0.5 then 90:10:1, by volume) to provide the title compound (10mg) as a pale yellow solid.

¹H NMR (400MHz, CD₃OD): δ = 2.05 (s, 3H), 3.62 (s, 2H), 3.79 (s, 2H), 7.16 (m, 1H), 7.18 (m, 1H), 7.38 (s, 1H), 8.15 (s, 1H), 8.54 (s, 1H), 8.84 (s, 1H).

LRMS (APCI): m/z 419 (M+Na⁺)

HRMS: $[\text{MH}^+]$ 397.1173. $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_2\text{Cl}$ requires 397.1175.

EXAMPLE 2702-[{[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}amino)methyl]isonicotinamide

To a stirred suspension of the amine from Preparation 115 (250mg, 1.66mmol) and the pyrazole from Preparation 18 (155mg, 0.42mmol) in isopropanol (6ml) was added tetrahydofuran (2ml). The mixture was heated at reflux for 2 hours after which the reaction mixture was concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (85:15:1, by volume) to provide an impure sample of the title compound. The product was further purified by HPLC using a Phenomenex Luna C₈(II) 10 μ M 150x21.2mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-6min 95:5 changing to 0:100; 6-10min 0:100) to provide the title compound (65mg) as an off-white solid.


Retention time: 3.40 minutes

¹H NMR (400MHz, CD₃OD): δ = 2.14 (s, 3H), 4.21 (s, 2H), 4.50 (s, 2H), 7.19 (s, 1H), 7.27 (m, 1H), 7.43 (m, 1H), 7.48 (m, 1H), 7.78 (m, 1H), 8.68 (d, 1H)

LRMS (electrospray): m/z 397 (MH^+)

Microanalysis: Found C, 44.56; H, 3.41; N, 14.07. C₁₉H₁₇N₆O₂Cl+1.9.CF₃CO₂H requires C, 44.64; H, 3.11; N, 13.70%.

EXAMPLE 271


Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl phosphate

To a stirred solution of the alcohol from Example 119 (500mg, 1.60mmol) in dichloromethane (5ml) was added tetrazole (226mg, 3.20mmol) followed by di-*tert*-butyl-N,N-diisopropylphosphoramidite (1.02ml, 3.20mmol). After stirring for 4 hours at room temperature the reaction mixture was cooled to 0°C and meta-chloroperoxybenzoic acid (1.0g of 50% by weight mixture, 3mmol) was added portionwise (CARE, EXOTHERM). After 10 minutes the mixture was warmed to room temperature and was diluted with dichloromethane (50ml). The solution was washed with saturated aqueous sodium carbonate solution (20ml) and the aqueous component was separated and extracted with dichloromethane (20ml). The combined organic components were washed with brine (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 99:1:0.1 then 98:2:0.2, by volume) to provide a sample of the title compound (660mg)

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 1.43 (s, 18H), 2.38 (q, 2H), 2.55 (q, 2H), 4.26 (m, 4H), 7.38 (s, 2H), 7.54 (s, 1H).

LRMS (electrospray): m/z 525 (MH⁺)

Microanalysis: Found C, 57.77; H, 7.38; N, 10.33. C₂₅H₃₅N₄O₅P+H₂O requires C, 57.68; H, 7.16; N, 10.76%.

EXAMPLE 2722-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl dihydrogen phosphate


To a stirred solution of the phosphate ester from Example 271 (250mg, 0.48mmol) in dichloromethane (10ml) at 0°C was added trifluoroacetic acid (0.5ml). The reaction mixture was allowed to warm to room temperature and after 4 hours it was concentrated under reduced pressure. The residue was purified by HPLC using a Phenomenex Luna C₈(II) 10μM 150x21.2mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-1.9min 95:5; 2-10min 90:10 changing to 30:70; 10.0-13.8min 30:70; 13.8-13.9min 30:70 changing to 95:5; 13.9-15min 95:5) to give a sample of the desired product. This sample was further purified by recrystallisation using acetonitrile/water which gave the title compound as a white solid, m.p. 198-199 °C.

Retention time: 2.31 minutes.

¹H NMR (400MHz, CD₃OD): δ = 1.09 (m, 6H), 2.35 (q, 2H), 2.61 (q, 2H), 4.28 (m, 4H), 7.55 (s, 2H), 7.79 (s, 1H).

LRMS (APCI): m/z 391 (MH⁺)


Microanalysis: Found C, 50.99; H, 4.92; N, 14.06. C₁₇H₁₉N₄O₅P+0.5H₂O requires C, 51.13; H, 5.05; N, 14.03%.

EXAMPLE 2735-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile sulfate salt

To a stirred solution of the pyrazole from Example 119 (200mg, 0.65mmol) in acetone (5ml) was added sulfuric acid (0.32ml of a 2M aqueous solution, 0.64mmol) and the mixture was stirred at room temperature and the solvent allowed to evaporate. The residue was recrystallised (toluene/acetone) to give the title compound (160mg) as a white powder, m.p. 105-110°C.

¹H NMR (400 MHz, CDCl₃): δ = 1.22 (m, 6H), 2.70 (m, 4H), 4.12 (bs, 1H), 4.59 (m, 2H), 4.75 (bs, 1H), 7.66 (s, 1H), 7.69 (m, 1H), 7.72 (s, 1H).

Microanalysis: Found C, 50.29; H, 4.90; N, 13.48. C₁₇H₁₈N₄O₂.H₂SO₄ requires C, 49.99; H, 4.93; N, 13.72%.


EXAMPLE 2745-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile benzenesulfonic acid salt

To a stirred solution of the pyrazole from Example 119 (20g, 65mmol) in acetone (200ml) was added benzenesulfonic acid (10.7g, 68mmol) and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure and the residue was recrystallised twice (acetone) to give the title compound (16.2g) as a white powder, m.p. 142-144°C.

¹H NMR (400 MHz, CDCl₃): δ = 1.05-1.08 (m, 6H), 2.59 (q, 2H), 2.68 (q, 2H), 4.04 (t, 2H), 4.54 (t, 2H), 7.35-7.42 (m, 3H), 7.55 (s, 1H), 7.64 (s, 1H), 7.86 (d, 2H).
Microanalysis: Found C, 58.86; H, 5.13; N, 11.88. C₂₃H₂₄N₄O₅S requires C, 58.96; H, 5.16; N, 11.96%.


EXAMPLE 275

5-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]isophthalonitrile tosylate salt



To a stirred suspension of the pyrazole from Example 119 (300mg, 1.00mmol) in ethanol (2ml) was added *p*-toluenesulfonic acid (202mg, 1.10mmol) and the mixture was heated on an oil bath until the solids dissolved. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was crystallised (diethyl ether), filtered and recrystallised (isopropyl alcohol) to give the title compound (200mg) as a white solid, m.p. 120°C.


¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.00 (m, 6H), 2.24 (m, 5H), 2.49 (m, 2H), 4.00 (m, 2H), 7.11 (d, 2H), 7.45 (d, 2H), 7.73 (s, 2H), 8.09 (s, 1H).
Microanalysis: Found C, 59.64; H, 5.46; N, 11.60. C₂₄H₂₆N₄O₅S requires C, 59.74; H, 5.43; N, 11.61%.

EXAMPLE 2765-{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile mesylate salt

To a stirred suspension of the pyrazole from Example 119 (250mg, 0.83mmol) in isopropyl alcohol (3ml) was added methanesulfonic acid (52µl, 0.91mmol) and the mixture was heated on an oil bath until the solids dissolved. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to a volume of 1ml. A white solid precipitated out which was washed with cold isopropyl alcohol to give the title compound (239mg) as a white solid, m.p. 144-146°C.

¹H NMR (400 MHz, DMSO-*d*₆): δ = 1.02 (m, 6H), 2.32 (q, 2H), 2.43 (s, 3H), 2.52 (m, 2H), 3.73 (m, 2H), 4.02 (m, 2H), 7.75 (s, 2H), 8.11 (s, 1H).

Microanalysis: Found C, 53.20; H, 5.52; N, 13.68. C₁₈H₂₂N₄O₅S requires C, 53.19; H, 5.46; N, 13.78%.

EXAMPLE 2773-{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile bis-mesylate salt


To a stirred solution of the amine from Example 125 (119mg, 0.40mmol) in ethanol (2ml) was added methanesulfonic acid (1.00ml of a 0.84M solution in ethanol, 0.84mmol). The reaction mixture was concentrated under reduced pressure to remove some of the ethanol. A mixture of diethyl ether and acetone were added and a white solid precipitated out which was filtered and washed (diethyl ether/acetone) to give the title compound (153mg) as a white solid, m.p. 146-148°C.

¹H NMR (400 MHz, CD₃OD): δ = 1.09 (m, 6H), 2.33 (s, 3H), 2.39 (q, 2H), 2.55 (q, 2H), 2.68 (s, 6H), 3.42 (t, 2H), 4.29 (t, 2H), 6.93 (s, 1H), 7.06 (s, 1H), 7.19 (s, 1H).
LRMS (thermospray): m/z [free base+H⁺] 299

Microanalysis: Found C, 45.83; H, 6.12; N, 11.27. C₁₉H₃₀N₄O₇S₂·0.50H₂O requires C, 45.68; H, 6.25; N, 11.21%.


EXAMPLE 278

3-{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile phosphate salt



To a stirred solution of the amine from Example 125 (251mg, 0.84mmol) in ethanol (5ml) was added phosphoric acid (63μl, 0.93mmol). The resulting precipitate was filtered, washed (ethanol then diethyl ether) and dried to give the title compound (265mg) as a white solid, m.p. 210-211°C.

¹H NMR (400 MHz, CD₃OD): δ = 1.08 (m, 6H), 2.32 (s, 3H), 2.39 (q, 2H), 2.56 (q, 2H), 3.39 (m, 2H), 4.29 (m, 2H), 6.93 (s, 1H), 7.05 (s, 1H), 7.18 (s, 1H).
LRMS (thermospray): m/z [free base+H⁺] 299
Microanalysis: Found C, 51.26; H, 6.36; N, 14.08. C₁₇H₂₅N₄O₅P requires C, 51.51; H, 6.36; N, 14.14%.


EXAMPLE 2793-[(1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile (L) tartrate salt

To a stirred solution of the amine from Example 125 (500mg, 1.68mmol) in acetone (15ml) was added (L)-tartaric acid (252mg, 1.68mmol) and the mixture was heated on an oil bath until complete dissolution had occurred. The mixture was cooled to room temperature and a white precipitate formed which was filtered and washed (acetone) to give the title compound (515mg) as a white powder, m.p. 159-161°C.

¹H NMR (400 MHz, CD₃OD): δ = 1.05-1.10 (m, 6H), 2.32 (s, 3H), 2.34-2.41 (m, 2H), 2.53-2.57 (m, 2H), 3.40 (m, 2H), 4.27 (m, 2H), 4.35 (s, 2H), 6.93 (s, 1H), 7.05 (s, 1H), 7.17 (s, 1H).

LRMS (electrospray): m/z [free base+H⁺] 299

Microanalysis: Found C, 54.80; H, 6.38; N, 12.11. C₂₁H₂₈N₄O₇·0.65H₂O requires C, 54.81; H, 6.42; N, 12.10%.

EXAMPLE 2803-[(1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile succinate salt

To a stirred solution of the amine from Example 125 (235mg, 0.79mmol) in acetone (7ml) was added succinic acid (93mg, 0.79mmol). After two minutes the mixture was concentrated to ~ 3ml using a stream of nitrogen gas which resulted in the formation of white crystals. The precipitate was filtered and washed (acetone) to give the title compound (172mg) as white crystals, m.p. 155°C.


¹H NMR (400 MHz, CD₃OD): δ = 1.03-1.07 (m, 6H), 2.34 (s, 3H), 2.40 (q, 2H), 2.50 (s, 4H), 2.59 (q, 2H), 3.34 (t, 2H), 4.23 (t, 2H), 6.95 (s, 1H), 7.06 (s, 1H), 7.22 (s, 1H).

LRMS (electrospray): m/z [free base+H⁺] 299

Microanalysis: Found C, 60.47; H, 6.77; N, 13.39. C₂₁H₂₈N₄O₅ requires C, 60.56; H, 6.78; N, 13.45%.

EXAMPLE 281

3-[{1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy]-5-methylbenzonitrile (L) citrate salt



To a stirred solution of the amine from Example 125 (140mg, 0.47mmol) in acetone (3ml) was added citric acid (90mg, 0.47mmol). The mixture was stirred until complete dissolution had occurred. The mixture was concentrated to ~ 1ml using a stream of nitrogen gas and cooled in a freezer for 1.5 hours. A precipitate collected which was filtered to give the title compound (149mg) as a white powder, m.p. 180-182°C.


¹H NMR (400 MHz, CD₃OD): δ = 1.04-1.07 (m, 6H), 2.35 (s, 3H), 2.40 (q, 2H), 2.58 (q, 2H), 2.73 (d, 2H), 2.80 (d, 2H), 3.42 (t, 2H), 4.30 (t, 2H), 6.95 (s, 1H), 7.08 (s, 1H), 7.21 (s, 1H).

LRMS (electrospray): m/z [free base+H⁺] 299

Microanalysis: Found C, 56.19; H, 6.20; N, 11.31. C₂₃H₃₀N₄O₈ requires C, 56.32; H, 6.16; N, 11.42%.

EXAMPLE 282

5-[(3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile



2-Hydroxyethylhydrazine (8.43ml, 124mmol) was added dropwise to a solution of the diketone of Preparation 45 (30.5g, 113mmol) in acetic acid (300ml) at room temperature under nitrogen. The reaction was stirred at room temperature for 90 minutes and the solvent removed under reduced pressure to give an orange solid. This was combined with an orange solid from another reaction carried out in an identical manner to this. The combined crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (75:25 by volume) to provide the title compound as a white solid. Analysis of the proton nmr showed minor impurities were present so the product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (50:50 by volume) to provide the title compound (50g) as a white solid, m.p. 125°C.


¹H-NMR (400MHz, CDCl₃): δ = 1.13 (6H, m), 2.40 (2H, q), 2.53 (2H, q), 3.53 (1H, m), 4.11 (4H, m), 7.40 (2H, s), 7.58 (1H, s).

LRMS (electrospray): m/z [MH⁺] 311.

Microanalysis: Found: C, 65.62; H, 5.85; N, 18.04. C₁₇H₁₈N₄O₂ requires C, 65.64; H, 5.84; N, 18.05%.

EXAMPLE 283

2-[4-(3,5-Dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine and 2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1*H*-pyrazol-1-yl]ethylamine



The pyrazole from Example 42 (1.03g, 4.00mmol) and 2-chloroethylamine hydrochloride (510mg, 4.40mmol) were heated as a melt at 150°C for 24 hours. The reaction was cooled and a solution of the residue in dichloromethane (100ml) was washed with an aqueous solution of 1M potassium carbonate (50ml), brine (50ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (93:7:1, by volume) to afford the title compounds (768mg) in a 85:15 ratio of regioisomers as a colourless oil.


¹H-NMR (400MHz, CDCl₃): δ = 1.16 (major, t, 3H), 1.16 (minor, t, 3H), 2.47 (major, q, 2H), 2.60 (minor, q, 2H), 3.13 (major, m, 2H), 3.13 (minor, m, 2H), 4.10 (major, m, 2H), 4.10 (minor, m, 2H), 4.24 (major, t, 2H), 4.24 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.02 (major, s, 1H), 7.02 (minor, s, 1H), 7.27 (major, s, 1H), 7.31 (minor, s, 1H).

LRMS (thermospray): m/z [MH⁺] 300.

The following Preparations describe the preparation of certain intermediates used in the preceding Examples.

PREPARATION 1

3-(3,5-Dichlorophenoxy)-2,4-pentanedione




3-Chloro-2,4-pentanedione (183 μ L, 1.53mmol) was added to a stirred suspension of 3,5-dichlorophenol (250mg, 1.53mmol) and potassium carbonate (233mg, 1.69mmol) in acetone (7.7ml) at room temperature under nitrogen. The mixture was stirred for 30 minutes and then heated under reflux for 3½ hours. After cooling, sodium iodide (230mg, 1.53mmol) was added and refluxing continued for a further 3½ hours. After cooling again the mixture was diluted with water (5ml) and concentrated under reduced pressure in a fumehood (Caution: possible residual lachrymator) to remove acetone. The resulting red aqueous solution was diluted with 2M hydrochloric acid (5ml) and extracted with dichloromethane (3x10ml). The combined organic layers were washed with saturated aqueous sodium sulphite solution (10ml) and brine (10ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a red oil (344mg). The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (20:1, by volume) to give the title compound (118mg) as a cream solid m.p. 91-92°C.

¹H-NMR (400MHz, CDCl₃): δ = 2.04 (s, 6H), 6.84 (s, 2H), 7.06 (s, 1H), 14.38 (br.s, 1H)

LRMS (thermospray): m/z [MNH₄⁺] 278.

Microanalysis: Found: C, 50.43; H, 3.84. C₁₁H₁₀Cl₂O₃ requires C, 50.60; H, 3.86%.


PREPARATION 2**4-Chloro-3,5-heptanedione**

Chlorotrimethylsilane (29.7ml, 0.234mol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium bromide (1.26g, 3.9mmol) in dry acetonitrile (116ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 3,5-heptanedione (10.6ml, 78.0mmol) and then dry dimethylsulphoxide (16.6ml, 0.234mol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature, with stirring, over 4 hours. The mixture was diluted with water (1litre), stirred for 10min and then extracted with ether (1x500ml, 2x250ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by distillation under reduced pressure to afford the title compound (5.5g) as a pale yellow oil, b.p. 102-105°C/54mmHg containing ca. 10% 4,4-dichloro-3,5-heptanedione as estimated by microanalysis.

¹H-NMR (400MHz, CDCl₃): δ = 1.12 (t, 6H), 2.59 (q, 4H), 4.77 (s, 0.2H, diketone), 15.50 (s, 0.8H, enol).

LRMS (thermospray): m/z [MNH₄⁺] 180 for title compound and 214 for dichlorinated impurity.

PREPARATION 3


Ethyl 4-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-3-oxobutanoate

Sodium hydride (60% dispersion in oil, 250mg, 6.17mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole (800mg, 2.81mmol, Example 3) in dry N,N-dimethylformamide (5ml) at 0°C under nitrogen. The mixture was stirred for 5 minutes during which time hydrogen was evolved and then ethyl 4-chloroacetoacetate (0.42ml, 3.09mmol) was added. After 30 minutes the reaction mixture was quenched by the addition of water (0.5ml) and concentrated under reduced pressure. A solution of the residue in ethyl acetate (50ml) was washed with saturated aqueous ammonium chloride solution (20ml) and water (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (1.1g) as a white solid, m.p. 82-84°C.

¹H-NMR (300MHz, CDCl₃): δ = 1.40 (6H, m), 1.26 (3H, t), 2.44 (4H, q), 3.47 (2H, s), 4.22 (2H, q), 4.96 (2H, s), 6.82 (2H, s), 7.02 (1H, s).

LRMS (thermospray): m/z [MH⁺] 413.


Microanalysis: Found: C, 55.13; H, 5.34; N, 6.98. C₁₅H₁₅Cl₂N₃O requires C, 55.22; H, 5.37; N, 6.78%.

PREPARATION 4[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetic acid

Aqueous sodium hydroxide solution (1N, 6.2ml, 6.2mmol) was added dropwise to a stirred solution of the ester (2g, 5.6mmol) of Example 9 in tetrahydrofuran (20ml) at 0°C. After 1 hour the solvent was removed under reduced pressure and aqueous hydrochloric acid (20ml) was added with vigorous stirring. The resulting white precipitate was collected by filtration, washed with ether (3x30ml) and dried in a vacuum pistol at 60°C/10mmHg to afford the title compound as a white solid (1.5g), m.p. 157-158°C.

¹H-NMR (300MHz, CDCl₃): δ = 1.13 (6H, m), 2.52 (2H, q), 2.60(2H, q), 5.03 (2H, s), 6.95 (2H, s), 7.14 (1H, s).

LRMS (electrospray): m/z [M-H⁺] 341.

PREPARATION 51-(3,5-Dichlorophenoxy)-2-butanone

Cesium carbonate (108g, 0.33mol) was added in one portion to a stirred solution of 3,5-dichlorophenol (49g, 0.30mol) in acetone (900ml) at room temperature under nitrogen. To this suspension a solution of 1-bromo-2-butanone (30.6ml, 0.30mol) in

200


acetone (300ml) was added dropwise and the resultant suspension was heated under reflux for 2 hours. The suspension was cooled to room temperature, water (200ml) was added and the acetone was removed under reduced pressure. The mixture was extracted with dichloromethane (2x300ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:cyclohexane (50:50, by volume) to provide the title compound (65g) as a yellow oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.13 (t, 3H), 2.60 (q, 2H), 4.58 (s, 2H), 6.78 (s, 2H), 7.01 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 250.

PREPARATION 6

2-(3,5-Dichlorophenoxy)-1-(dimethylamino)-1-penten-3-one




A solution of the ketone of Preparation 5 (65g, 0.28mol) in *N,N*-dimethylformamide dimethylacetal (75ml, 0.56mol) was heated at 100°C using a Dean-Stark apparatus for 10 hours. The reaction was cooled and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) and then pentane:ethyl acetate (60:40, by volume) to provide the title compound (55g) as a yellow oil that solidified upon standing. The resultant yellow solid was washed with pentane (100ml) and dried to provide the title compound (28g) as a yellow solid, m.p. 96-97°C.

¹H-NMR (400MHz, CDCl₃): δ = 0.98 (t, 3H), 2.30 (br s, 2H), 2.94 (s, 6H), 6.77 (s, 2H), 6.95 (s, 1H), 7.24 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 288.

PREPARATION 7


1-Acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazole



Sodium hydride (60% dispersion in oil, 684mg, 17.1mmol) was added to a stirred solution of acetyl chloride (1.21ml, 17.1mmol) and the pyrazole of Example 53 (4.00g, 15.6mmol) in *N,N*-dimethylformamide (20ml) at 0°C under nitrogen. The reaction was stirred at 0°C for 1 hour and then quenched by the addition of water (100ml). The aqueous extracted was with ether (2x50ml). The combined organic phases were washed with water (30ml) and brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ether (90:10, by volume) to provide the title compound (3.0g) as a white solid, m.p. <60°C.

¹H-NMR (300MHz, CDCl₃): δ = 2.11 (s, 3H), 2.43 (s, 3H), 2.70 (s, 3H), 6.78 (s, 2H), 7.03 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 299.

PREPARATION 8**1-Acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-1*H*-pyrazole**

N-Bromosuccinimide (2.70g, 15.0mmol) was added to a stirred solution of the pyrazole of Preparation 7 (3.00g, 10.0mmol) in 1,1,1-trichloroethane (40ml) at room temperature under nitrogen. The reaction was heated at 80°C for 1 hour and then azobisisobutyronitrile (2mg) was added and the reaction mixture was heated for a further 3 hours. The reaction was cooled to room temperature and a solid removed by filtration. The filtrate was concentrated under reduced pressure and the resulting yellow oil was dissolved in ethyl acetate (100ml). The ethyl acetate was washed with 1M aqueous sodium carbonate solution (30ml), water (30ml) and brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide a yellow solid that was washed with ice cold ether (20ml) to provide the title compound (2.3g) as a white solid, m.p. 111-113°C.

¹H-NMR (300MHz, CDCl₃): δ = 2.10 (s, 3H), 2.73 (s, 3H), 4.73 (s, 2H), 6.86 (s, 2H), 7.11 (s, 1H).


LRMS (thermospray): m/z [MH⁺] 379.

PREPARATION 94-(3-Cyanophenoxy)-3,5-heptanedione

A mixture of the β -diketone of Preparation 2 (1.79g, 11.0mmol), 3-cyanophenol (1.31g, 11.0mmol), cesium carbonate (3.58g, 11.0mmol) and acetone (44ml) was heated under reflux for 2 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (50ml) and water (25ml). The organic layer was separated, washed with brine (25ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (10:90, by volume) to provide the title compound (1.10g) as a yellow oil.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ = 1.04 (t, 6H), 2.49 (q, 4H), 7.16 (m, 2H), 7.30 (d, 1H), 7.39 (t, 2H), 14.51 (s, 1H).

LRMS (thermospray): m/z $[\text{MNH}_4^+]$ 263.

PREPARATION 10tert-Butyl 3-(hydroxymethyl)-4-morpholinecarboxylate


Borane (38.1ml of a 1.0M solution in tetrahydrofuran, 38.1mmol) was added dropwise to a stirred suspension of 3-morpholinecarboxylic acid (1.00g, 7.63mmol) in tetrahydrofuran (50ml) at room temperature under nitrogen. The reaction was heated under reflux and the reaction became homogeneous and heating was continued for 12 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The residue was dissolved in 1M aqueous sodium hydroxide solution and stirred at room temperature for 5 days. After this time di-*tert*-butyl dicarbonate (1.66g, 7.63mmol) was added and the reaction was stirred for 12 hours. The reaction was diluted with ether (100ml). The organic layer was separated, washed with brine (10ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) and then ethyl acetate to provide the title compound (1.30g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.48 (s, 9H), 2.05 (s, 1H), 3.19 (br t, 1H), 3.47 (td, 1H), 3.60 (dd, 1H), 3.87 (m, 6H).

LRMS (thermospray): m/z [MH⁺] 218.

PREPARATION 11

tert-Butyl 3-[(methylsulfonyl)oxy]methyl}-4-morpholinecarboxylate



Triethylamine (1.15ml, 8.29mmol) was added dropwise to a stirred solution of the alcohol of Preparation 10 (1.20g, 5.52mmol) and methanesulfonic anhydride (1.44g, 5.52mmol) in dichloromethane (50ml) at room temperature under nitrogen. The reaction was stirred for 1 hour and then poured onto water (50ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography


on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (1.20g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.49 (s, 9H), 3.06 (s, 3H), 3.50 (td, 1H), 3.60 (dd, 1H), 3.80 (m, 4H), 4.26 (br s, 1H), 4.39 (m, 2H).

LRMS (thermospray): m/z [MNH₄⁺] 313.

PREPARATION 12


Methyl-2-(3,5-dichlorophenoxy)-3-oxopentanoate



A mixture of methyl-2-chloro-3-pentanoate (25.0g, 152mmol), 3,5-dichlorophenol (24.6g, 152mmol), cesium carbonate (54.4g, 167mmol) and acetone (500ml) was heated under reflux for 2 hours. After cooling the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (100ml) and water (50ml). The organic layer was separated, washed with brine (25ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:toluene (90:10, by volume) to provide the title compound (40.0g) as a pink oil.

¹H-NMR (300MHz, CDCl₃): δ = 1.16 (t, 3H), 2.60 (m, 2H), 3.77 (s, 3H), 5.13 (s, 1H), 6.84 (s, 2H), 7.10 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 308.

PREPARATION 13**4-(3,5-Dichlorophenoxy)-5-ethyl-2-(2-hydroxyethyl)-2,4-dihydro-3*H*-pyrazol-3-one**


A solution of 2-hydroxyethylhydrazine (4.30g, 56.7mmol) in glacial acetic acid (2.0ml) was added to a stirred solution of the ketoester of Preparation 12 (15.0g, 51.5mol) in glacial acetic acid (100ml) and the resulting solution was stirred at room temperature for 48 hours. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (10.1g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.02 (t, 3H), 2.29 (m, 2H), 3.63 (m, 2H), 3.80 (m, 2H), 6.92 (s, 2H), 7.21 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 317.

Microanalysis: Found: C, 48.86; H, 4.44; N, 9.01. C₁₃H₁₄N₂O₃Cl₂ requires C, 49.23; H, 4.45; N, 8.83%.

PREPARATION 14


2-(2-{{[tert-Butyl(dimethyl)silyl]oxy}ethoxy}-4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-3H-pyrazol-3-one

tert-Butyldimethylsilyl chloride (8.14g, 54.0mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 13 (14.3g, 45.0mmol) and imidazole (3.98g, 58.5mmol) in *N,N*-dimethylformamide (90ml) and the resulting solution was stirred at room temperature for 48 hours. The mixture was partitioned between ethyl acetate (100ml) and water (300ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (9.56g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 0.15 (s, 6H), 0.94 (s, 9H), 1.16 (t, 3H), 2.45 (m, 2H), 3.94 (m, 4H), 6.85 (s, 2H), 6.97 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 431.


Microanalysis: Found: C, 52.87; H, 6.52; N, 6.46. C₁₉H₂₈N₂O₃Cl₂Si requires C, 52.90; H, 6.54; N, 6.49%.

PREPARATION 15**1-(2-{[tert-Butyl(dimethyl)silyloxy}ethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-yl trifluoromethanesulfonate**

Phenyltriflame (3.70g, 10.5mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 14 (4.10g, 9.50mmol) and triethylamine (1.60ml, 11.4mmol) in dichloromethane (20ml) at room temperature under nitrogen. The reaction was stirred for 2 hours and then poured onto water (50ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the title compound (5.10g) as a purple oil.

¹H-NMR (300MHz, CDCl₃): δ = 0.01 (s, 6H), 0.86 (s, 9H), 1.17 (t, 3H), 2.45 (q, 2H), 4.01 (m, 2H), 4.14 (m, 2H), 6.84 (s, 2H), 7.08 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 563.


PREPARATION 16**3-(1-Acetyl-2-oxoproxy)-5-chlorobenzonitrile**

A mixture of 3-chloro-2,4-pentanedione (6.73g, 50.0mmol), the phenol of Preparation 36 (7.67g, 50.0mmol), cesium carbonate (18.0g, 55.4mmol) and acetone (40ml) was heated under reflux for 2 hours. The reaction was cooled to room temperature, *N,N*-dimethylformamide (6ml) and acetone (30ml) were added and the reaction was heated at 70°C for a further 12 hours. After cooling, the solid was removed by filtration and dissolved in 1M aqueous hydrochloric acid (150ml). The resulting solution was extracted with dichloromethane (3x100ml) and the combined organic phases were washed with brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (5.50g) as a brown solid, m.p. 105-108°C.

¹H-NMR (300MHz, CDCl₃): δ = 2.04 (s, 6H), 7.13 (s, 1H), 7.19 (s, 1H), 7.35 (s, 1H), 14.40 (s, 1H).

PREPARATION 17

3-[(1-Acetyl-3,5-dimethyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile




Sodium hydride (60% dispersion in oil, 840mg, 21.0mmol) was added to a stirred solution of acetyl chloride (1.50ml, 21.0mmol) and the pyrazole of Example 76 (4.80g, 19.4mmol) in *N,N*-dimethylformamide (20ml) at 0°C under nitrogen. The reaction was stirred at 0°C for 15 minutes and then quenched by the addition of water (200ml). The reaction mixture was extracted with ethyl acetate (3x120ml). The combined organic phases were washed with water (50ml) and brine (50ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the title compound (5.00g) as a white solid, m.p. <60°C.

¹H-NMR (400MHz, CDCl₃): δ = 2.06 (s, 3H), 2.38 (s, 3H), 2.65 (s, 3H), 6.99 (m, 1H), 7.08 (m, 1H), 7.29 (m, 1H).

LRMS (thermospray): m/z [MH⁺] 290.


PREPARATION 18

3-{[1-Acetyl-3-(bromomethyl)-5-methyl-1*H*-pyrazol-4-yl]oxy}-5-chlorobenzonitrile




N-Bromosuccinimide (4.60g, 25.6mmol) was added to a stirred solution of the pyrazole of Preparation 17 (5.00g, 17.3mmol) in 1,1,1-trichloroethane (70ml) and azobisisobutyronitrile (20mg) at room temperature under nitrogen. The reaction was heated at 80°C for 3 hours and then cooled to room temperature. A second portion of *N*-bromosuccinimide (2.00g, 11.2mmol) was added and the reaction mixture was heated at 80°C for a further 4 hours. The reaction was cooled to room temperature and concentrated under reduced pressure and the resulting yellow oil was purified by flash column chromatography on silica gel eluting with pentane:dichloromethane (25:75, by volume) to provide the title compound (2.30g) as a white solid, m.p. 122-123°C.

¹H-NMR (300MHz, CDCl₃): δ = 2.10 (s, 3H), 2.74 (s, 3H), 4.73 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.39 (s, 1H).

PREPARATION 193-Chloro-5,5-dimethyl-2,4-hexanedione

Chlorotrimethylsilane (26.8ml, 0.21mol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium bromide (1.13g, 3.50mmol) in dry acetonitrile (100ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 5,5-dimethylhexane-2,4-dione (10.0g, 70.4mmol) and then dry dimethylsulphoxide (14.7ml, 0.21mol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature with stirring over 3 hours. The mixture was diluted with water (1000ml) and stirred for 10min and then extracted with ether (1x500ml, 2x250ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by distillation under reduced pressure to provide the title compound (10.0g) as a pale yellow oil, b.p. 220-225°C/60mmHg.

¹H-NMR (400MHz, CDCl₃): δ = 1.25 (s, 9H), 2.39 (s, 3H), 5.10 (s, 1H).
LRMS (thermospray): m/z [MNH₄⁺] 194.

PREPARATION 204-[(Methylamino)methyl]benzonitrile


4-Cyanobenzaldehyde (12.0g, 92.0mmol), methylamine (69ml of a 2.0M solution in tetrahydrofuran, 137mmol) and magnesium sulphate (45g) were stirred in dichloromethane (300ml) at room temperature for 5 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (200ml) and sodium borohydride (4.10g, 109mmol) was added cautiously with vigorous stirring. Once the addition was complete the reaction was stirred for 1 hour and the mixture was concentrated under reduced pressure. The residue was dissolved in 1M aqueous sodium hydroxide solution (200ml) and the mixture was stirred at room temperature for 1 hour. The resulting solution was extracted with dichloromethane (2x200ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (13.4g) as a pale yellow oil.

¹H-NMR (300MHz, CDCl₃): δ = 1.46 (s, 1H), 2.46 (s, 3H), 3.82 (s, 2H), 7.47 (d, 2H), 7.64 (d, 2H).

LRMS (electrospray): m/z [MH⁺] 147.

PREPARATION 21

4-{{(2-Hydroxyethyl)amino}methyl}benzonitrile



A mixture of 4-Cyanobenzaldehyde (14.1g, 107mmol), ethanolamine (6.56g, 107mmol) and toluene (100ml) was heated under reflux for 14 hours using a Dean-Stark apparatus to remove water. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in dichloromethane (200ml), cooled to 0°C and triethylamine (16.3ml, 117mmol) and chlorotrimethylsilane (14.9ml, 117mmol) were added dropwise. A white precipitate formed and after stirring for 1 hour the mixture was filtered. The filtrate was


concentrated under reduced pressure to leave an orange solid (25.0g). The orange solid was dissolved in methanol (200ml) and sodium borohydride (4.50g, 122mmol) was added cautiously with vigorous stirring. Once the addition was complete the reaction was stirred for 1 hour and the mixture was then concentrated under reduced pressure. The residue was dissolved in 1M aqueous sodium hydroxide solution (200ml) and the mixture was stirred at room temperature for 1 hour. The resulting solution was extracted with dichloromethane (3x200ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (12.0g) as a pale yellow oil which solidified on standing to leave a yellow solid, m.p. <60°C.

¹H-NMR (300MHz, CDCl₃): δ = 1.84 (s, 2H), 2.84 (t, 2H), 3.68 (t, 2H), 3.89 (s, 2H), 7.45 (d, 2H), 7.65 (d, 2H).

LRMS (thermospray): m/z [MH⁺] 177.

PREPARATION 22

N-{[1-(2-{{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}-N-(3-pyridinylmethyl)amine



3-(Methylamino)pyridine (327mg, 3.04mmol) was added in one portion to a stirred solution of the bromide of Preparation 28 (300mg, 0.610mmol) in isopropanol (5ml) at room temperature. The mixture was heated at 50°C for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave an orange oil. The crude product was purified by flash column chromatography on silica gel eluting with


dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (50mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 0.15 (s, 6H), 0.77 (s, 9H), 2.02 (s, 3H), 3.64 (s, 2H), 3.70 (s, 2H), 3.95 (t, 2H), 4.17 (t, 2H), 6.75 (s, 2H), 6.97 (s, 1H), 7.15 (dd, 1H), 7.53 (d, 1H), 8.47 (m, 2H).

LRMS (thermospray): m/z [MH⁺] 521.

PREPARATION 23


3-Chloro-5-methyl-2,4-hexanedione



Chlorotrimethylsilane (13.4ml, 105mmol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium iodide (566mg, 1.53mmol) in dry acetonitrile (100ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 5-methylhexane-2,4-dione (4.50g, 35.1mmol) and then dry dimethylsulphoxide (7.47ml, 105mmol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature with stirring over 1 hour. Tetrabutylammonium bromide (566mg, 1.75mmol) was then added in one portion and the reaction was stirred at room temperature for 2 hours. The mixture was diluted with water (200ml), stirred for 10min and then extracted with ether (3x100ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (98:2, by volume) to provide the title compound (2.00g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.15 (d, 6H), 2.29 (s, 3H), 3.25 (sept, 1H), 15.60 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 180.


PREPARATION 245-(1-Acetyl-3-methyl-2-oxobutoxy)isophthalonitrile

A mixture of the dione of Preparation 23 (1.12g, 6.94mmol), the phenol of Preparation 39 (1.00g, 6.94mmol), cesium carbonate (2.25g, 6.94mmol) and acetone (30ml) was heated under reflux for 4 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown solid. The solid was dissolved in 1M aqueous hydrochloric acid (50ml) and the solution was extracted with dichloromethane (3x30ml). The combined organic phases were washed with brine (30ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (580mg) as a yellow solid.

¹H-NMR (300MHz, CDCl₃): δ = 1.08 (d, 6H), 2.02 (s, 3H), 2.24 (sept, 1H), 7.47 (s, 2H), 7.63 (s, 1H), 14.71 (s, 1H).

LRMS (electrospray): m/z [M-H⁺] 269.

PREPARATION 25

5-{[1-(2-{{[tert-Butyl(dimethyl)silyl]oxy}ethyl}-3-isopropyl-5-methyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile


Sodium hydride (60% dispersion in oil, 45mg, 1.12mmol) was added to a stirred solution of 2-bromoethoxy-*t*-butyldimethylsilane (270mg, 1.12mmol) and the pyrazole of Example 95 (250mg, 0.930mmol) in *N,N*-dimethylformamide (5ml) at 0°C under nitrogen. The reaction was warmed to room temperature and stirred for 12 hours. The reaction mixture was quenched by the addition of water (50ml) and the aqueous phase was extracted with ethyl acetate (3x30ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting pentane:ethyl acetate (80:20, by volume) to provide the title compound (60mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 0.02 (s, 6H), 0.85 (s, 9H), 1.19 (d, 6H), 2.09 (s, 3H), 2.79 (sept, 1H), 3.99 (m, 2H), 4.10 (m, 2H), 7.39 (s, 2H), 7.57 (s, 1H).

LRMS (electrospray): m/z [MH⁺] 425.

PREPARATION 26

di(*tert*-Butyl) 2-[4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylimidodicarbonate and di(*tert*-butyl) 2-[4-(3,5-dichlorophenoxy)-5-ethyl-1*H*-pyrazol-1-yl]ethylimidodicarbonate




Di-*t*-butyldicarbonate (14.0g, 64.2mmol) and 4,4-dimethylaminopyridine (630mg, 5.14mmol) were added portionwise to a stirred solution of the amines of Example 283 (7.72g, 25.7mmol) in acetonitrile (128ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and concentrated under reduced pressure. A solution of the residue in dichloromethane (300ml) was washed with water (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to afford the title compounds (12.3g) in a 85:15 ratio of regioisomers as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 1.15 (major, t, 3H), 1.15 (minor, t, 3H), 1.52 (major, s, 18H), 1.52 (minor, s, 18H), 2.47 (major, q, 2H), 2.56 (minor, q, 2H), 4.00 (major, t, 2H), 4.00 (minor, t, 2H), 4.24 (major, t, 2H), 4.24 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.00 (major, s, 1H), 7.00 (minor, s, 1H), 7.21 (major, s, 1H), 7.25 (minor, s, 1H).

LRMS (thermospray): m/z [MH⁺] 500.

Microanalysis: Found: C, 54.94; H, 6.26; N, 8.27. C₂₃H₃₁Cl₂N₃O₅ requires C, 55.20; H, 6.24; N, 8.40%.

PREPARATION 27


1-(2-{{[tert-Butyl(dimethyl)silyloxy]ethyl}-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazole

Chloro-*t*-butyldimethylsilane (1.93g, 12.8mmol) was added in one portion to a stirred solution of the pyrazole of Example 1 (3.50g, 11.6mmol) and imidazole (1.03g, 15.1mmol) in *N,N*-dimethylformamide (23ml) at room temperature under nitrogen. The reaction was stirred for 2 days and water (200ml) was added. The aqueous phase was extracted with diethyl ether (3x200ml) and the combined organic phases were washed with water (2x50ml) and brine (2x50ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (4.82g) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 0.09 (s, 6H), 0.78 (s, 9H), 2.01 (s, 3H), 2.05 (s, 3H), 3.88 (q, 2H), 4.02 (q, 2H), 6.76 (s, 2H), 6.88 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 415.

PREPARATION 28

5-(Bromomethyl)-1-(2-{{[tert-butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazole


N-Bromosuccinimide (640mg, 3.60mmol) was added to a stirred solution of the pyrazole of Preparation 27 (1.00g, 2.40mmol) in carbon tetrachloride (15ml) and azobisisobutyronitrile (20mg) at room temperature under nitrogen. The reaction was heated under reflux for 5 hours then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (97:2.5:0.5, by volume) to provide the title compound (300mg) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = 0.04 (s, 6H), 0.82 (s, 9H), 2.02 (s, 3H), 3.96 (m, 2H), 4.22 (m, 2H), 4.41 (s, 2H), 6.81 (s, 2H), 7.01 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 495.

PREPARATION 29

3-{{1-(2-{{tert-Butyl(dimethyl)silyl}oxy}ethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl}oxy}-5-chlorobenzonitrile



Chloro-t-butyldimethylsilane (2.78g, 18.5mmol) was added in one portion to a stirred solution of the pyrazole of Example 114 (4.89g, 16.8mmol) and imidazole (1.48g, 21.8mmol) in *N,N*-dimethylformamide (30ml) at room temperature under nitrogen. The reaction was stirred for 3 days and water (200ml) was added. The aqueous phase was extracted with diethyl ether (3x200ml) and the combined organic phases were washed with water (2x50ml) and brine (2x50ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane to provide the title compound (5.60g) as a yellow oil.


¹H-NMR (400MHz, CDCl₃): δ = -0.02 (s, 6H), 0.82 (s, 9H), 2.02 (s, 3H), 2.12 (s, 3H), 3.97 (q, 2H), 4.06 (m, 2H), 7.02 (s, 1H), 7.11 (s, 1H), 7.24 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 408.

Microanalysis: Found: C, 58.95; H, 6.96; N, 10.22. $C_{20}H_{28}N_3O_2ClSi$ requires C, 59.13; H, 6.95; N, 10.35%.

PREPARATION 30

3-{{[5-(Bromomethyl)-1-(2-{{[tert-butyl(dimethyl)silyloxy}ethyl}-3-methyl-1*H*-pyrazol-4-yl]oxy}-5-chlorobenzonitrile




N-Bromosuccinimide (2.44g, 13.7mmol) was added to a stirred solution of the pyrazole of Preparation 29 (5.56g, 13.7mmol) in carbon tetrachloride (50ml) and azobisisobutyronitrile (20mg) at room temperature under nitrogen. The reaction was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:dichloromethane acetate (75:25, by volume) to provide the title compound (3.00g) as a colourless oil.

¹H-NMR (300MHz, CDCl₃): δ = -0.02 (s, 6H), 0.83 (s, 9H), 2.04 (s, 3H), 3.97 (q, 2H), 4.25 (m, 2H), 4.43 (s, 2H), 7.09 (s, 1H), 7.18 (s, 1H), 7.33 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 486.

PREPARATION 31

3-{[5-(Aminomethyl)-1-(2-{{[tert-butyl(dimethyl)silyl]oxy}ethyl}-3-methyl-1*H*-pyrazol-4-yl]oxy}-5-chlorobenzonitrile




The bromide of Preparation 30 (1.58g, 3.26mmol) was added to a saturated solution of ammonia in isopropanol (50ml) at 0°C. The reaction was stirred for 6 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (50ml). The solution was washed with 1M aqueous sodium carbonate solution (2x20ml) and brine (20ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (1.00g) as a yellow oil.

¹H-NMR (300MHz, CDCl₃): δ = -0.23 (s, 6H), 0.62 (s, 9H), 1.22 (s, 2H), 1.82 (s, 3H), 2.56 (s, 2H), 3.78 (m, 2H), 4.02 (m, 2H), 6.85 (s, 1H), 6.96 (s, 1H), 7.06 (s, 1H).
LRMS (thermospray): m/z [MH⁺] 421.

PREPARATION 32

1-Bromo-3-chloro-5-methoxybenzene




Sodium methoxide (2.20ml of a 4.5M solution in methanol, 10.0mmol) was added dropwise to a stirred solution of 1-fluoro-3-chloro-5-bromobenzene (1.00g, 4.77mmol) in methanol (28ml) at room temperature under nitrogen. The reaction was heated under reflux for 3 days and cooled to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (30ml). The resulting solution was washed with water (2x20ml) dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with cyclohexane to provide the title compound (302mg) as a colourless oil.

¹H-NMR (400MHz, CDCl₃): δ = 3.77 (s, 3H), 6.82 (s, 1H), 6.94 (s, 1H), 7.09 (s, 1H).
Microanalysis: Found: C, 37.94; H, 2.75. C₇H₆BrClO requires C, 37.96; H, 2.73%.

PREPARATION 33

3-Fluoro-5-methoxybenzonitrile




Sodium methoxide (1.50ml of a 4.5M solution in methanol, 7.10mmol) was added dropwise to a stirred solution of 3,5-difluorobenzonitrile (1.00g, 7.10mmol) in *N,N*-dimethylformamide (36ml) at 0°C under nitrogen. The reaction was allowed to warm to room temperature and stirred for 14 hours. The reaction was diluted with ether (40ml), washed with water (3x100ml) and brine (100ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (95:5, by volume) to provide the title compound (418mg) as a yellow oil.

¹H-NMR (400MHz, CDCl₃): δ = 3.84 (s, 3H), 6.82 (dd, 1H), 6.95 (dd, 1H), 6.96 (s, 1H).

LRMS (thermospray): m/z [MNH₄⁺] 169.


Microanalysis: Found: C, 63.46; H, 3.95; N, 9.14. C₈H₆NOF requires C, 63.58; H, 4.00; N, 9.27%.

PREPARATION 343-Fluoro-5-hydroxybenzonitrile

Boron trichloride (1.65ml of a 1.0M solution in dichloromethane, 1.65mmol) was added dropwise to a stirred solution of the nitrile of Preparation 33 (100mg, 0.660mmol) and tetrabutylammonium iodide (268mg, 0.728mmol) in dichloromethane (3ml) at -78°C. The reaction was allowed to warm 0°C, stirred for 2 hours and then allowed to warm to room temperature and stirred for 14 hours. The reaction was cooled to 0°C, cautiously quenched with ice and then concentrated under reduced pressure. The residue was dissolved in ether (40ml) and the resulting solution was washed with water (3x40ml) and brine (40ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (90:10, by volume) to provide the title compound (50mg) as a white solid, m.p. 138-139°C.

¹H-NMR (300MHz, CDCl₃): δ = 5.81 (s, 1H), 6.80 (dd, 1H), 6.94 (dd, 1H), 6.95 (s, 1H).

Microanalysis: Found: C, 60.99; H, 3.01; N, 10.16. C₇H₄NOF requires C, 61.32; H, 2.94; N, 10.22%.

PREPARATION 353-Chloro-5-methoxybenzonitrile


Palladiumtetrakis(triphenylphosphine) (174mg, 0.150mmol) was added in one portion to a stirred solution of the bromide of Preparation 32 (500mg, 2.26mmol) and

zinc cyanide (146mg, 1.24mmol) in *N,N*-dimethylformamide (3ml) at room temperature under nitrogen. The reaction was heated at 100°C for 14 hours and cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (95:5, by volume) to provide the title compound (380mg) as a yellow oil.

¹H-NMR (300MHz, CDCl₃): δ = 3.82 (3H, s), 7.04 (s, 1H), 7.12 (s, 1H), 7.23 (s, 1H).
Microanalysis: Found: C, 57.50; H, 3.63; N, 8.16. C₈H₆NOCl requires C, 57.33; H, 3.61; N, 8.36%.

PREPARATION 36

3-Chloro-5-hydroxybenzonitrile




Boron trichloride (26.0ml of a 1.0M solution in dichloromethane, 26.0mmol) was added dropwise to a stirred solution of the nitrile of Preparation 35 (1.80g, 10.0mmol) and tetrabutylammonium iodide (4.36g, 11.0mmol) in dichloromethane (50ml) at -78°C. The reaction was allowed to warm to room temperature and stirred for 14 hours. The reaction was cooled to 0°C, cautiously quenched with ice and diluted with dichloromethane (100ml). The organic phase was washed with water (3x40ml) and brine (40ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound (900mg) as a white solid.

¹H-NMR (400MHz, d₆DMSO): δ = 7.12 (m, 2H), 7.38 (s, 1H), 10.65 (s, 1H).
Microanalysis: Found: C, 54.76; H, 2.81; N, 8.94. C₇H₄NOCl requires C, 54.75; H, 2.63; N, 9.12%.

PREPARATION 37

1,3-Dibromo-5-methoxybenzene

226



Sodium methoxide (8.80ml of a 4.5M solution in methanol, 41.0mmol) was added dropwise to a stirred solution of 3,5-dibromofluorobenzene (5.00g, 19.0mmol) in *N,N*-dimethylformamide (95ml) at 0°C under nitrogen. The reaction was allowed to warm to room temperature, stirred for 1 hour and then concentrated under reduced pressure. The residue was dissolved in ether and the resulting solution was washed with water (3x300ml) and brine (300ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (5.13g) as a white solid.


¹H-NMR (300MHz, CDCl₃): δ = 3.79 (s, 3H), 7.00 (s, 2H), 7.26 (s, 1H).

LRMS (thermospray): m/z [MH⁺] 266.

Microanalysis: Found: C, 31.56; H, 2.29. C₇H₆OB₂ requires C, 31.62; H, 2.27%.

PREPARATION 38

3,5-Dicyanomethoxybenzene




Tris(dibenzylideneacetone)dipalladium (6.53g, 7.15mmol) was added in one portion to a stirred solution of the bromide of Preparation 37 (38.0g, 143mmol) and zinc cyanide (20.0g, 172mmol) in *N,N*-dimethylformamide (300ml) at room temperature under nitrogen. The reaction was heated at 100°C for 14 hours and cooled to room temperature. Water (1500ml) was added and the mixture was extracted with ethyl acetate (3x500ml). The combined organics were filtered and the filtrate was washed with water (500ml), dried over magnesium sulphate, filtered and concentrated under

reduced pressure. The resulting solid was triturated with toluene (1000ml) to provide the title compound (18.0g) as a tan solid.

¹H-NMR (300MHz, CDCl₃): δ = 3.83 (3H, s), 7.31 (2H, s), 7.48 (1H, s).

PREPARATION 39

3,5-Dicyanohydroxybenzene




The nitrile of Preparation 38 (9.60g, 60.7mmol) was added portionwise to a stirred suspension of aluminium trichloride (32.4g, 243mmol) in dichloromethane (250ml) at 0°C under nitrogen. The suspension was heated to 45°C and stirred for 6 days. The reaction was cooled to room temperature and cautiously poured onto ice (450ml). Concentrated hydrochloric acid (450ml) was added dropwise and the resulting suspension was stirred for 10 minutes at room temperature. The resulting solid was collected by filtration, washed with water and dried over phosphorus pentoxide to provide the title compound (7.83g) as a tan solid containing approximately 11 % starting material by ¹H-NMR and microanalysis.

¹H-NMR (400MHz, CDCl₃): δ = 7.36 (m, 2H), 7.56 (m, 1H).

PREPARATION 40

3-Methoxy-5-methylphenyl trifluoromethanesulfonate




Trifluoromethanesulphonic anhydride (2.02ml, 12.0mmol) was added dropwise to a stirred solution of 3-methoxy-5-methylphenol (1.50g, 10.9mmol) in pyridine (20ml) at -20°C under nitrogen. The reaction was warmed to 0°C, stirred for 90 minutes and re-cooled to -20°C. More trifluoromethanesulphonic anhydride (1.01ml, 6.00mmol) was added dropwise. The reaction was allowed to warm to room temperature, stirred for 14 hours and cautiously poured into water (100ml). The aqueous phase was extracted with ether (150ml) and the organic phases were washed with water (3x75ml), 0.2M hydrochloric acid (3x75ml), 1.0M aqueous sodium carbonate solution (2x75ml), water (75ml) and brine (75ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (2.86g) as a pale brown oil.

¹H-NMR (400MHz, CDCl₃): δ = 2.35 (s, 3H), 3.80 (s, 3H), 6.60 (s, 1H), 6.68 (s, 1H), 6.73 (s, 1H).

PREPARATION 41

3-Methoxy-5-methylbenzonitrile




The triflate of Preparation 40 (1.94g, 7.10mmol), dibromobis(triphenylphosphine)nickel (369mg, 0.490mmol), 1,1'bis(diphenylphosphino)ferrocene (331mg, 0.590mmol) and potassium cyanide (1.38g, 21.3mmol) were added consecutively to a stirred suspension of Rieke® zinc (supplied by the Aldrich chemical company as a suspension; 5g Zinc in 100ml tetrahydrofuran) (74mg, 1.14mmol) in acetonitrile (4ml) at room temperature. The reaction was heated to 75°C for 8 hours and then cooled to room temperature. The mixture was partitioned between ether (200ml) and water (150ml) and the organic phase was separated, washed with water (2x100ml) and brine (75ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a pale brown oil. The crude product was purified by flash chromatography on silica gel

eluting with pentane:ethyl acetate (85:15, by volume) to provide the title compound (815mg) as a white solid.

¹H-NMR (400MHz, CDCl₃): δ = 2.34 (s, 3H), 3.80 (s, 3H), 6.93 (s, 1H), 6.94 (s, 1H), 7.04 (s, 1H).

PREPARATION 42

3-Hydroxy-5-methylbenzonitrile




Boron trichloride (17.6ml of a 1.0M solution in dichloromethane, 17.6mmol) was added dropwise to a stirred solution of the nitrile of Preparation 41 (866mg, 5.88mmol) and tetrabutylammonium iodide (2.61g, 7.05mmol) in dichloromethane (50ml) at -78°C. The reaction was allowed to warm to room temperature and stirred for 20 minutes. The reaction was cooled to 0°C, cautiously quenched with ice and diluted with dichloromethane (100ml). The organic phase was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (677mg) as a white solid.

¹H-NMR (400MHz, CDCl₃): δ = 2.32 (s, 3H), 5.05 (s, 1H), 6.88 (s, 1H), 6.90 (s, 1H), 7.04 (s, 1H).


PREPARATIONS 43 TO 46

The compounds of the following tabulated Preparations of the general formula:



were prepared by a similar method to that of Preparation 9 using the appropriate phenol starting material and the chloride of Preparation 2.

Preparation No. (Phenol No.)	R	LRMS	Analytical Data
43 (Phenol Preparation 34)	F	m/z [MNH ₄ ⁺] 281. (thermospray)	¹ H-NMR (300MHz, CDCl ₃): δ = 1.05 (t, 6H), 2.27 (q, 4H), 6.89 (m, 1H), 7.03 (s, 1H), 7.04 (m, 1H).
44 (Phenol Preparation 42)	Me	m/z [M-H ⁺] 258. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.09 (t, 6H), 2.32 (q, 4H), 2.37 (s, 3H), 6.96 (s, 1H), 6.97 (s, 1H), 7.15 (s, 1H), 14.50 (s, 1H).
45 (Phenol Preparation 39)	CN	m/z [M-H ⁺] 269. (electrospray)	¹ H-NMR (300MHz, CDCl ₃): δ = 1.09 (m, 6H), 2.30 (m, 4H), 7.42 (s, 2H), 7.61 (s, 1H), 14.56 (s, 1H).
46 (Phenol Preparation 36)	Cl	m/z [MH ⁺] 280. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): δ = 1.08 (m, 6H), 2.31 (q, 4H), 7.12 (s, 1H), 7.19 (s, 1H), 7.31 (s, 1H).

PREPARATION 471-Cyclopropyl-1,3-pentanedione


A stirred suspension of magnesium turnings (1.83g, 75.0mmol) in methanol (85ml) was heated under reflux for 90 minutes. The suspension was cooled to room temperature and a solution of 3-ketopentanoic acid (17.4g, 150.0mmol) in methanol (15ml) was added. The white suspension dissolved to give a pale yellow solution. The reaction was stirred at room temperature for 1 hour and then concentrated under reduced pressure to give a pale yellow solid which was dissolved in *N,N*-dimethylformamide (50ml). In a separate flask carbonyldiimidazole (13.4g, 83.0mmol) was added portionwise to a stirred solution of cyclopropanecarboxylic acid (6.46g, 75.0mmol) in *N,N*-dimethylformamide (150ml) at room temperature under nitrogen. The reaction was stirred for 90 minutes and then the magnesium salt previously prepared was added dropwise. The reaction was stirred for 3 days and then poured into 1.0M hydrochloric acid (150ml). The aqueous phase was extracted with ether (3x200ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (9.33g) as a yellow oil.

¹H-NMR (400MHz, CDCl₃): keto and enol forms present with enol as major component; enol signals δ = 1.00 (m, 7H), 1.60 (m, 1H), 2.25 (m, 2H), 5.59 (s, 1H), 15.62 (s, 1H); keto signals δ = 1.00 (m, 7H), 2.01 (m, 1H), 2.52 (m, 2H), 3.68 (s, 2H). LRMS (electrospray): m/z [M-H⁺] 139.

Microanalysis: Found: C, 68.35; H, 8.72. C₈H₁₂O₂ requires C, 68.55; H, 8.63%.

PREPARATION 48

The compound of the following tabulated Preparation of the general formula:




was prepared by a similar method to that of Preparation 47 using the appropriate ketoacid and carboxylic acid starting materials.

Preparation No.	R	R'	LRMS	Analytical Data
48	iPr	Et	[M-H ⁺] m/z 141. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): keto and enol forms present with enol major δ = 1.12 (m, 18H, keto and enol), 2.32 (m, 4H, keto and enol), 2.49 (m, 2H, keto and enol), 3.61 (s, 2H, keto), 5.49 (s, 1H, enol), 15.52 (s, 1H, enol). Microanalysis: Found: C, 67.22; H, 9.95. C ₈ H ₁₄ O ₂ requires C, 67.57; H, 9.92%.

PREPARATIONS 49 TO 51

The compounds of the following tabulated Preparations of the general formula:




were prepared by a similar method to that of Preparation 2 using the appropriate diketone starting material.

Preparation No. (Diketone No.)	R	R'	LRMS	Analytical Data
49 (Preparation 47)	cycloPr	Et	m/z 173. (electrospray)	[M-H ⁺] ¹ H-NMR (400MHz, CDCl ₃): 1.10 (m, 7H), 2.41 (m, 1H), 2.61 (m, 2H), 15.90 (s, 1H).
50 (Commercially available diketone used)	Me	Et	m/z 166. (thermospray)	[MNH ₄ ⁺] ¹ H-NMR (300MHz, CDCl ₃): 1.19 (m, 3H), 2.27 (s, 3H), 2.67 (q, 2H), 15.40 (s, 1H).
51 (Preparation 48)	iPr	Et	m/z 175. (electrospray)	[M-H ⁺] ¹ H-NMR (400MHz, CDCl ₃): 1.18 (m, 9H), 2.64 (q, 2H), 3.20 (m, 1H), 15.80 (s, 1H).


PREPARATIONS 52 TO 54

The compounds of the following tabulated Preparations of the general formula:



were prepared by a similar method to that of Preparation 9 using the appropriate diketone starting material and the phenol of Preparation 39.


Preparation No. (Diketone No.)	R	R'	LRMS	Analytical Data
52 (Preparation 49)	cycloPr	Et	m/z [M-H ⁺] 282. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): 0.93 (m, 2H), 1.12 (t, 3H), 1.21 (m, 2H), 1.78 (m, 1H), 2.29 (q, 2H), 7.49 (s, 2H), 7.61 (s, 1H), 14.87 (s, 1H).
53 (Preparation 19)	tBu	Me	m/z [MNH ₄ ⁺] 301. (thermospray)	¹ H-NMR (400MHz, CDCl ₃): 1.08 (s, 9H), 1.84 (s, 3H), 7.30 (s, 1H), 7.57 (s, 2H), 15.42 (s, 1H).
54 (Preparation 51)	iPr	Et	m/z [M-H ⁺] 283. (electrospray)	¹ H-NMR (400MHz, CDCl ₃): 1.03 (m, 9H), 2.23 (q, 2H), 2.58 (m, 1H), 7.41 (s, 2H), 7.59 (s, 1H), 14.63 (s, 1H).

PREPARATION 554-(Aminomethyl)benzamide

5

Powdered potassium hydroxide (340mg, 6mmol) was added in one portion to a stirred solution of 4-(aminomethyl)benzonitrile (200mg, 1.5mmol) in 2-methyl-2-propanol (20ml) at reflux under nitrogen. The reaction was heated at reflux for 30 minutes and cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:5:0.5, by volume) to provide the title compound (150mg) as a white solid.


15 ¹H-NMR (300MHz, CD₃OD): δ = 3.85 (s, 2H), 7.43 (d, 2H), 7.82 (d, 2H).
 LRMS (thermospray): m/z [MH⁺] 151.

PREPARATION 563-Oxopentanoic acid

20

Sodium hydroxide (54g, 1.35mol) was added portionwise to a solution of 3-oxopentanoic acid methyl ester (80g, 0.62mol) in tetrahydrofuran (300ml) and water (300ml) at 0°C. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The reaction mixture was washed with diethylether (500ml) and the aqueous phase was acidified to pH1 at 0°C with concentrated hydrochloric acid (140ml). The aqueous phase was extracted with dichloromethane (2x300ml) and the combined organic extracts dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (44g) as a white solid.


¹H NMR (400MHz, CDCl₃): δ = 1.12 (t, 3H), 2.59 (q, 2H), 3.49 (s, 2H).

PREPARATION 573-(Benzyl)propanoic acid

5

Sodium metal (249mg, 10.8mmol) was added to benzyl alcohol (30g, 278mmol) at room temperature under nitrogen and the reaction was stirred for 30 minutes. Methyl acrylate (25.9ml, 259mmol) was then added dropwise and the reaction was stirred at room temperature for 18h. After quenching with saturated aqueous ammonium chloride solution (200ml) the mixture was extracted with ethyl acetate (2x300ml) and the combined organic extracts were washed with brine (100ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was dissolved in ethanol (300ml) and 1M aqueous sodium hydroxide solution (300ml) was added dropwise. After 3 hours the ethanol was removed under reduced pressure and the aqueous residue was washed with dichloromethane (200ml). The aqueous phase was then acidified with 2N aqueous hydrochloric acid (150ml), extracted with dichloromethane (2x250ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was dissolved in 10% aqueous potassium carbonate solution (300ml), washed with diethylether (300ml) and the aqueous phase was acidified to pH1 using concentrated hydrochloric acid. The mixture was then extracted with dichloromethane (2x300ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (44.4g) as a colourless oil.

¹H NMR (300MHz, CDCl₃): δ = 2.67 (t, 2H), 3.89 (t, 2H), 4.58 (s, 2H), 7.18 (m, 5H).

30 **PREPARATION 58**(4Z)-1-(Benzyl)-5-hydroxy-4-hepten-3-one

A suspension of magnesium turnings (1.74g, 71.6mmol) in methanol (85ml) was heated to reflux under nitrogen for 1.5 hours, cooled to room temperature and the β -keto acid from Preparation 56 (16.6g, 143mmol) was added. The reaction 5 was stirred for 1.5 hours and the solvent was removed under reduced pressure to give the magnesium salt of the acid as a white solid. Meanwhile, the acid from Preparation 57 (12.9g, 71.6mmol) was dissolved in dimethylformamide (150ml) and carbonyldiimidazole (12.8g, 78.8mmol) was added portionwise under nitrogen at room temperature. This was stirred for 1 hour and the magnesium 10 salt from above was added as a solution in dimethylformamide (50ml). Evolution of gas was noted, and the reaction was allowed to stir at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residual orange oil was dissolved in dichloromethane (300ml), washed with 0.5M aqueous hydrochloric acid (250ml) containing methanol (10ml) and the aqueous phase 15 was separated and extracted with dichloromethane (2x300ml). The combined organic extracts were washed with brine (300ml) containing methanol (20ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound 20 (12.0g) as an orange oil.


^1H NMR (400MHz, CDCl_3): δ = 1.17 (t, 3H), 2.33 (q, 2H), 2.58 (t, 2H), 3.76 (t, 2H), 4.53 (s, 2H), 5.57 (s, 1H), 7.13 (m, 5H).

LRMS (electrospray) : m/z [MNa $^+$] 257.

25 Microanalysis: Found C, 71.77; H, 7.74. $\text{C}_{14}\text{H}_{18}\text{O}_3$ requires C, 71.76; H, 7.69%.

PREPARATION 59

(4E)-1-(Benzylxy)-4-chloro-5-hydroxy-4-hepten-3-one



30

Trimethylsilyl chloride (10ml, 51.3mmol) was added to a solution of the enol from Preparation 58 (4.0g, 17.1mmol) in acetonitrile (25ml) under nitrogen at 0°C. Dimethylsulfoxide (3.6ml, 51.3mmol) followed by tert-butylammonium bromide 35 (275mg, 0.85mmol) were then added and the reaction was stirred at 0°C for 2 hours. The mixture was diluted with water (100ml), extracted with diethylether

(100ml) and the organic phase was washed with brine (50ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual pink oil was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound 5 (3.76g) as a pink oil.


¹H NMR (400MHz, CDCl₃): δ = 1.17 (t, 3H), 2.62 (q, 2H), 2.96 (t, 2H), 3.79 (t, 2H), 4.57 (s, 2H), 7.12 (m, 5H), 15.49 (s, 1H).

LRMS (electrospray) : m/z [MNa⁺] 291.

10

PREPARATION 60

3-((1*E*)-1-[3-(benzyloxy)propanoyl]-2-hydroxy-1-butene}oxy)-5-fluorobenzonitrile




15

Sodium hydride (60% dispersion in oil, (1.92g, 48.0mmol) was added to a stirred solution of the phenol from Preparation 34 (8.80g, 48.0mmol) in tetrahydrofuran (450ml) under nitrogen at room temperature. After stirring for 1 hour, the enol from Preparation 59 (12.9g, 48.0mmol) was added and the reaction was stirred 20 for 64 hours. The mixture was diluted with water (200ml) and 2N aqueous hydrochloric acid (40ml), extracted with ethyl acetate (2x150ml) and the combined organic extracts were washed with brine (100ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with cyclohexane:pentane (10:90, by volume) to provide the title compound (5.80g) as 25 an orange oil.


¹H NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 2.31 (q, 2H), 2.59 (t, 2H), 3.75 (t, 2H), 4.45 (s, 2H), 6.92 (m, 1H), 7.02 (m, 2H), 7.29 (m, 5H), 14.50 (s, 1H).

30 LRMS (electrospray) : m/z [MNa⁺] 392.

PREPARATION 61**5-((1*E*)-1-[3-(Benzyl)oxy]propanoyl]-2-hydroxy-1-butene}oxy)isophthalonitrile**

5 Sodium hydride (60% dispersion in oil, 412mg, 12.3mmol) was added to a stirred solution of the phenol from Preparation 39 (1.48g, 10.3mmol) in tetrahydrofuran (70ml) under nitrogen at room temperature. After stirring for 30 minutes, the enol from Preparation 59 (2.76g, 10.3mmol) was added and the reaction was stirred for 18 hours. Water (100ml) and 2N aqueous hydrochloric acid (10ml) were
10 cautiously added and the mixture extracted with ethyl acetate (2x150ml). The organics were combined, washed with brine (100ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with (pentane:ethyl acetate 90:10, by volume) to provide the title compound (1.00g) as a yellow oil.
15

LRMS (thermospray) : m/z [MH⁺] 375.


PREPARATION 62**3-[(1-(2-[(tert-Butyl(dimethyl)silyl)oxy]ethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy]-5-fluorobenzonitrile**

Imidazole (477mg, 7.02mmol) and tert-butyl-dimethyl-silyl chloride (977mg, 6.48mmol) were sequentially added to a solution of the alcohol from Example 117 (1.65g, 5.40mmol) in dimethylformamide (11ml) at room temperature under nitrogen. The reaction was stirred for 18 hours and the mixture was diluted with 5 water (100ml) and extracted with diethylether (4x50ml). The combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (2.12g) as a colourless oil.

10 ¹H NMR (400MHz, CDCl₃): δ = 0.03 (s, 6H), 0.84 (s, 9H), 1.10 (m, 6H), 2.42 (q, 2H), 2.56 (q, 2H), 4.00 (t, 2H), 4.09 (t, 2H), 6.86 (d, 1H), 6.99 (m, 2H).
LRMS (thermospray) : m/z [MH⁺] 419.
Microanalysis: Found C, 62.73; H, 7.83; N, 9.75. C₂₂H₃₂FN₃O₂Si.0.06CH₂Cl₂
15 requires C, 62.68; H, 7.66; N, 9.94%.

PREPARATION 63

3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile



20

p-Toluene-sulphonic acid (32mg, 0.17mmol) was added to a solution of the alcohol from Example 117 (5.04g, 16.6mmol) and dihydropyran (7.57ml, 83mmol) in dichloromethane (65ml) at room temperature under nitrogen. The 25 reaction was stirred for 2 hours, but starting material still remained so a further aliquot of p-toluene-sulphonic acid (284mg, 1.49mmol) was added and the reaction was stirred for 1 hour. The mixture was diluted with diethylether (90ml) and washed with a mixed aqueous solution (water (50ml), brine (25ml) and saturated aqueous sodium bicarbonate solution (25ml)). The aqueous phase was 30 extracted with diethylether (2x60ml) and the combined organic extracts were

dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (6.31g) as an oil.

5


¹H NMR (400MHz, CDCl₃): δ = 1.08 (m, 6H), 1.52 (m, 6H), 2.39 (q, 2H), 2.54 (q, 2H), 3.45 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.06 (m, 1H), 4.17 (t, 2H), 4.51 (s, 1H), 6.82 (d, 1H), 7.22 (m, 2H).

LRMS (thermospray) : m/z [MH⁺] 388.

10

PREPARATION 64

3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-fluorobenzamide



15

Cesium carbonate (269mg, 0.82mmol) was added to a solution of 3-methyl-3-pyrazolin-5-one (74mg, 0.75mmol) in dimethylsulfoxide (1ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl fluoride from Preparation 63 (291mg, 0.75mmol) dissolved in dimethylsulfoxide (1ml) was then added and the reaction was heated to 100°C for 18 hours. After cooling to room temperature the reaction was diluted with water (7ml) and extracted with diethylether (12ml). The organic phase was washed with brine (3.5ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (99:1 changing to 95:5, by volume) to provide the unexpected title compound (108mg) as an oil.

¹H NMR (400MHz, CDCl₃): δ = 1.12 (m, 6H), 1.56 (m, 6H), 2.44 (q, 2H), 2.59 (q, 2H), 3.48 (m, 1H), 3.69 (m, 1H), 3.79 (m, 1H), 4.08 (m, 1H), 4.20 (t, 2H), 4.54 (s, 1H), 6.72 (d, 1H), 7.15 (m, 2H).


30

LRMS (thermospray) : m/z [MH⁺] 406.

Microanalysis: Found C, 60.57; H, 6.97; N, 9.97.
 $C_{21}H_{28}FN_3O_4 \cdot 0.08CH_2Cl_2 \cdot 0.32H_2O$ requires C, 60.57; H, 6.94; N, 10.05%.

5 PREPARATION 65

3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-(1H-pyrazol-1-yl)benzonitrile



10

Cesium Carbonate (269mg, 0.82mmol) was added to a solution of pyrazole (51mg, 0.75mmol) in dry dimethylsulfoxide (1ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl fluoride from Preparation 63 (291mg, 0.75mmol) dissolved in dry dimethylsulfoxide (1ml) was then added and the reaction was heated to 100°C for 18 hours. After cooling to room temperature the reaction was diluted with water (7ml) and extracted with diethylether (10ml). The organic phase was washed with brine (3ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 90:10, by volume) to provide the title compound (55mg).

¹H NMR (400MHz, CDCl₃): δ = 1.13 (m, 6H), 1.58 (m, 6H), 2.44 (q, 2H), 2.60 (q, 2H), 3.49 (m, 1H), 3.69 (m, 1H), 3.80 (m, 1H), 4.10 (m, 1H), 4.21 (t, 2H), 4.55 (s, 1H), 6.50 (s, 1H), 6.98 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H), 7.72 (s, 1H), 7.89 (s, 1H).


LRMS (thermospray) : m/z [MH⁺] 436, [MNa⁺] 458.

HRMS: [MH⁺] Found 436.2352. $C_{24}H_{30}N_5O_3$ requires 436.2343

[MNa⁺] Found 458.2168. $C_{24}H_{29}N_5O_3Na$ requires 458.2162.

PREPARATIONS 66-68

The preparation of the following tabulated Preparations of the general formula



5

were performed by a similar method to that of Preparation 65 using the appropriate heterocycle as the starting material.


Preparation No. (Starting material preparation no.)	R	Analytical Data
66 (63)		<p>¹H NMR (400MHz, CDCl₃): δ = 1.13 (m, 6H), 1.63 (m, 6H), 2.44 (q, 2H), 2.60 (q, 2H), 3.46 (m, 1H), 3.67 (m, 1H), 3.79 (m, 1H), 4.08 (m, 1H), 4.20 (t, 2H), 4.53 (s, 1H), 6.26 (t, 1H), 6.64 (d, 1H), 7.17 (s, 1H), 7.21 (s, 1H), 7.34 (s, 1H), 7.41 (t, 1H).</p> <p>LRMS (thermospray) : m/z [MH⁺] 463, [MNa⁺] 485.</p> <p>HRMS: [MH⁺] Found 463.2353. C₂₆H₃₁N₄O₄ requires 463.2340</p> <p>[MNa⁺] Found 485.2166. C₂₆H₃₀N₄O₄Na requires 485.2159.</p>

67 (63)		^1H NMR (400MHz, CDCl_3): δ = 1.10 (m, .6H), 1.56 (m, 6H), 2.41 (q, 2H), 2.56 (q, 2H), 3.44 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.05 (m, 1H), 4.17 (t, 2H), 4.50 (s, 1H), 7.00 (d, 1H), 7.08 (s, 1H), 7.20 (m, 1H), 7.51 (s, 1H), 7.64 (s, 1H), 7.86 (s, 1H). LRMS (thermospray) : m/z $[\text{MH}^+]$ 464, $[\text{MNa}^+]$ 486. HRMS: $[\text{MH}^+]$ Found 464.2297. $\text{C}_{25}\text{H}_{30}\text{N}_5\text{O}_4$ requires 464.2293 $[\text{MNa}^+]$ Found 486.2113. $\text{C}_{25}\text{H}_{29}\text{N}_5\text{O}_4\text{Na}$ requires 486.2112.
68 ¹ (63)		^1H NMR (400MHz, CDCl_3): δ = 1.08 (m, 6H), 1.48 (m, 6H), 2.23 (s, 3H), 2.38 (q, 2H), 2.53 (q, 2H), 3.43 (m, 1H), 3.63 (m, 1H), 3.66 (s, 3H), 3.73 (m, 1H), 4.04 (m, 1H), 4.15 (t, 2H), 4.50 (s, 1H), 5.59 (s, 1H), 6.76 (s, 1H), 6.88 (s, 1H), 6.95 (s, 1H). LRMS (thermospray) : m/z $[\text{MH}^+]$ 480, $[\text{MNa}^+]$ 502.

¹ The eluent used for flash column chromatography purification of this compound was dichloromethane:methanol (99:1 changing to 95:5, by volume).

PREPARATION 69

5 tert-Butyl 3-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-1-azetidinecarboxylate



10 Sodium hydride (60% dispersion in oil, 33mg, 0.82mmol) was added to a solution of the pyrazole from Example 122 (200mg, 0.75mmol) in dimethylformamide (3ml) at 0°C under nitrogen and the reaction was stirred for 10 minutes. 3-Iodo-

azetidine-1-carboxylic acid tert-butyl ester (234mg, 0.82mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was quenched with water (0.2ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5ml) and water (5ml) and the 5 organic phase was isolated using a 5 μ M Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80 then 25:75 then 34:66 then 50:50 then 75:25 then 100:0, by volume) changing to ethyl acetate:methanol (10:1, by volume) then 10 dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (189mg) as a pale yellow oil.


¹H NMR (400MHz, CDCl₃): δ = 1.03-1.17 (m, 6H), 1.49 (s, 9H), 2.39-2.52 (m, 4H), 4.32 (m, 2H), 4.50 (m, 2H), 4.94 (m, 1H), 7.38 (s, 2H), 7.56 (s, 1H).

15 LRMS (thermospray) : m/z [MH⁺] 422, [MNa⁺] 444.

Microanalysis: Found C, 65.08; H, 6.49; N, 16.48. C₂₃H₂₇N₅O₃·0.18H₂O requires C, 65.04; H, 6.49; N, 16.49%.

PREPARATION 70

20 5-({3,5-Diethyl-1-[3-(tetrahydro-2H-pyran-2-yloxy)propyl}-1*H*-pyrazol-4-yl)oxy)isophthalonitrile



25 Sodium hydride (60% dispersion in oil, 33mg, 0.82mmol) was added to a solution of the pyrazole from Example 122 (200mg, 0.75mmol) in dimethylformamide (3ml) at 0°C under nitrogen and the reaction was stirred for 10 minutes. 2-(3-bromo-propoxy)-tetrahydro-pyran (184mg, 0.82mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was 30 quenched with water (0.2ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5ml) and water (5ml) and the

organic phase was isolated using a 5 μ M Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80 then 25:75 then 34:66 then 50:50 then 75:25 then 100:0, 5 by volume) changing to ethyl acetate:methanol (10:1, by volume) then dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (238mg) as a pale yellow oil.


10 1 H NMR (400MHz, CDCl₃): δ = 1.09 (m, 6H), 1.47-1.63 (m, 2H), 1.66-1.88 (m, 2H), 2.15 (dd, 2H), 2.38 (q, 2H), 2.53 (q, 2H), 3.37-3.55 (m, 2H), 3.75-3.90 (m, 2H), 4.11 (m, 2H), 4.56 (m, 1H), 7.37 (s, 2H), 7.55 (s, 1H).
 LRMS (electro) : m/z [MH⁺] 409, [MNa⁺] 421.

Microanalysis: Found C, 66.59; H, 6.91; N, 13.40. C₂₃H₂₈N₄O₃.0.36H₂O requires C, 66.57; H, 6.98; N, 13.50%.

15

PREPARATION 71

3-[(1-Acetyl-3,5-dimethyl-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile



20 The phenol from Preparation 34 (10.0g, 72.7mmol), 3-chloro-2,4-pentanedione (7.10g, 72.7mmol) and cesium carbonate (23.6g, 72.9mmol) were heated to reflux in acetone (100ml) under nitrogen for 2 hours. The reaction was cooled to room temperature, 1N aqueous hydrochloric acid (50ml) was added slowly and the mixture was extracted with ethyl acetate (3x100ml). The combined organic extracts dried over magnesium sulphate and concentrated under reduced pressure. The residual yellow oil was dissolved in methanol (100ml), hydrazine (5.3ml, 109mmol) was added and the reaction was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and the residue was dissolved in dimethylformamide (50ml) at 0°C. Acetyl chloride (5.1ml, 72.0mmol) was added slowly followed by sodium hydride (60% dispersion in oil, 2.8g, 72.0mmol) portionwise. The reaction was stirred for 15 minutes and sat. ammonium chloride solution (50ml) was added, and the reaction was allowed to warm to room temperature. The mixture was extracted

with ethyl acetate (3x100ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure giving an oil. After standing for 18 hours, a solid had formed within the oil which was isolated by filtration, washing with diethylether (50ml) to provide the title compound 5 (3.50g) as a white solid, m.p. 109-111°C.


¹H NMR (400MHz, CDCl₃): δ = 2.06 (s, 3H), 2.37 (s, 3H), 2.65 (s, 3H), 6.81 (d, 1H), 6.91 (s, 1H), 7.04 (d, 1H).

LRMS (thermospray) : m/z [MH⁺] 273.

10 Microanalysis: Found C, 61.62; H, 4.44; N, 15.09. C₁₄H₁₂N₃O₂F requires C, 61.53; H, 4.43; N, 15.38%.

PREPARATIONS 72-74

The tabulated compounds of the general formula



15

were performed by a similar method to that of Preparation 71 using the appropriate phenol as the starting material.

Preparation no. (Starting material preparation no.)	R'	Analytical Data
72 (39)	CN	<p>m.p. 204-206°C</p> <p>¹H NMR (400MHz, CDCl₃): δ = 2.06 (s, 3H), 2.38 (s, 3H), 2.66 (s, 3H), 7.33 (s, 2H), 7.58 (s, 1H).</p> <p>LRMS (thermospray) : m/z [MH⁺] 281.</p> <p>Microanalysis: Found C, 63.30; H, 4.25; N, 19.59. C₁₅H₁₂N₄O₂·0.30H₂O requires C, 63.06; H, 4.45; N, 19.61%.</p>
73 ¹ (42)	Me	<p>m.p. 152-154°C</p> <p>¹H NMR (400MHz, CDCl₃): δ = 2.05 (s, 3H), 2.33 (s, 3H), 2.38 (s, 3H), 2.66 (s, 3H), 6.88 (s, 1H), 6.91 (s, 1H), 7.12 (s, 1H).</p>

		LRMS (thermospray) : m/z [MH ⁺] 270. Microanalysis: Found C, 66.67; H, 5.71; N, 15.25. C ₁₅ H ₁₅ N ₃ O ₂ requires C, 66.9; H, 5.61; N, 15.60%.
74 ² (Commercial)	H	m.p. 131-133°C ¹ H NMR (400MHz, CDCl ₃): δ = 2.13 (s, 3H), 2.40 (s, 3H), 2.70 (s, 3H), 7.15 (m, 2H), 7.35 (m, 1H), 7.40 (m, 1H). LRMS (thermospray) : m/z [MH ⁺] 278. Microanalysis: Found C, 65.87; H, 5.11; N, 16.33. C ₁₄ H ₁₃ N ₃ O ₂ requires C, 65.87; H, 5.13; N, 14.46%.


¹ The product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (10:90, by volume).

² The product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (10:90 changing to 20:80, by volume).

5

PREPARATION 75

3-{{[1-Acetyl-3-(bromomethyl)-5-methyl-1*H*-pyrazol-4-yl]oxy}-5-fluorobenzonitrile



10

The pyrazole from Preparation 71 (1.00g, 3.66mmol) was dissolved in carbon tetrachloride (20ml) and the solution was degassed by bubbling nitrogen through it for 20 minutes at room temperature. *N*-Bromosuccinimide (973mg, 5.49mmol) followed by 2,2'-azobisisobutyronitrile (30mg) were added and the reaction was


15 heated to 95°C for 1 hour. The reaction was cooled to room temperature, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (1.30g) as a pale yellow oil.

20 ¹H NMR (400MHz, CDCl₃): δ = 2.05 (s, 3H), 2.69 (s, 3H), 4.68 (s, 2H), 6.89 (d, 1H), 6.99 (s, 1H), 7.08 (d, 1H).
LRMS (thermospray) : m/z [M-BrH⁺] 272.

Microanalysis: Found C, 45.08; H, 3.14; N, 11.44. $C_{14}H_{11}BrN_3O_2F \cdot 1.05H_2O$ requires C, 45.31; H, 3.56; N, 11.32%.

PREPARATIONS 76-78

5 The preparation of the following tabulated Preparations of the general formula



10 were performed by a similar method to that of Preparation 75 using the appropriate pyrazole as the starting material.

Preparation no. (Starting material preparation no.)	R	Analytical Data
76 (72)	CN	<p>m.p. 132-134 °C</p> <p>1H NMR (400MHz, $CDCl_3$): δ = 2.06 (s, 3H), 2.66 (s, 3H), 4.67 (s, 2H), 7.40 (s, 2H), 7.63 (s, 1H).</p> <p>Microanalysis: Found C, 47.65; H, 3.03; N, 14.79. $C_{15}H_{11}BrN_4O_2 \cdot 0.93H_2O$ requires C, 47.92; H, 3.45; N, 14.90%.</p>
77 ^{1,2} (73)	Me	<p>m.p. 107-109°C</p> <p>1H NMR (400MHz, $CDCl_3$): δ = 2.05 (s, 3H), 2.35 (s, 3H), 2.70 (s, 3H), 4.70 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.18 (s, 1H).</p> <p>Microanalysis: Found C, 50.34; H, 3.89; N, 11.58. $C_{15}H_{14}BrN_3O_2 \cdot 0.40H_2O$ requires C, 50.69; H, 4.20; N, 11.82%.</p>
78 ^{1,3} (74)	H	<p>m.p. 120-124°C</p> <p>1H NMR (400MHz, $CDCl_3$): δ = 2.05 (s, 3H), 2.70 (s, 3H), 4.75 (s, 2H), 7.20 (m, 2H), 7.45 (m, 1H).</p>

		Microanalysis: Found C, 49.01; H, 3.47; N, 12.14. C ₁₄ H ₁₂ BrN ₃ O ₂ .0.50H ₂ O requires C, 49.00; H, 3.82; N, 12.24%.
--	--	---

¹ A further aliquot of 2,2'-azobisisobutyronitrile (30mg) was added to this reaction, and refluxing was continued for a further 2 hours.


² The product was purified by flash column chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (0:100 then 2:98 then 5:95 then

5 10:90 then 15:85 then 30:70, by volume).

³ The product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (10:90 changing to 20:80, by volume).

PREPARATION 79

10 3-Cyanobenzamide




0.88 Ammonia solution (30ml) was slowly added to a solution of 3-cyanobenzoyl chloride (10g, 60.3mmol) in dichloromethane (100ml) at 0°C under nitrogen and 15 the reaction was stirred for 20 minutes. The mixture was filtered and the solid was washed with water (50ml) then diethylether (50ml), azeotroped with toluene and dried *in vacuo* to provide the title compound (9g) as a white solid.

20 ¹H NMR (400MHz, CD₃OD): δ = 7.62 (m, 1H), 7.86 (m, 1H), 8.12 (m, 1H), 8.18 (s, 1H).

PREPARATION 80

3-(Aminomethyl)benzamide



25

The nitrile from Preparation 79 (6.4g, 43.8mmol) was suspended in acetic acid (60ml) and 10% palladium on carbon (100mg) was added. The reaction was

pressurised to 60psi at room temperature with hydrogen, and stirred for 18 hours. Starting material remained, so a further aliquot of 10% palladium on carbon (500mg) was added and the procedure was repeated. The reaction mixture was filtered through arbocel washing with acetic acid and the filtrate was concentrated


5 under reduced pressure. The residue was azeotroped with toluene and purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 changing to 90:10:1 then 85:15:1.5, by volume) to provide the title compound (5.3g) as a colourless oil.

10 ^1H NMR (400MHz, CD_3OD): δ = 3.83 (s, 2H), 7.39 (dd, 1H), 7.49 (d, 1H), 7.73 (d, 1H), 7.81 (s, 1H).

PREPARATION 81

2-Chloro-1,3-dicyclopropyl-1,3-propanedione

15




Trimethylsilyl chloride (16.6ml, 130mmol) was added to a solution of tert-butylammonium bromide (0.70g, 2.17mmol) in acetonitrile (50ml) under nitrogen

20 at 0°C. 1,3-Dicyclopropyl-propane-1,3-dione (ref: WO98155438) (6.62g, 43.5mmol) in acetonitrile (15ml) was then added followed by dimethylsulfoxide (9.25ml, 130mmol) dropwise, and the reaction was allowed to warm to room temperature over 4 hours. The mixture was diluted with water (75ml), extracted with diethylether (3x35ml) and the combined organic extracts dried over

25 magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with pentane:diethylether (95:5, by volume) to provide the title compound (3.76g) as an oil, which was an 80:20 mixture of enol:keto forms.

30 ^1H NMR (400MHz, CDCl_3): δ = 1.02 (m, 4H), 1.17 (m, 4H), 2.24 (m, 0.2H), 2.39 (m, 0.8H), 5.05 (s, 0.2H), 16.34 (s, 0.8H).

Microanalysis: Found C, 57.59; H, 5.89. $\text{C}_9\text{H}_{11}\text{ClO}_2 \cdot 0.02\text{CH}_2\text{Cl}_2$ requires C, 57.92; H, 5.94.

PREPARATION 825-[2-Cyclopropyl-1-(cyclopropylcarbonyl)-2-oxoethoxy]isophthalonitrile

5

Cesium carbonate (1.97g, 6.06mmol) was added to a stirred solution of the phenol from Preparation 39 (0.865g, 6.00mmol) in acetone (24ml) under nitrogen at reflux. After stirring for 5 minutes, the diketone from Preparation 81 (1.12g, 6.00mmol) in acetone (6ml) was added and the reaction was stirred for 4 hours.


10 After cooling the mixture was diluted with water (25ml) and the acetone was removed under reduced pressure. The aqueous phase was acidified with 2N aqueous hydrochloric acid, extracted with dichloromethane (50ml) and the organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica

15 gel eluting with a solvent gradient of pentane:ethyl acetate (95:5 changing to 90:10 then 80:20, by volume) to provide the title compound (1.03g) as a white solid, which existed as the enol tautomer, m.p. 135-137°C.

20 ^1H NMR (400MHz, CDCl_3): δ = 0.93 (m, 4H), 1.19 (m, 4H), 1.74 (m, 2H), 7.53 (s, 2H), 15.25 (s, 1H).

LRMS (electrospray) : m/z [M-H $^+$] 293.

Microanalysis: Found C, 69.18; H, 4.82; N, 9.35. $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}_3$ requires C, 69.38; H, 4.79; N, 9.52%.

25 **PREPARATION 83**3-Oxobutanoic acid

30 Sodium hydroxide (37.9g, 0.947mol) was dissolved in water (770ml) and added to a solution of 3-oxo-butanoic acid methyl ester (100g, 0.861mol) at room temperature over 20 minutes. The reaction was stirred for 18 hours, quenched


with ammonium sulfate (700g) and acidified slowly with a solution of concentrated Hydrochloric acid (21.5ml) in water (250ml) with ice cooling. The reaction mixture was extracted with diethylether (6x200ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (58.2g) as a pale yellow oil which was a mixture of keto:enol tautomers.

¹H NMR (400MHz, CDCl₃): δ = 2.00 (s, 3H-enol), 2.30 (s, 3H-keto), 3.51 (s, 2H-keto), 5.02 (s, 1H-enol).

10

PREPARATION 84

1-Cyclopropyl-1,3-butanedione



15

Magnesium turnings (3.04g, 125mmol) suspended in methanol (145ml) were heated to reflux under nitrogen for 1 hour, cooled to room temperature and the β-keto acid from Preparation 83 (25.5g, 250mmol) dissolved in methanol (25ml) was added dropwise with ice-cooling. The reaction was stirred for 1 hour at room temperature and the solvent was removed under reduced pressure to give the magnesium salt of the acid. Meanwhile, cyclopropane-carboxylic acid (9.91ml, 125mmol) was dissolved in dimethylformamide (200ml) and carbonyldiimidazole (22.4g, 138mmol) was added portionwise under nitrogen at 0°C. This was stirred for 1.5 hour and the magnesium salt from above was added as a solution in dimethylformamide (100ml) at 0°C. The reaction was allowed to stir at room temperature for 92 hours and the mixture was poured into 2M aqueous hydrochloric acid (85ml) then diluted with water (170ml). The mixture was extracted with diethylether (6x200ml) and the combined organic extracts were washed with brine (3x200ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with pentane:diethylether (100:0 changing to 90:10 then 80:20, by volume) to provide the title compound (7.39g) as a yellow oil.


35 ¹H NMR (400MHz, CDCl₃): δ = 0.83-0.95 (m, 2H), 1.06-1.10 (m, 2H), 1.54-1.63 (m, 1H), 2.00 (s, 3H).

LRMS (electrospray) : m/z [MNa⁺] 149.

PREPARATION 85

2-Chloro-1-cyclopropyl-1,3-butanedione

5




Trimethylsilyl chloride (18.9ml, 174mmol) was added to a solution of tert-butylammonium bromide (932mg, 2.89mmol) in dry acetonitrile (50ml) under nitrogen at room temperature and the mixture was cooled to 0°C. The diketone from Preparation 84 (7.3g, 57.9mmol) in acetonitrile (36ml) was then added followed by dropwise addition of dry dimethylsulfoxide (12.3ml, 174mmol). The reaction was stirred at 0°C for 1.5 hours and the mixture was diluted with water (500ml), extracted with diethylether (2x200ml and 100ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with pentane:diethylether (100:0 changing to 95:5 then 90:10, by volume) to provide the title compound (5.76g) as a colourless oil.

20 ¹H NMR (400MHz, CDCl₃): δ = 0.99-1.08 (m, 2H), 1.15-1.20 (m, 2H), 2.27 (s, 3H), 2.38-2.46 (m, 1H).

LRMS (electrospray): m/z [M-H⁺] 159.

PREPARATION 86

3-[1-(Cyclopropylcarbonyl)-2-oxopropoxy]-5-methylbenzonitrile




30 Cesium carbonate (2.45g, 8.30mmol) and the phenol from Preparation 42 (1g, 7.50mmol) were added to a stirred solution of the diketone from Preparation 85

(1.3g, 8.30mmol) in acetone (44ml) under nitrogen at 60°C and the reaction was stirred for 5 hours. After cooling the mixture was quenched with water and the acetone was removed under reduced pressure. The aqueous phase was acidified with 1N aqueous hydrochloric acid, extracted with ethyl acetate and the 5 organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (85:15, by volume) to provide the title compound (1.03g) as a pale red solid.

10 ^1H NMR (400MHz, CDCl_3): δ = 0.85 (m, 2H), 1.12 (m, 2H), 1.86 (m, 1H), 1.94 (s, 3H), 2.35 (s, 3H), 6.99 (m, 2H), 7.10 (s, 1H).
 LRMS (electrospray) : m/z [M-H $^+$] 256.

PREPARATION 87

15 4-(3,5-Difluorophenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole



20 p-Toluene-sulphonic acid (360mg, 1.89mmol) was added to a solution of the alcohol from Example 38 (5.6g, 18.9mmol) and dihydropyran (8.62ml, 94.5mmol) in dichloromethane (75ml) at room temperature under nitrogen. The reaction was stirred for 2 hours, diluted with diethylether (100ml) and washed with a mixed aqueous solution (water (60ml), brine (30ml) and saturated aqueous sodium bicarbonate solution (30ml)). The aqueous phase was extracted with diethylether (2x60ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound 25 (6.31g) as an oil.


¹H NMR (400MHz, CDCl₃): δ = 1.09 (m, 6H), 1.57 (m, 6H), 2.40 (q, 2H), 2.55 (q, 2H), 3.44 (m, 1H), 3.62 (m, 1H), 3.73 (m, 1H), 4.05 (m, 1H), 4.16 (t, 2H), 4.50 (s, 1H), 6.39 (m, 3H).

LRMS (thermospray) : m/z [MH⁺] 381.

5 Microanalysis: Found C, 62.16; H, 6.92; N, 7.16. C₂₀H₂₆N₂O₃.0.09CH₂Cl₂ requires C, 62.18; H, 6.80; N, 7.22%.

PREPARATION 88


10 4-[3,5-Di(1*H*-pyrazol-1-yl)phenoxy]-3,5-diethyl-1-[2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]-1*H*-pyrazole



and

15 **PREPARATION 89**

3,5-Diethyl-4-[3-fluoro-5-(1*H*-pyrazol-1-yl)phenoxy]-1-[2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]-1*H*-pyrazole




Cesium Carbonate (538mg, 1.65mmol) was added to a solution of pyrazole (102mg, 1.50mmol) in dry dimethylsulfoxide (2ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl difluoride from 5 Preparation 87 (570mg, 1.50mmol) dissolved in dry dimethylsulfoxide (2ml) was then added and the reaction was heated to 100°C for 18 hours. After cooling to room temperature the reaction was diluted with water (20ml) and extracted with diethylether (2x20ml). The organic phase was washed with brine (10ml), dried 10 over magnesium sulphate, concentrated under reduced pressure. Some starting material remained, so the residue was dissolved in dimethylsulfoxide (12ml), pyrazole (510mg, 7.50mmol) followed by cesium carbonate (2.5g, 7.66mmol) were added and the reaction was heated to 100°C for 18 hours. After cooling to room temperature the reaction was diluted with water (6ml), extracted with diethylether (20ml) and the organic phase was washed with brine (10ml), dried 15 over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 96:4, by volume). This gave two fractions, the first of which was a single product (least polar) and the other a mixture of two products. The second fraction was re-purified eluting with 20 dichloromethane:acetonitrile (93:7 changing to 90:10, by volume) to provide the most polar product.

Least Polar Product – Preparation 88 (254mg)

25 ^1H NMR (400MHz, CDCl_3): δ = 1.11 (m, 6H), 1.50 (m, 6H), 2.46 (q, 2H), 2.58 (q, 2H), 3.43 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.04 (m, 1H), 4.18 (t, 2H), 4.50 (s, 1H), 6.42 (s, 2H), 7.15 (s, 2H), 7.67 (s, 3H), 7.90 (s, 2H).
LRMS (electrospray) : m/z $[\text{MH}^+]$ 477, $[\text{MNa}^+]$ 499.
HRMS: $[\text{MH}^+]$ Found 477.2612. $\text{C}_{26}\text{H}_{33}\text{N}_6\text{O}_3$ requires 477.2609.

Most Polar Product – Preparation 89 (37.7mg)

30 ^1H NMR (400MHz, CDCl_3): δ = 1.11 (m, 6H), 1.46 (m, 6H), 2.43 (q, 2H), 2.57 (q, 2H), 3.43 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.05 (m, 1H), 4.17 (t, 2H), 4.51 (s, 1H), 6.42 (m, 2H), 7.07 (m, 2H), 7.66 (s, 1H), 7.82 (s, 1H).
LRMS (thermospray) : m/z $[\text{MH}^+]$ 429.

PREPARATION 90**3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-methoxybenzonitrile**

5 Sodium methoxide (25% w/v in methanol, 230 μ l, 1.00mmol) was added dropwise to a solution of the aryl fluoride from Preparation 63 (387mg, 1.00mmol) and in dimethylformamide (5ml) at room temperature under nitrogen. The reaction was stirred for 5 hours, diluted with water (10ml) and extracted with diethylether (50ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (400mg) as an oil.


10

15 1 H NMR (400MHz, CDCl_3): δ = 1.09 (m, 6H), 1.49 (m, 6H), 2.41 (q, 2H), 2.55 (q, 2H), 3.46 (m, 1H), 3.66 (m, 1H), 3.77 (m + s, 4H), 4.07 (m, 1H), 4.19 (t, 2H), 4.52 (m, 1H), 6.66 (s, 1H), 6.69 (s, 1H), 6.77 (s, 1H).

LRMS (thermospray) : m/z [MH $^+$] 400.

Microanalysis: Found C, 65.59; H, 7.32; N, 10.42. $\text{C}_{22}\text{H}_{29}\text{N}_3\text{O}_4 \cdot 0.04\text{CH}_2\text{Cl}_2$ requires C, 65.71; H, 7.28; N, 10.43%.

20


PREPARATION 91**3-(1-Acetyl-3-methyl-2-oxobutoxy)-5-methylbenzonitrile**

Cesium carbonate (1.50g, 4.61mmol) and the phenol from Preparation 42 (609mg, 4.61mmol) were added to a stirred solution of the diketone from Preparation 23 (750mg, 4.61mmol) in acetone (23ml) under nitrogen at 50°C and 5 the reaction was stirred for 3 hours. After cooling the mixture was quenched with water (10ml) and the acetone was removed under reduced pressure. The aqueous phase was extracted with dichloromethane (4x25ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica 10 gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (544mg).

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.09 (s, 3H), 2.42 (s, 3H), 2.69 (m, 1H), 7.00 (s, 2H), 7.19 (s, 1H).
15 LRMS (thermospray) : m/z[MNH₄⁺] 277.

PREPARATION 92

[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetic acid



20

The pyrazole of Example 208 (400mg, 1.41mmol) was stirred at 100°C for 14 hours in concentrated hydrochloric acid (20ml). The mixture was cooled to room temperature and the solvent removed under reduced pressure to give a yellow 25 solid. The solid was dissolved in dichloromethane (50ml) and 1N aqueous hydrochloric acid (50ml) and the organic layer was separated. The organics were washed with 1N aqueous hydrochloric acid (50ml), dried over magnesium sulphate, filtered and the solvent removed under reduced pressure to provide the title compound (400mg) as pale yellow solid, m.p. 156-158°C.


30

¹H NMR (400MHz, CD₃OD): δ = 2.02 (s, 3H), 4.89 (s, 2H), 6.82 (s, 2H), 7.02 (s, 1H).
LRMS (thermospray) : m/z [MH⁺] 303.

Microanalysis: Found C, 47.50; H, 3.50; N, 9.46. $C_{12}H_{10}Cl_2N_2O_3$ requires C, 47.86; H, 3.35; N, 9.30%.

PREPARATION 93

5 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-(methylsulfanyl)benzonitrile



10 Sodium thiomethoxide (180mg, 2mmol) was added to a stirred solution of the aryl fluoride from Preparation 63 (774mg, 2.00mmol) in dimethylformamide (10ml) at room temperature under nitrogen. The reaction mixture was stirred for 5 hours before being heated at 100°C for 18 hours. A second portion of sodium thiomethoxide (90mg, 1mmol) was added and the reaction mixture was heated at 100°C for a further 5 hours. After cooling to room temperature the mixture was 15 diluted with water (10ml) and extracted with diethylether (2x50ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (700mg) as an oil.


20

1H NMR (400MHz, $CDCl_3$): δ = 1.14 (m, 6H), 1.52 (m, 6H), 2.44 (q, 2H), 2.49 (s, 3H), 2.59 (q, 3H), 3.50 (m, 1H), 3.70 (m, 1H), 3.80 (m, 1H), 4.10 (m, 1H), 4.23 (m, 2H), 4.55 (m, 1H), 6.82 (s, 1H), 7.01 (s, 1H), 7.09 (s, 1H).

LRMS (APCI+): m/z [MH $^+$] 416.

25

PREPARATION 94

3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-[2-(dimethylamino)ethoxy]benzonitrile

5

To a stirred solution of N,N-dimethylethanamine (83 μ l, 0.83mmol) in dimethylformamide (2ml) was added sodium hydride (36mg of 60% by weight dispersion in oil, 0.90mmol). After 10 minutes a solution of the aryl fluoride from

10 Preparation 63 (291mg, 0.75mmol) in dimethylformamide (2ml) was added and the reaction mixture was stirred at room temperature for 18 hours. The mixture was diluted with 10% aqueous potassium carbonate solution (12ml) and extracted with diethyl ether (2x7ml). The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure. The

15 crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 90:10, by volume) to provide the title compound (180mg) as an oil.


1H NMR (400MHz, CDCl₃): δ = 1.09 (m, 6H), 1.50 (m, 6H), 2.39 (q, 2H), 2.47 (s, 6H), 2.55 (q, 2H), 2.87 (m, 2H), 3.47 (m, 1H), 3.67 (m, 1H), 3.78 (m, 1H), 4.05 (m, 1H), 4.17 (m, 4H), 4.52 (m, 1H), 6.70 (s, 2H), 6.79 (s, 1H).

20 LRMS (electrospray): m/z [MH⁺] 457.

HRMS: [MH⁺] 457.2810. C₂₅H₃₇N₄O₄ requires 457.2810.

PREPARATIONS 95-97

The preparation of the following tabulated Preparations of the general formula



5

were performed by a similar method to that of Preparation 94 using the appropriate alcohol as the starting material.


Preparation no. (Starting material preparation no)	R	Analytical Data
95 (63)	CH ₂ CH ₂ NHMe	¹ H NMR (400MHz, CDCl ₃): δ = 1.09 (m, 6H), 1.50 (m, 6H), 2.39 (q, 2H), 2.54 (m, 5H), 3.04 (t, 2H), 3.46 (m, 1H), 3.66 (m, 1H), 3.78 (m, 1H), 4.05 (m, 1H), 4.11 (t, 2H), 4.17 (t, 2H), 4.52 (s, 1H), 6.70 (s, 2H), 6.81 (s, 1H). LRMS (electrospray): m/z [MH ⁺] 443 HRMS: [MH ⁺] 443.2654. C ₂₄ H ₃₅ N ₄ O ₄ requires 443.2653.

96 (63)	CH ₂ CONH ₂	¹ H NMR (400MHz, CDCl ₃): δ = 1.11 (m, 6H), 1.48 (m, 6H), 2.43 (q, 2H), 2.58 (q, 2H), 3.46 (m, 1H), 3.67 (m, 1H), 3.80 (m, 1H), 4.08 (m, 1H), 4.25 (m, 2H), 4.45 (s, 2H), 4.52 (m, 1H), 5.54 (broad s, 1H), 6.37 (broad s, 1H), 6.72 (s, 1H), 6.85 (s, 2H). LRMS (electrospray): m/z 465 (MH ⁺) HRMS: [MH ⁺] 443.2282. C ₂₃ H ₃₁ N ₄ O ₅ requires 443.2289.
97 (63)	CH ₂ CH ₂ OCH ₃	¹ H NMR (400MHz, CDCl ₃): δ = 1.10 (m, 6H), 1.50 (m, 6H), 2.41 (q, 2H), 2.55 (q, 2H), 3.41 (s, 3H), 3.47 (m, 1H), 3.70 (m, 3H), 3.79 (m, 1H), 4.06 (m, 3H), 4.20 (m, 2H), 4.52 (s, 1H), 6.70 (s, 2H), 6.79 (s, 1H). LRMS (electrospray): m/z 466 (MH ⁺) HRMS: [MH ⁺] 443.2282. C ₂₄ H ₃₄ N ₃ O ₅ requires 443.2289.

PREPARATION 98

5-Methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-ol

5




To a stirred solution of 1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ol (600mg, 2.86mmol; Kenkyu Hokoku - Asahi Garasu Kogyo Gijutsu Shoreikai 10, 1988, 51, 139-49) in dichloromethane (10ml) and ethyl acetate (4ml) was added para-toluenesulphonic acid (27mg, 0.14mmol) followed by 3,4-dihydro-2H-pyran (340μl, 3.7mmol). The reaction mixture was stirred at room temperature for 3 hours before being concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with

pentane:ethyl acetate (60:40, by volume) to provide the title compound (560mg) as white solid.

5 ^1H NMR (400MHz, CDCl_3): δ = 1.60 (m, 6H), 2.23 (s, 3H), 3.44 (m, 1H), 3.60 (m, 1H), 3.72 (m, 1H), 4.04 (m, 1H), 4.18 (m, 2H), 4.50 (broad s, 1H).
 10 LRMS (electrospray): m/z [M-H $^+$] 293.

PREPARATION 99


10 3-Fluoro-5-[(5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]benzonitrile



15 To a stirred solution of the pyrazole (214mg, 0.73mmol) from Preparation 98 in dimethylformamide (0.7ml) was added 3,5-difluorobenzonitrile (304mg, 2.2mmol) and potassium carbonate (304mg, 2.2mmol). The reaction mixture was heated at 90°C for 7 hours. After cooling to room temperature brine (20ml) was added and the mixture was extracted with ethyl acetate (20ml). The organic component was separated, washed with brine (20 ml), dried over magnesium sulphate and 20 concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (267mg) as a colourless oil.

25 ^1H NMR (400MHz, CDCl_3): δ = 1.61 (m, 6H), 2.18 (s, 3H), 3.48 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.30 (t, 2H), 4.50 (broad s, 1H), 6.85 (d, 1H), 6.94 (s, 1H), 7.05 (d, 1H).
 20 LRMS (electrospray): m/z [M-H $^+$] 412.

PREPARATION 100


3-Cyano-5-[(3,5-diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1*H*-pyrazol-4-yl)oxy]benzamide

5

To a stirred solution of the pyrazole from Example 261 (193mg, 0.49mmol) in tetrahydrofuran (2ml) was added 2M aqueous sodium hydroxide solution (8.7 μ l, 0.49mmol) and the reaction mixture was heated at 65°C for 24 hours. After 10 cooling to room temperature a second portion of 2M sodium hydroxide solution (8.7 μ l, 0.49mmol) was added and the mixture was heated at 65°C for 24 hours. 6M aqueous sodium hydroxide solution (100 μ l) was added and the mixture was heated at 65°C for 24 hours. The reaction mixture was concentrated under reduced pressure, diluted with water (75ml), neutralised to pH7 using 2M aqueous hydrochloric acid solution and extracted with dichloromethane (2x25ml). 15 The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure to give a crude product mixture which was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (100:0, 98:2, 96.5:3.5 then 95:5, by volume) to 20 provide the title compound (60mg) as a colourless oil.

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.55 (q, 2H), 3.36 (s, 3H), 3.50 (q, 2H), 3.59 (q, 2H), 3.94 (q, 2H), 4.20 (q, 2H), 4.64 (s, 2H), 7.30 (s, 1H), 7.59 (s, 1H), 7.70 (s, 1H).

25

PREPARATION 101**5-[(1-Acetyl-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile**


5

To a stirred solution of the pyrazole from Example 122 (3.0g, 11.3mmol) in dimethylformamide (45ml) at 0°C was added acetyl chloride (1.2ml, 17.0mmol), followed by sodium hydride portionwise (678mg of 60 % by weight dispersion in oil, 17.0mmol). The cooling bath was removed and the reaction mixture was stirred at room temperature for 40 minutes. The reaction was quenched by addition of saturated aqueous ammonium chloride solution (4ml) and concentrated under reduced pressure to give an orange residue. This material was partitioned between ethyl acetate (200ml) and water (200ml). The organic component was washed with water (100ml), brine (75ml) and then dried over magnesium sulphate before being concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (100:0, 99:1, then 98:2, by volume) to provide the title compound (2.67g) as a white solid.

20 ^1H NMR (400MHz, CDCl_3): δ = 1.15 (t, 3H), 1.19 (t, 3H), 2.43 (q, 2H), 2.72 (s, 3H), 3.85 (q, 2H), 7.38 (s, 2H), 7.61 (s, 1H).
 LRMS (electrospray): m/z 331 [M+Na $^+$].

PREPARATION 102

25 **5-[(1-Acetyl-3-(1-bromoethyl)-5-ethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile**



A solution of the pyrazole from Preparation 101 (881mg, 2.86mmol) in carbontetrachloride (12ml) was degassed by passing a stream of nitrogen through the solution for 20 minutes. N-bromosuccinimide (763mg, 4.28mmol) 5 was added followed by AIBN (30mg) and the reaction mixture was heated at 85°C for 4 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (a gradient from 100:0 to 67:33, by volume) to provide the title compound (348mg) as a colourless 10 oil.


¹H NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 2.00 (d, 3H), 2.70 (s, 3H), 2.80 (m, 2H), 4.95 (q, 1H), 7.42 (s, 2H), 7.60 (s, 1H).

LRMS (electrospray): m/z 283 [MH⁺].

15

PREPARATION 103

5-({5-Ethyl-3-(1-hydroxyethyl)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)isophthalonitrile



20 To a stirred solution of the pyrazole from Example 263 (197mg, 0.70mmol) in dimethylformamide (3ml) at 0°C was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (105μl, 0.70mmol) followed by sodium hydride (31mg, 0.77mmol). After 15 minutes the cooling bath was removed and the mixture was stirred at room temperature for 60 hours. The reaction mixture was quenched by addition of 25 saturated aqueous ammonium chloride solution (0.5ml) and then concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 95:5, by volume) to provide the title compound (84mg) as a white foam which reverts to an oil on standing.

30

¹H NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 1.45 (d, 3H), 1.65 (m, 6H), 2.59 (q, 2H), 3.50 (m, 1H), 3.70 (m, 1H), 3.81 (m, 1H), 4.11 (m, 1H), 4.25 (t, 2H), 4.56 (m, 1H), 4.76 (m, 1H), 7.40 (s, 2H), 7.55 (s, 1H).


LRMS (electrospray): m/z 411 [MH⁺].

5

PREPARATION 104

3-Cyano-5-[(3,5-diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1*H*-pyrazol-4-yl)oxy]-*N*-hydroxybenzenecarboximidamide

10



To a stirred solution of the pyrazole from Example 261 (1.5g, 3.76mmol) in ethanol (7.5ml) was added a solution of sodium carbonate (200mg, 1.88mmol) and hydroxylamine hydrochloride (262mg, 3.76mmol) in water (7.5ml). After 15 stirring for 5 hours at room temperature the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (50ml) and water (40ml). The aqueous phase was separated and extracted with dichloromethane (30ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on 20 silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 96:4, by volume) to provide the title compound (1.13mg) as a colourless oil.


¹H NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 2.42 (q, 2H), 2.58 (q, 2H), 3.41 (s, 25 3H), 3.59 (m, 4H), 3.95 (t, 2H), 4.17 (t, 2H), 4.61 (s, 2H), 4.77 (broad s, 2H), 7.38 (m, 1H), 7.49 (m, 2H).

LRMS (electrospray): m/z 432 [MH⁺].

Microanalysis: Found C, 57.50; H, 6.71; N, 16.01. C₂₁H₂₆N₄O₄+0.4H₂O requires C, 57.50; H, 6.85; N, 15.96%.

30

PREPARATION 105

3-[3,5-Diethyl-1-{2-[2-methoxyethoxy)methoxy]ethyl}-1*H*-pyrazol-4-yl]oxy]-5-[trifluoromethyl]-1,2,4-oxadiazol-3-yl]benzonitrile

5 To a stirred solution of the amidoxime from Preparation 104 (300mg, 0.70mmol) in pyridine (3ml) was added trifluoroacetic anhydride (118 μ l, 0.83mmol). After stirring at room temperature for 2 hours the reaction mixture was heated at 110°C for 18 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the residue was partitioned between 2M aqueous HCl solution (6ml) and dichloromethane (6ml). The organic phase was separated and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 90:10, by volume) to provide the title compound (259mg) as a colourless oil.


10

15 1 H NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 2.46 (q, 2H), 2.59 (q, 2H), 3.39 (s, 3H), 3.53 (q, 2H), 3.59 (q, 2H), 3.95 (q, 2H), 4.29 (q, 2H), 4.68 (s, 2H), 7.34 (s, 1H), 7.87 (s, 1H), 8.04 (s, 1H).

20 LRMS (APCI): m/z 532 (MH⁺)

PREPARATIONS 106-108

The preparation of the following tabulated Preparations of the general formula




were performed by a similar method to that of Preparation 105 using the appropriate acid chloride as the acylating agent in place of trifluoroacetic anhydride.

Preparation no.	R	Analytical Data
106	Me	<p>¹H NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 2.46 (q, 2H), 2.59 (q, 2H), 2.67 (s, 3H), 3.39 (s, 3H), 3.55 (q, 2H), 3.59 (q, 2H), 3.95 (q, 2H), 4.22 (q, 2H), 4.68 (s, 2H), 7.27 (s, 1H), 7.82 (s, 1H), 8.00 (s, 1H).</p> <p>LRMS (electrospray): m/z 478 [M+Na⁺]</p> <p>Microanalysis: Found C, 59.91; H, 6.27; N, 15.38.</p> <p>C₂₃H₂₉N₅O₅+0.3H₂O requires C, 59.94; H, 6.475; N, 15.19%.</p>
107	Et	<p>¹H NMR (400MHz, CDCl₃): δ = 1.14 (m, 6H), 1.44 (t, 3H), 2.42 (q, 2H), 2.48 (q, 2H), 2.98 (q, 2H), 3.39 (s, 3H), 3.53 (q, 2H), 3.59 (q, 2H), 3.95 (q, 2H), 4.20 (q, 2H), 4.48 (s, 2H), 7.30 (s, 1H), 7.84 (s, 1H), 8.01 (s, 1H).</p> <p>LRMS (electrospray): m/z 492 (M+Na⁺)</p>
108	iPr	<p>¹H NMR (400MHz, CDCl₃): δ = 1.11 (m, 6H), 1.49 (d, 6H), 2.44 (q, 2H), 2.49 (q, 2H), 3.30 (sept, 1H), 3.39 (s, 3H), 3.54 (m, 2H), 3.59 (m, 2H), 3.95 (t, 2H), 4.23 (t, 2H), 4.91 (s, 2H), 7.22 (m, 1H), 7.83 (m, 1H), 8.02 (m, 1H).</p> <p>LRMS (electrospray): m/z 506 (M+Na⁺)</p> <p>Microanalysis: Found C, 61.87; H, 6.76; N, 14.62.</p> <p>C₂₅H₃₃N₅O₅ requires C, 62.10; H, 6.88; N, 14.48%.</p>

PREPARATION 109

Ethyl 5-[(tert-butoxycarbonyl)amino]methyl]nicotinate



To a stirred solution of ethyl-5-cyanonicotinate (3.0g, 17.0mmol; Annalen Der Chemie, 1959, 621, 106-136) in ethanol (200ml) was added concentrated hydrochloric acid (3.4ml) followed by 5% palladium on carbon (300mg). The

5 reaction mixture was stirred at room temperature under an hydrogen atmosphere (50psi) for 18 hours. The reaction mixture was filtered through Arbocel® and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.880 ammonia (a gradient from 95:5:0.5 to 85:5:1.5, by volume) to provide the

10 intermediate amine (2.1g) as a yellow oily solid. This material (2.1g, 11.7mmol) was suspended in dichloromethane (22ml) to which was added triethylamine (1.8ml, 13.0mmol) followed by di-tert-butyl dicarbonate (2.84g, 13mmol). After 48 hours the reaction mixture was diluted with dichloromethane (50ml) and washed with water (50ml). The organic component was dried over magnesium sulphate


15 and concentrated under reduced pressure before being purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (a gradient from 100:0:0 to 95:5:0.5, by volume) to provide the title compound (2.0g) as a yellow oil.

20 ^1H NMR (400MHz, CDCl_3): δ = 1.40 (m, 12H), 4.42 (m, 4H), 8.22 (s, 1H), 8.71 (s, 1H), 9.12 (s, 1H).

LRMS (APCI): m/z 279 (M-H⁺)

PREPARATION 110

25 5-[(tert-Butoxycarbonyl)amino]methyl]nicotinic acid



To a stirred solution of the ester from Preparation 109 (2.00g, 7.10mmol) in 1M aqueous sodium hydroxide solution (15ml, 15mmol) was added methanol (15ml). The reaction mixture was stirred at room temperature for 18 hours, after which time the methanol was removed under reduced pressure. The aqueous solution was washed with diethyl ether (2x25ml), cooled to 0°C and neutralised to pH7 by addition of 2M aqueous hydrochloric acid solution (7.5ml). The mixture was


30 concentrated under reduced pressure to give a yellow oil (1.5g).

35

¹H NMR (400MHz, (CD₃)₂SO): δ = 1.37 (s, 9H), 4.16 (d, 2H), 7.51 (m, 1H), 8.07 (s, 1H), 8.50 (s, 1H), 8.88 (s, 1H).
 LRMS (APCI): m/z 251 (M-H⁺)

5 **PREPARATION 111**


5-(Aminomethyl)nicotinamide



To a stirred solution of the acid from Preparation 110 (770mg, 3.10mmol) in
 10 dimethylformamide (15ml) was added carbonyldiimidazole (600mg, 3.70mmol). After 10 minutes 0.880 ammonia (1ml) was added. After a further 1 hour the reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (a gradient from 95:5:0.5 to 80:20:1, by volume) to provide the boc-protected intermediate. To a stirred solution of this material in dichloromethane (20ml) was added trifluoroacetic acid (6ml). After 18 hours a second portion of trifluoroacetic acid (6ml) was added and the reaction mixture was stirred at room temperature for 24 hours. The solution was concentrated under reduced pressure to give an oily residue which was purified
 15 by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 90:10:1 then 80:20:1, by volume) to provide the title compound (650mg) as a yellow oil.
 20

¹H NMR (400MHz, (CD₃)₂SO): δ = 4.11 (s, 2H), 7.5 (broad s), 7.59 (broad s), 8.14 (broad s), 8.31 (m, 1H), 8.72 (m, 1H), 8.90 (m, 1H).
 25 LRMS (electrospray): m/z 152 (MH⁺)
 HRMS: [MH⁺] 152.0819. C₇H₁₀N₃O requires 152.0818

PREPARATION 112


Ethyl 2-[(*tert*-butoxycarbonyl)amino]methylisonicotinate

5

To a stirred solution of ethyl 2-cyanoisonicotinate (2.00g, 11.0mmol, J. Med. Chem., 1976, 19, 483) in ethanol (20ml) was added 2M aqueous hydrochloric acid solution (7.5ml) followed by 5% palladium on carbon (200mg). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (60psi) for 48 hours. The mixture was filtered through arbocel and the filtrate was concentrated under reduced pressure. The residue was dried by azeotropic distillation using toluene under reduced pressure. To a stirred solution of the residue (3.00g) in dichloromethane (22ml) was added triethylamine (4.6ml, 33mmol) followed by di-*tert*-butyl dicarbonate (2.62g, 12.0mmol). After stirring for 1 hour at room temperature the reaction mixture was diluted with dichloromethane (100ml) and washed with water (50ml). The organic component was washed with brine (50ml), dried over magnesium sulphate and concentrated under reduced pressure to give a brown oily solid. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (98:2:0.2 then 97:3:0.3, by volume) to provide the title compound (2.20g) as a yellow oil.

¹H NMR (400MHz, CDCl₃): δ = 1.38 (t, 3H), 1.45 (s, 9H), 4.38 (q, 2H), 4.50 (m, 2H), 5.50 (broad s, 1H), 7.73 (d, 1H), 7.81 (s, 1H), 8.65 (d, 1H).


25 LRMS (electrospray): m/z 281 (MH⁺)

PREPARATION 1132-[(tert-Butoxycarbonyl)amino]methyl]isonicotinic acid

5

To a stirred solution of the ester from Preparation 112 (1.50g, 5.35mmol) in methanol (10ml) was added 1M aqueous sodium hydroxide solution (10ml). After 1 hour the reaction mixture was cooled to 0°C and neutralised by addition of 2M aqueous hydrochloric acid solution (5ml). The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.880 ammonia (80:20:1, by volume) to provide the title compound (1.30g) as a yellow foam.

15 ¹H NMR (400MHz, (CD₃OD): δ = 1.43 (s, 9H), 4.36, (s, 2H), 7.68 (m, 1H), 7.81 (s, 1H), 8.47 (m, 1H).
 LRMS (electrospray): m/z 251 (M-H⁺)
 HRMS: [MH⁺] 253.1179. C₁₂H₁₇N₂O₄ requires 253.1183

PREPARATION 11420 tert-Butyl [4-(aminocarbonyl)-2-pyridinyl]methylcarbamate


25 To a stirred solution of the acid from Preparation 113 (1.3g, 5.20mmol) in dimethylformamide (10ml) was added 1-hydroxybenzotriazole (950mg, 6.20mmol) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride salt (1.20g, 6.20mmol). After 1 hour 0.880 ammonia (5ml) was added and the reaction mixture was stirred at room temperature for 1.5 hours. The mixture was concentrated under reduced pressure and dried by azeotropic

distillation using toluene under reduced pressure to give a yellow semi-solid. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (1.1g) as a clear oil which crystallised on standing. This
5 material was further purified by triturating with diethyl ether (10ml) which gave a sample of the desired product (1.0g) white powder/

¹H NMR (400MHz, D6-DMSO): δ = 1.39 (s, 9H), 4.25 (m, 2H), 7.44 (m, 1H), 7.61 (m, 1H), 7.66 (broad s, 2H), 8.21 (broad s, 1H), 8.59 (d, 1H).
10 LRMS (electrospray): m/z 250 (M-H⁺)
Microanalysis: Found C, 57.26; H, 6.86; N, 16.65. C₁₂H₁₇N₃O₃ requires C, 57.36; H, 6.82; N, 16.72%.

PREPARATION 115

15 2-(Aminomethyl)isonicotinamide




To a stirred solution of the pyridine from Preparation 114 (1.00g, 3.98mmol) in
20 dichloromethane (50ml) was added trifluoroacetic acid (15ml). After stirring at room temperature for 18 hours the reaction mixture was concentrated under reduced pressure and purified by ion-exchange chromatography on Dowex 50-X8-200 eluting with water followed by 0.880 ammonia:methanol:water (5:5:90, by volume) to provide the title compound (265mg) as a white solid.

25 ¹H NMR (400MHz, D6-DMSO) : δ = 2.1 (broad s, 1H), 3.4 (broad s, 1H), 3.85 (2H, s), 7.57 (m, 1H), 7.60 (broad s, 1H), 7.80 (m, 1H), 8.16 (broad s, 1H), 8.59 (m, 1H).
LRMS (APCI): m/z 152 (MH⁺)

CLAIMS

1. A compound of the formula (I)



5

or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

either R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, -CN, -OR⁷, -CO₂R¹⁰, -CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR¹⁰, S(O)_xR¹⁰, -CO₂R¹⁰, -CONR⁵R¹⁰, -OCONR⁵R¹⁰, -NR⁵CO₂R¹⁰, -NR¹⁰R¹¹, -NR⁵COR¹⁰, -SO₂NR⁵R¹⁰, -NR⁵CONR⁵R¹⁰, -NR⁵SO₂R¹⁰ or R¹⁰; and

15 R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -OR⁵, -OR¹², -CN, -CO₂R⁷, -OCONR⁵R⁵, -CONR⁵R⁵, -C(=NR⁵)NR⁵OR⁵, -CONR⁵NR⁵R⁵, -NR⁶R⁶, -NR⁵R¹², -NR⁵COR⁵, -NR⁵COR⁸, -NR⁵COR¹², -NR⁵CO₂R⁵, -NR⁵CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -NR⁵SO₂NR⁵R⁵, R⁸ or R⁹;

20

or, R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, optionally substituted by oxo, optionally wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R¹⁰;

25

R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, -CN, -OR⁷, -CO₂R⁵, -CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR⁵, -CO₂R⁵, -CONR⁵R⁵, -OCONR⁵R⁵, -NR⁵CO₂R⁵, -NR⁶R⁶, -NR⁵COR⁵, -SO₂NR⁵R⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹;

30 R⁴ is phenyl, naphthyl or pyridyl, each being optionally substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, -CONR⁵R⁵,

OR¹³, SO_xR⁶, O-(C₁-C₆ alkylene)-CONR⁵R⁵, O-(C₁-C₆ alkylene)-NR⁵R⁵, or O-(C₁-C₆ alkylene)-OR⁶;

each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by halo, oxo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl;

R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being optionally substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, -SO₂R⁵, -CONR⁵R⁵, -COOR⁵, -CO-(C₁-C₆ alkylene)-OR⁵ or -COR⁵ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -NR⁵COOR⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵ or -CN;

R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by -OR⁵, -OR¹³, R⁸, R⁹, R¹³ or -COR¹³;

R¹¹ is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by -OR⁵, -NR⁵R⁵, -NR⁵COR⁵, -CONR⁵R⁵, R⁸ or R⁹;

R¹² is C₁-C₆ alkyl substituted by R⁸, R⁹, -OR⁵, -CONR⁵R⁵, -NR⁵COR⁵ or -NR⁵R⁵;

R^{13} is phenyl optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and

5 x is 0, 1 or 2;

with the proviso that (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl.

10 2. A compound according to claim 1 wherein R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -OR⁷, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being optionally substituted by halo, -CN, -OR¹⁰, S(O)_xR¹⁰, -CO₂R¹⁰, -CONR⁵R¹⁰, -OCONR⁵R¹⁰, -NR⁵CO₂R¹⁰, -NR¹⁰R¹¹, -NR⁵COR¹⁰, -SO₂NR⁵R¹⁰, -NR⁵CONR⁵R¹⁰, -NR⁵SO₂R¹⁰ or R¹⁰.

15

3. A compound according to claim 1 or 2 wherein R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or -OR⁷, said C₁-C₆ alkyl being optionally substituted by halo, -OR¹⁰, -NR¹⁰R¹¹, -NR⁵COR¹⁰ or R¹⁰.

20 4. A compound according to any preceding claim wherein R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being optionally substituted by halo, -OR⁵, -OR¹², -CN, -CO₂R⁷, -OCONR⁵R⁵, -CONR⁵R⁵, -C(=NR⁵)NR⁵OR⁵, -CONR⁵NR⁵R⁵, -NR⁶R⁶, -NR⁵R¹², -NR⁵COR⁵, -NR⁵COR⁸, -NR⁵COR¹², -NR⁵CO₂R⁵, -NR⁵CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹.

25

5. A compound according to any preceding claim wherein R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being optionally substituted by -OR⁵, -OR¹², -CN, -CO₂R⁷, -CONR⁵R⁵, -C(=NR⁵)NR⁵OR⁵, -CONR⁵NR⁵R⁵, -NR⁶R⁶, -NR⁵R¹², -NR⁵COR⁸, -NR⁵COR¹², -NR⁵CO₂R⁵, R⁸ or R⁹.

30

6. A compound according to claim 1 wherein R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, optionally substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R¹⁰.

35

7. A compound according to claims 1 or 6 wherein R¹ and R², when taken together, represent unbranched propylene wherein one methylene group is replaced by an oxygen atom or unbranched butylene wherein one methylene group is replaced by a nitrogen atom, said propylene and butylene being

optionally substituted by oxo and said nitrogen atom being optionally substituted by R¹⁰.

8. A compound according to any preceding claim wherein R³ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being optionally substituted by halo, -CN, -OR⁵, -CO₂R⁵, -CONR⁵R⁵, -OCONR⁵R⁵, -NR⁵CO₂R⁵, -NR⁶R⁶, -NR⁵COR⁵, -SO₂NR⁵R⁵, -NR⁵CONR⁵R⁵, -NR⁵SO₂R⁵, R⁸ or R⁹.

9. A compound according to any preceding claim wherein R³ is H or C₁-C₆ alkyl.

10. A compound according to any preceding claim wherein R⁴ is phenyl optionally substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, -CONR⁵R⁵, OR¹³, SO_xR⁶, O-(C₁-C₆ alkylene)-CONR⁵R⁵, 15 O-(C₁-C₆ alkylene)-NR⁵R⁵, or O-(C₁-C₆ alkylene)-OR⁶; or naphthyl.

11. A compound according to any preceding claim wherein R⁴ is phenyl substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, -CONR⁵R⁵, OR¹³, SO_xR⁶, O-(C₁-C₆ alkylene)-CONR⁵R⁵, 20 O-(C₁-C₆ alkylene)-NR⁵R⁵, or O-(C₁-C₆ alkylene)-OR⁶.

12. A compound according to any preceding claim wherein R⁴ is phenyl substituted by R⁸, halo, -CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.

25 13. A compound according to any preceding claim wherein R⁴ is phenyl substituted by halo, -CN or C₁-C₆ alkyl.

30 14. A compound according to any preceding claim wherein R⁸ is pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furanyl, thieryl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each being optionally substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.

35 15. A compound according to any preceding claim wherein R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being optionally substituted by halo, -CN, -COR⁵,

$-\text{CONR}^5\text{R}^5$, $-\text{SO}_2\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{SO}_2\text{R}^5$, $-\text{OR}^5$, $-\text{NR}^5\text{R}^5$, $-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{-NR}^5\text{R}^5$, $\text{C}_1\text{-C}_6 \text{ alkyl}$, fluoro($\text{C}_1\text{-C}_6$)alkyl or $\text{C}_3\text{-C}_7$ cycloalkyl.

16. A compound according to any preceding claim wherein R^8 is imidazolyl, 5 pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being optionally substituted by $-\text{OR}^5$, $-\text{NR}^5\text{R}^5$ or $\text{C}_1\text{-C}_6 \text{ alkyl}$.

17. A compound according to any preceding claim wherein R^9 is azetidinyl, 10 tetrahydropyrrolyl, piperidinyl, azepinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranlyl, oxepinyl, morpholinyl, piperazinyl or diazepinyl, each being optionally substituted by oxo, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_7$ cycloalkyl, $-\text{SO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^5$, $-\text{COOR}^5$, $-\text{CO}-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{-OR}^5$ or $-\text{COR}^5$ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, $-\text{OR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{COR}^5$, $-\text{NR}^5\text{COOR}^5$, $-\text{NR}^5\text{CONR}^5\text{R}^5$, $-\text{NR}^5\text{SO}_2\text{R}^5$ or $-\text{CN}$. 15

18. A compound according to any preceding claim wherein R^9 is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being optionally substituted by oxo, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_7$ cycloalkyl, $-\text{SO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^5$, $-\text{COOR}^5$, $-\text{CO}-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{-OR}^5$ or $-\text{COR}^5$ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by halo, $-\text{OR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{COR}^5$, $-\text{NR}^5\text{COOR}^5$, $-\text{NR}^5\text{CONR}^5\text{R}^5$, $-\text{NR}^5\text{SO}_2\text{R}^5$ or $-\text{CN}$. 20

19. A compound according to any preceding claim wherein R^9 is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being optionally substituted by $\text{C}_1\text{-C}_6$ alkyl, $-\text{SO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^5$, $-\text{COOR}^5$, $-\text{CO}-(\text{C}_1\text{-C}_6 \text{ alkylene})\text{-OR}^5$ or $-\text{COR}^5$ and optionally substituted on a carbon atom which is not adjacent to a heteroatom by $-\text{OR}^5$ or $-\text{NR}^5\text{COR}^5$. 25

20. A compound according to any preceding claim wherein R^{10} is H , R^8 , R^9 , R^{13} , 30 $\text{C}_1\text{-C}_6$ alkyl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-}(\text{C}_3\text{-C}_7 \text{ cycloalkyl})$, said $\text{C}_1\text{-C}_6$ alkyl being optionally substituted by $-\text{OR}^5$, $-\text{OR}^{13}$, R^8 , R^9 , R^{13} or $-\text{COR}^{13}$.

21. A compound according to any preceding claim wherein R^{10} is H , R^8 , R^9 , R^{13} , 35 $\text{C}_1\text{-C}_6$ alkyl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-}(\text{C}_3\text{-C}_7 \text{ cycloalkyl})$, said $\text{C}_1\text{-C}_6$ alkyl being optionally substituted by $-\text{OR}^5$ or R^{13} .

22. A compound according to any preceding claim wherein R^{11} is H or $\text{C}_1\text{-C}_6$ alkyl, said $\text{C}_1\text{-C}_6$ alkyl being optionally substituted by $-\text{OR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{COR}^5$, $-\text{CONR}^5\text{R}^5$, R^8 or R^9 .

23. A compound according to any preceding claim wherein R^{11} is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being optionally substituted by -OR⁵ or -NR⁵COR⁵.

5 24. A compound according to any preceding claim wherein R^{12} is C₁-C₄ alkyl substituted by R⁸, R⁹, -OR⁵, -CONR⁵R⁵, -NR⁵COR⁵ or -NR⁵R⁵.

25. A compound according to any preceding claim wherein R^{12} is C₁-C₄ alkyl substituted by R⁹, -OR⁵, -NR⁵COR⁵ or -NR⁵R⁵.

10 26. A compound according to any preceding claim wherein R^{13} is phenyl substituted by halo, -CN, -COR⁵, -CONR⁵R⁵, -SO₂NR⁵R⁵, -NR⁵SO₂R⁵, -OR⁵, -NR⁵R⁵, -(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.

15 27. A compound according to any preceding claim wherein R^{13} is phenyl substituted by halo, -CN, -CONR⁵R⁵, -SO₂NR⁵R⁵ or -OR⁵.

28. 2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanol;

20 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole;

[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetonitrile;

5-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1*H*-pyrazol-3-ol;

6-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-2-methyl-4(3*H*)-

25 pyrimidinone;

2-Amino-6-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-4(3*H*)-pyrimidinone;

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-*N*-hydroxyethanimidamide;

30 Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate;

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide;

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetohydrazide;

5-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1,3,4-oxadiazol-2(3*H*)-one;

35 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethylamine;

3-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1,2,4-oxadiazol-5-ol;

5-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl]-1,3,4-oxadiazol-2-amine;

N-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-methoxyacetamide;

N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-pyridinecarboxamide;

5 *N*-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-pyrazinecarboxamide;

3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]benzonitrile;

4-[[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]-3,5-dimethylbenzonitrile;

3-chloro-4-[[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]benzonitrile;

10 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]-2-fluorobenzonitrile;

2-[4-(4-chlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3-chlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2-chlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2,6-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

15 2-[4-(2,3-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2,4-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[3,5-diethyl-4-(2-fluorophenoxy)-1*H*-pyrazol-1-yl]ethanol;

2-[3,5-diethyl-4-(3-fluorophenoxy)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dimethylphenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

20 2-[3,5-diethyl-4-(4-fluoro-3-methylphenoxy)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,4-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(2,6-difluorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

25 2-[4-(2,5-difluorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-difluorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1*H*-pyrazole;

4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)-1*H*-pyrazole;

4-(3,5-dichlorophenoxy)-3,5-diethyl-1-methyl-1*H*-pyrazole;

30 4-(3,5-Dichlorophenoxy)-3-ethyl-1*H*-pyrazole;

4-[2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl]morpholine;

N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N*-(2-methoxyethyl)amine;

1-(1-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-4-

35 piperidinyl)ethanone;

N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N,N*-dimethylamine;

N-[2-({2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}amino)ethyl]acetamide;

N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N*-methylamine;
N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N*-(tetrahydro-2-furanyl methyl)amine;
3-{{4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl}methyl}morpholine;

5 1-(3-Azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole;
7-(3,5-Dichlorophenoxy)-6-ethyl-2,3-dihydropyrazolo[5,1-*b*][1,3]oxazole;
4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1*H*-pyrazole;
1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-2-propanol;
2-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethoxy}ethanamine;

10 4-{{4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}morpholine;
4-(3,5-Dichlorophenoxy)-3-methyl-5-[(2-methyl-1*H*-imidazol-1-yl)methyl]-1*H*-pyrazole;
2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1*H*-pyrazol-1-yl]ethanol;
1-{{4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-1*H*-1,2,4-triazole;

15 3-[(3,5-Diethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-{{1-(2-Aminethyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy}benzonitrile;
2-[4-(3-Cyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide;
Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate;
1-Allyl-4-(3,5-dichlorophenoxy)-3,5-diethyl-1*H*-pyrazole;

20 *N*-{{4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-*N*-(4-methoxybenzyl)amine;
N-(cyclopropylmethyl)[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methanamine;
[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N,N*-dimethylmethanamine;

25 [4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-methylmethanamine;
1-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-4-methylpiperazine;
1-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-4-piperidinecarboxamide;

30 *N*-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-2-methoxyethanamine;
1-acetyl-4-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}piperazine;
N-[2-({{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}amino)ethyl]acetamide;

35 *N*-(1-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-4-piperidinyl)acetamide;
1-{{4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}-4-methoxypiperidine;
3-Chloro-5-[(3,5-dimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-{{5-(Aminomethyl)-3-methyl-1*H*-pyrazol-4-yl}oxy}-5-chlorobenzonitrile;

3-Chloro-5-[[3-methyl-5-(1-piperazinyl)methyl]-1*H*-pyrazol-4-yl]oxy]benzonitrile;
3-Chloro-5-[(5-[(4-cyanobenzyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-
yl]oxy]benzonitrile;
3-Chloro-5-[(3-methyl-5-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-1*H*-pyrazol-4-
yl]oxy]benzonitrile;
5 3-Chloro-5-[(5-[[4-(methoxyacetyl)-1-piperazinyl]methyl]-3-methyl-1*H*-pyrazol-4-
yl]oxy]benzonitrile;
Methyl 4-[[4-(3-chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]-1-
piperazinecarboxylate;
10 4-[[[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-
yl]methyl]amino)methyl]benzenesulfonamide;
4-(3,5-Dichlorophenoxy)-5-(methoxymethyl)-3-methyl-1*H*-pyrazole;
3-*tert*-Butyl-4-(3,5-dichlorophenoxy)-5-methyl-1*H*-pyrazole;
4-(3,5-Dichlorophenoxy)-3-ethyl-5-methyl-1*H*-pyrazole;
15 4-Cyano-*N*-[[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-
yl]methyl]benzamide;
3-Cyano-*N*-[[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-
yl]methyl]benzamide;
20 *N*-[[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]-*N*-(3-
pyridinylmethyl)amine;
3-[[5-[(4-Acetyl-1-piperazinyl)methyl]-3-methyl-1*H*-pyrazol-4-yl]oxy]-5-
chlorobenzonitrile;
3-Chloro-5-[(5-[(4-cyanobenzyl)(methyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-
yl]oxy]benzonitrile;
25 3-Chloro-5-[(5-[(4-cyanobenzyl)(2-hydroxyethyl)amino]methyl)-3-methyl-1*H*-
pyrazol-4-yl]oxy]benzonitrile;
3-Chloro-5-[(3-methyl-5-[(2-methyl-1*H*-imidazol-1-yl)methyl]-1*H*-pyrazol-4-
yl]oxy]benzonitrile;
2-4-(3,5-Dichlorophenoxy)-3-methyl-5-[(3-pyridinylmethyl)amino]methyl]-1*H*-
30 pyrazol-1-yl)ethanol;
5-[(3-Isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
5-[(1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-*a*]pyrazin-4(5*H*)-one;
3-(3,5-Dichlorophenoxy)-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazine;
35 3-(3,5-Dichlorophenoxy)-2-ethyl-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazine;
4-[(3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-*a*]pyrazin-5(4*H*)-
yl)methyl]benzonitrile;

3-(3,5-Dichlorophenoxy)-2-ethyl-5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazine;
[1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-yl]methanol;
2-[4-(3,5-Dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine;

5 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1*H*-pyrazol-1-ylmethyl)-1*H*-pyrazol-1-yl]ethylamine;
N-{[1-(2-aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-yl]methyl}-*N*-(4-methoxybenzyl)amine;
4-[(1-(2-aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-
10 yl)methyl]amino)methyl]benzonitrile;
2-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine;
N-[2-([(1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-5-
yl)methyl]amino)ethyl]acetamide;

15 [4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methanamine hydrobromide;
N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl}-*N*-(4-fluorobenzyl)amine;
4-[(4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-
yl)methyl]amino)methyl]benzonitrile;

20 3-Chloro-5-[(1,3,5-trimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-Chloro-5-[(5-[(4-cyanobenzyl)amino]methyl)-1,3-dimethyl-1*H*-pyrazol-4-
yl)oxy]benzonitrile;
3-Chloro-5-[(1-(2-hydroxyethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-Chloro-5-[(5-[(4-cyanobenzyl)amino]methyl)-1-(2-hydroxyethyl)-3-methyl-1*H*-
25 pyrazol-4-yl)oxy]benzonitrile;
4-[(4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-
yl)methyl]amino)methyl]benzamide;
3-[(3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;
3-[(3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile;

30 5-[(3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
3-chloro-5-[(3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-[(3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;
5-[(3,5-diethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;

35 3-[(3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile;
3-[(1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile;
3-[(1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile;
5-[(1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
-3-[(1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;

5-[(3-cyclopropyl-5-ethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
5-[(3-*tert*-butyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
5-[(5-ethyl-3-isopropyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(1-methyl-3-azetidinyl)-1*H*-pyrazole;

5 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylamine;
2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1*H*-pyrazol-1-yl]ethylamine;
tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-[4-(3,5-dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;

10 *tert*-Butyl 2-[5-(bromomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-[5-(aminomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;

15 *tert*-Butyl 2-[5-[(4-acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1*H*-pyrazol-1-yl)methyl]-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-[5-{[(2-(acetylamino)ethyl]amino)methyl]-4-(3,5-dichlorophenoxy)-3-

20 ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-(4-(3,5-dichlorophenoxy)-3-ethyl-5-[(4-methoxybenzyl)amino]methyl]-1*H*-pyrazol-1-yl]ethylcarbamate;
tert-Butyl 2-[5-[(4-cyanobenzyl)amino]methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1*H*-pyrazol-1-yl]ethylcarbamate;

25 3-[(5-(Bromomethyl)-1,3-dimethyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile;
3-[(3,5-Diethyl-1-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-[(3,5-Diethyl-1-(2-methoxyethyl)-1*H*-pyrazol-4-yl)oxy]benzonitrile;
3-[(5-[2-(Benzyl)oxy]ethyl)-3-ethyl-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;

30 3-[(3-Ethyl-5-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;
3-[(5-[2-(4-Cyanophenoxy)ethyl]-3-ethyl-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;
3-[(3-Ethyl-5-{2-[(2-methyl-3-pyridinyl)oxy]ethyl}-1*H*-pyrazol-4-yl)oxy]-5-

35 fluorobenzonitrile;
3-[(3-Ethyl-5-[2-(3-pyridinyl)oxy]ethyl)-1*H*-pyrazol-4-yl)oxy]-5-fluorobenzonitrile;
3-[(5-{2-[(2-Amino-3-pyridinyl)oxy]ethyl}-3-ethyl-1*H*-pyrazol-4-yl)oxy]-5-

40 fluorobenzonitrile;
5-[(5-[2-(benzyl)oxy]ethyl)-3-ethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
5-[(3-Ethyl-5-(2-hydroxyethyl)-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
3-[(5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazol-4-yl)oxy]-5-

45 chlorobenzonitrile;

5-[(1-Allyl-3-*tert*-butyl-5-methyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;
5-{{3-*tert*-Butyl-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{1-(2-Aminoethyl)-3-*tert*-butyl-5-methyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(1*H*-1,2,4-triazol-1-
5 yl)benzonitrile;
3-{{3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(4-oxo-1(4*H*)-
pyridinyl)benzonitrile;
3-{{3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(1*H*-1,2,3-triazol-1-
10 yl)benzonitrile;
3-{{3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(2*H*-1,2,3-triazol-2-
yl)benzonitrile;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-fluorobenzamide;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(1*H*-pyrazol-1-
15 yl)benzamide;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(2-oxo-1(2*H*)-
pyridinyl)benzamide;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(6-oxo-1(6*H*)-
pyridazinyl)benzamide;
3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(2,3-dimethyl-5-oxo-2,5-
20 dihydro-1*H*-pyrazol-1-yl)benzamide;
5-{{3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
25 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl carbamate;
N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}sulfamide;
N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-
methoxyacetamide;
5-{{1-(3-Azetidinyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
30 5-{{3,5-Diethyl-1-(3-hydroxypropyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{(3,5-Diethyl-1-methyl-1*H*-pyrazol-4-yl)oxy}isophthalonitrile};
5-{{3,5-Diethyl-1-(2-methoxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
5-{{1-(3-Aminopropyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
methyl [4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate;
35 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]acetamide;
5-{{3,5-Diethyl-1-(hydroxymethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;
3-{{({4-(3-cyano-5-fluorophenoxy)-3-methyl-1*H*-pyrazol-5-
yl}methyl)amino}methyl}benzamide;

4-[[[4-(3-Cyano-5-fluorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]amino)methyl]benzamide;

4-[[[4-(3,5-Dicyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]amino)methyl]benzamide;

5 3-[[[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]amino)methyl]benzamide;

4-[[[4-(3-Cyano-5-methylphenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]amino)methyl]benzamide;

4-[[[4-(3-Cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl]methyl]amino)methyl]benzamide;

10 5-[(3,5-Dicyclopethyl-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;

5-[[3,5-Dicyclopethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]isophthalonitrile;

5-[[1-(2-Aminoethyl)-3,5-dicyclopethyl-1*H*-pyrazol-4-yl]oxy]isophthalonitrile;

3-[[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazol-4-yl]oxy]-5-

15 methylbenzonitrile;

3-[[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]-5-methylbenzonitrile;

3-[3-Cyclopropyl-1-(2-amino-ethyl)-5-methyl-1*H*-pyrazol-4-yl]oxy]-5-methylbenzonitrile;

20 3-[(3-Cyclopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile;

3-[[1-(3-Aminopropyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy]-5-methylbenzonitrile;

3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]-4-methoxybenzonitrile;

2-[3,5-Diethyl-4-(1-naphthyl)oxy]-1*H*-pyrazol-1-yl]ethanol;

2-[3,5-Diethyl-4-(2-naphthyl)oxy]-1*H*-pyrazol-1-yl]ethanol;

25 2-{4-[3,5-Di(1*H*-pyrazol-1-yl)phenoxy]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol;

2-{3,5-Diethyl-4-[3-fluoro-5-(1*H*-pyrazol-1-yl)phenoxy]-1*H*-pyrazol-1-yl}ethanol;

3-[[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]-5-methoxybenzonitrile;

2-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethylamine;

3-[[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy]-5-fluorobenzamide;

30 3-[(3-Isopropyl-5-methyl-1*H*-pyrazol-4-yl)oxy]-5-methylbenzonitrile;

3-[[1-(2-Aminoethyl)-3-isopropyl-5-methyl-1*H*-pyrazol-4-yl]oxy]-5-methylbenzonitrile;

2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]-*N*-(2-pyridinylmethyl)acetamide;

35 [4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetonitrile;

1-[[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetyl]piperidine;

(3*R*)-1-[[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetyl]-3-piperidinol;

N-(2,4-Dichlorobenzyl)-2-[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetamide;

2-[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-(6-methyl-2-pyridinyl)acetamide;

2-[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-[4-(trifluoromethyl)benzyl]acetamide;

5 *N*-(3-Chlorobenzyl)-2-[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]acetamide;

2-[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-[2-(trifluoromethyl)benzyl]acetamide;

2-[4-(3,5-Dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-(4-fluorobenzyl)acetamide;

10 *N*-Benzyl-2-[4-(3,5-dichlorophenoxy)-3-methyl-1*H*-pyrazol-5-yl]-*N*-methylacetamide;

3-chloro-5-[(5-[(2-chlorobenzyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile;

15 3-((5-[(Benzylamino)methyl]-3-methyl-1*H*-pyrazol-4-yl)oxy)-5-chlorobenzonitrile;

3-[(5-[(Benzyl(methyl)amino)methyl]-3-methyl-1*H*-pyrazol-4-yl)oxy]-5-chlorobenzonitrile;

3-Chloro-5-[(5-((5-chloro-2-pyridinyl)methyl)amino)methyl]-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile;

20 3-Chloro-5-[(3-methyl-5-[(4-pyridinylmethyl)amino]methyl)-1*H*-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-[(4-methylbenzyl)amino]methyl)-1*H*-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-5-[(5-[(3-methoxypropyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile;

25 4-[2-((4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl)amino]ethyl]benzenesulfonamide;

3-Chloro-5-[(3-methyl-5-((1*S*)-1-phenylethyl)amino)methyl]-1*H*-pyrazol-4-yl]oxy]benzonitrile;

30 3-Chloro-5-[(5-[(4-chlorobenzyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-[(methyl(2-phenylethyl)amino)methyl]-1*H*-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-[(1*H*-pyrazol-3-ylamino)methyl]-1*H*-pyrazol-4-yl]oxy]benzonitrile;

35 *N*-[2-((4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl)methyl)amino]ethyl]acetamide;

3-Chloro-5-[(5-[(3-chlorobenzyl)amino]methyl)-3-methyl-1*H*-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-5-{{5-{{3-fluoro-5-(trifluoromethyl)benzyl}amino}methyl}-3-methyl-1*H*-pyrazol-4-yl}oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-{{(6-methyl-2-pyridinyl)amino}methyl}-1*H*-pyrazol-4-yl)oxy]benzonitrile;

5 3-Chloro-5-[(5-{{(4-hydroxy-6-methyl-2-pyrimidinyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

3-Chloro-5-[(5-{{(4-fluorobenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

10 3-Chloro-5-{{5-{{(1*R*)-2-hydroxy-1-phenylethyl}amino}methyl}-3-methyl-1*H*-pyrazol-4-yl}oxy]benzonitrile;

3-{{5-[(Benzylamino)methyl]-3-methyl-1*H*-pyrazol-4-yl}oxy}-5-chlorobenzonitrile;

3-Chloro-5-[(5-{{(3-methoxybenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

15 3-Chloro-5-{{3-methyl-5-{{(4-(trifluoromethyl)benzyl)amino}methyl}-1*H*-pyrazol-4-yl}oxy}benzonitrile;

3-Chloro-5-{{5-{{(1*R*)-1-(hydroxymethyl)-2-methylpropyl}amino}methyl}-3-methyl-1*H*-pyrazol-4-yl}oxy]benzonitrile;

3-Chloro-5-[(5-{{(2-methoxybenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

20 3-Chloro-5-{{3-methyl-5-{{(2-(2-thienyl)ethyl)amino}methyl}-1*H*-pyrazol-4-yl}oxy}benzonitrile;

3-Chloro-5-[(3-methyl-5-{{(3-pyridinylmethyl)amino}methyl}-1*H*-pyrazol-4-yl)oxy]benzonitrile;

3-Chloro-5-{{3-methyl-5-{{(2-(trifluoromethyl)benzyl)amino}methyl}-1*H*-pyrazol-4-yl}oxy}benzonitrile;

25 3-Chloro-5-[(5-{{(2,4-dichlorobenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-{{(2-pyridinylmethyl)amino}methyl}-1*H*-pyrazol-4-yl)oxy]benzonitrile;

30 3-Chloro-5-[(5-{{(3,4-dichlorobenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

3-Chloro-5-[(3-methyl-5-{{(3-phenylpropyl)amino}methyl}-1*H*-pyrazol-4-yl)oxy]benzonitrile;

3-Chloro-5-[(5-{{(4-methoxybenzyl)amino}methyl}-3-methyl-1*H*-pyrazol-4-yl)oxy]benzonitrile;

35 3-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(methylsulfonyl)benzonitrile;

3-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(methylsulfinyl)benzonitrile;

3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(methylsulfonyl)benzonitrile;

3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-[2-(dimethylamino)ethoxy]benzonitrile;

5 3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-[2-(methylamino)ethoxy]benzonitrile;

2-(3-Cyano-5-{{3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}phenoxy)acetamide;

3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(2-methoxyethoxy)benzonitrile;

10 3-{{1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy}-5-methoxybenzonitrile;

3-{{1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl}oxy}-5-(1*H*-pyrazol-1-yl)benzonitrile;

3,5-Dichlorophenyl-3-methyl-5-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1*H*-pyrazol-4-yl ether;

15 3-Fluoro-5-{{1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-4-yl}oxy}benzonitrile;

5-[(3,5-Diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1*H*-pyrazol-4-yl)oxy]isophthalonitrile;

20 3-Cyano-5-{{3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}benzamide;

5-{{5-Ethyl-3-(1-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;

5-{{5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}isophthalonitrile;

3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile;

25 3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(5-methyl-1,2,4-oxadiazol-3-yl)benzonitrile;

3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(5-ethyl-1,2,4-oxadiazol-3-yl)benzonitrile;

30 3-{{3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl}oxy}-5-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzonitrile;

5-{{4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}amino)methyl]nicotinamide;

2-{{4-(3-Chloro-5-cyanophenoxy)-3-methyl-1*H*-pyrazol-5-yl}methyl}amino)methyl]isonicotinamide;

35 Di(*tert*-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl phosphate;

2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl dihydrogen phosphate;

5-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile sulfate salt;

5-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile ;

5-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile tosylate salt;

5-{{[3,5-Diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile mesylate salt;

3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile bis-mesylate salt;

10 3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile phosphate salt;

3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) tartrate salt;

3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile

15 succinate salt;

3-{{[1-(2-Aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) citrate salt;

or a pharmaceutically acceptable salt, solvate or derivative thereof.

20 29. 3-{{[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}-5-fluorobenzonitrile;

3-{{[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile;

5-{{[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}isophthalonitrile;

3-chloro-5-{{[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy}benzonitrile;

5-{{[3,5-diethyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile;

25 3-{{(3,5-diethyl-1*H*-pyrazol-4-yl)oxy}-5-methylbenzonitrile;

3-chloro-5-{{(3,5-diethyl-1*H*-pyrazol-4-yl)oxy}benzonitrile;


3-{{[1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-methylbenzonitrile;

3-{{[1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}-5-chlorobenzonitrile;

5-{{[1-(2-aminoethyl)-3,5-diethyl-1*H*-pyrazol-4-yl]oxy}isophthalonitrile;

30 or a pharmaceutically acceptable salt, solvate or derivative thereof

30. A compound of the formula (I)



35 or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is H, C_1 - C_6 alkyl, $-OC_1$ - C_6 alkyl, $-OC_3$ - C_7 cycloalkyl, said C_1 - C_6 alkyl being optionally substituted by R^{15} ;

5 R^2 is H, C_1 - C_3 alkyl, propenyl or C-linked R^{15} , said C_1 - C_3 alkyl being optionally substituted by $-OH$, $-OCH_3$, $-OCH_2CH_2NH_2$, $-CN$, $-CO_2CH_3$, $-CONH_2$, $-C(=NH)NH_2$, $-CONHNH_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCH_2CH_2NHCOCH_3$, $-NHCH_2CH_2OCH_3$, $-NHCH_2R^{15}$, $-NHCOR^{15}$, $-NHCOCH_2OCH_3$, or R^{15}

10 R^3 is C_1 - C_6 alkyl;

R^4 is phenyl optionally substituted by halo, $-CN$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_7 cycloalkyl or C_1 - C_6 alkoxy; and

15 R^{15} is azetidinyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyridinyl or pyrimidinyl each being optionally substituted by $-OH$, $-NH_2$, oxo or C_1 - C_6 alkyl or $-CO(C_1$ - C_6 alkyl).

20 31. A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, according to any preceding claim, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

25 32. A pharmaceutical composition according to claim 31 including one or more additional therapeutic agents.

30 33. A compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32, for use as a medicament.


35 34. A compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32, for use as a reverse transcriptase inhibitor or modulator.

35. A compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32, for use in the treatment

of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS).

36. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32, for the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity.
37. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32, for the manufacture of a medicament for the treatment of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS).
38. A method of treatment of a mammal, including a human being, with a reverse transcriptase inhibitor or modulator including treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32.
39. A method of treatment of a mammal, including a human being, with an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS), including treating said mammal with an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any of claims 1 to 30, or a pharmaceutical composition according to claim 31 or 32.
40. A process for preparing a compound of the formula (I) or a salt, solvate or pharmaceutically acceptable derivative thereof according to any of claims 1 to 30, which comprises:

(A) except where either R^1 or R^3 is halo, $-OR^8$ or $-CN$, condensation of a compound of the formula (II), (VI) or (VII)



5


with a compound of the formula




10 or a salt or hydrate thereof;

(B) for the preparation of a compound of the formula (I) in which R^1 or R^3 is $-OR^8$, reaction of, respectively, a compound of the formulae (XIII) or (XIV)

15



with an alcohol of the formula (XXI)




20


in the presence of a suitable palladium catalyst and carbon monoxide;

(C) for the preparation of a compound of the formula (I) in which R^1 or R^3 is $-OR^8$, reaction of, respectively, a compound of the formulae (XV) or (XVI),

25



with a compound of the formula (XXI)




5

under dehydrating conditions; or

(D) for the preparation of a compound of the formula (I) in which R^1 or R^3 is halo, reaction of, respectively, a compound of the formulae (XV) or (XVI)

10



or

with a halogenating agent; or

(E) interconversion of a compound of formula (I) into another compound of formula (I); or

15

(F) deprotecting a protected derivative of compound of formula (I); and

optionally converting a compound of formula (I) prepared by any one of processes (A) to (F) into pharmaceutically acceptable salt, solvate or derivative thereof.

20

41. A compound of the formulae (II), (VI), (VII), (XIII) or (XIV).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01234

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D231/18	C07D231/20	A61K31/415	A61K31/4162	A61K31/4155
	A61P31/18	C07D403/06	C07D413/06	C07D401/12	C07D403/12
	C07D405/12	C07D403/04	C07D498/04	C07D401/06	C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 963 742 A (CROSS BARRINGTON ET AL) 15 June 1976 (1976-06-15) example 25 ---	1,10-13
A	GENIN M J ET AL: "NOVEL 1,5-DIPHENYL PYRAZOLE NONNUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS WITH ENHANCED ACTIVITY VERSUS THE DELAVIRDINE-RESISTANT P236L MUTANT: LEAD IDENTIFICATION AND SAR OF 3- AND 4-SUBSTITUTED DERIVATIVES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 1034-1040, XP002178918 ISSN: 0022-2623 cited in the application the whole document --- -/-	1,39

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 June 2002

Date of mailing of the International search report

17/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/IB 02/01234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SMODIS J ET AL: "The Synthesis and Transformations of Substituted 2-Hydroxy-3-dimethylaminopropenoates. The Preparation of Condensed 3-Hydroxypyran-2-ones" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 54, no. 33, 13 August 1998 (1998-08-13), pages 9799-9810, XP004127445 ISSN: 0040-4020 page 9801 ---	41
X	LIPINSKI ET AL: "Bronchodilator and antiulcer Phenoxyprimidinones" JOURNAL OF MEDICINAL CHEMISTRY., vol. 23, 1980, pages 1026-1031, XP002201971 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 table II ---	41
X	REGITZ; SCHÄFER: "Stabile enole von alpha-'Aryl(alkyl)oxy!dibenzoylmethanen" LIEBIGS ANNALEN DER CHEMIE., vol. 7, 1981, pages 1172-1185, XP002201972 VERLAG CHEMIE GMBH. WEINHEIM., DE ISSN: 0170-2041 page 1174 ---	41
X	MUNCH; HAUSER: "Acylations of certain alpha-alkoxy and alpha-aryloxy ketones and esters" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 71, 1949, pages 770-773, XP002201973 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US ISSN: 0002-7863 page 770, right-hand column ---	41
X	ORAZIO ET AL: "Reaction of some 1,2-diaza-1,3-butadienes with activated methine compounds" JOURNAL OF ORGANIC CHEMISTRY., vol. 63, 1998, pages 9880-9887, XP002201974 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 compound 2s ---	41
		-/-

INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/IB 02/01234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OLSEN ET AL: "Synthesis of functionalized aryloxy" JOURNAL OF ORGANIC CHEMISTRY., vol. 60, no. 19, 1995, pages 6025-6031, XP002201975 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 compound 16 -----	41

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/IB 02/01234

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 38,39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.: 1-12, 14-27, 30-35, 40, 41 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 02 01234

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-12,14-27,30-35,40,41

Present claims 1-12,14-27,30-35,40,41 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search was only comprehensive for compounds according to claim 13 and their corresponding intermediates of formula XIII and XIV. It should however be noted that the search report can be considered as complete, for all claimed compounds insofar the prior art documents mention their reverse transcriptase inhibiting activity or their anti HIV activity.

The initial phase of the search for compounds of formula (II), (VI) and (VII) according to claim 41, revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of claim 41 is impossible. Consequently, the search for compounds of formula (II), (VI) and (VII) was only comprehensive for compounds according to the examples.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern Application No

PCT/1B 02/01234

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 3963742	A 15-06-1976	US 4041046	A	09-08-1977
		US 4058391	A	15-11-1977
		AR 216425	A1	28-12-1979
		AU 498491	B2	15-03-1979
		AU 8236375	A	06-01-1977
		BE 831272	A4	12-01-1976
		CA 1066294	A1	13-11-1979
		DK 317975	A	13-01-1976
		FI 752005	A	13-01-1976
		FR 2295027	A2	16-07-1976
		GB 1519494	A	26-07-1978
		IT 1050692	B	20-03-1981
		NZ 177874	A	28-04-1978
		RO 68992	A1	30-07-1981
		SE 7508002	A	11-02-1976
		ZA 7503894	A	26-05-1976

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.